Vascular Insulin Resistance Through Fat: Intracellular Signaling, Genetic Interferences and Hemodynamics by Bakker, W.
Vascular Insulin Resistance 
Through Fat 
Intracellular Signaling, Genetic Interferences and Hemodynamics
  
The research presented in this thesis is part of the research program of the Institute for 
Cardiovascular Research at the VU free university (ICAR-VU). The studies were performed 
at Laboratory of Physiology, VU medical center, Amsterdam, the Netherlands.  
Financial support by the Dutch Heart Foundation is greatly acknowledged. 
The publication of this thesis is further financially supported by: 
Dutch Diabetes foundation, Laboratory of Physiology, JE Juriaanse Foundation, Siemens, 
DSI, Astra Zeneca, Merck Sharp & Dohme, Bracco. 
ISBN: 9789461080363 
Printed by:     Gildeprint BV, Enschede 
Cover:     Inverted image of a  fluorescent stained cross section of the arterial wall    
                        (made in 2006)  
Cover design:  Marloes Bakker 
Lay out:     Laura Kok 
©  2010 W. Bakker 
All rights reserved. No part of this book may be reproduced or transmitted in any form or by any means, without prior 
written permission of the author.
VRIJE UNIVERSITEIT 
ACADEMISCH PROEFSCHRIFT 
ter verkrijging van de graad Doctor aan 
de Vrije Universiteit Amsterdam, 
op gezag van de rector magnificus 
prof.dr. L.M. Bouter 
in het openbaar te verdedigen 
ten overstaan van de promotiecommissie 
van de faculteit der Geneeskunde 
op donderdag 20 mei 2010 om 11.45 uur 
in de aula van de universiteit, 
De Boelelaan 1105 
door 
Wineke Bakker 
geboren te Hoorn 
Vascular Insulin Resistance 
Through Fat 
Intracellular Signaling, Genetic Interferences and Hemodynamics
  
  
promotoren:   prof.dr. V.W.M. van Hinsbergh 
                    prof.dr. C.D.A. Stehouwer 
copromotoren:  dr. P. Sipkema 
  dr. E.C. Eringa 
“Logic will get you from A to B. Imagination will take you everywhere.”
   
                           - Albert Einstein - 
  
Overige leden promotiecommissie prof.dr. E.T. van Bavel 
    prof.dr. M. Diamant 
    prof.dr. A.C. Gittenberger-de Groot 
    prof.dr. J.A. Maassen 
    dr. D. Merkus 
    prof.dr. J.C. Seidell 
    dr. P.J. Voshol 
    prof.dr. J.S. Yudkin 
Table of Contents 
CONTENTS
                    
General Introduction and Outline of the Thesis 
Endothelial Dysfunction and Diabetes: Roles of impaired insulin  
signaling, obesity and perivascular adipose tissue 
Cell Tissue Research 2009; 335 (1): 165-189 
Microcirculation 2007; 14 (4): 389-402 
IRS1 Deficiency reduces Endothelin-1 Sensitivity in Muscle Arterioles  
and affect Muscle Vascularization 
Submitted for publication  
IRS2 Deficiency decreases Blood Pressure by Impairment of Insulin-mediated 
Endothelin-1 Activation in Muscle Arterioles 
Submitted for publication 
PKC-theta Activation induces Insulin-mediated Constriction of Muscle Arterioles 
Diabetes, 2008; 57 (3): 706-713 
Selective PKC-theta Activation in Muscle- opposed to Adipose Tissue  
Arterioles during Obesity. Consequences for Tissue Perfusion 
Submitted for publication
Muscle Perivascular Adipose Tissue interferes in Insulin-mediatedVasoreactivity 
by Activation of AMPK 
Conclusions and General Discussion 
Summary / Samenvatting 
Acknowledgements / Dankwoord 
List of Publications 
Curriculum Vitae 
I. 
II. 
III. 
IV. 
V. 
VI. 
VII. 
VIII. 
IX. 
X.

General Introduction 
I.1
General 
Introduction 
and 
Outline 
of the 
Thesis
Chapter I 
I.2 
General Introduction 
 
I.3
Textbox 1. Body Mass Index (BMI) 
BMI indicates weight in relation to height. 
Classification of overweight and obesity in 
adults:  
 
BMI (kg/m2)  Definition1                 
<18.5   Underweight 
18.5-24.9   Normal weight 
25-29.9   Overweight 
30-34.9   Moderate obese 
35-39.9   Severe obese 
40-44.9   Extreme obese 
≥45   Very extreme obese 
I. General Introduction 
 
Obesity, a worldwide problem 
 
Adipose tissue, or body fat, was previously thought to function as energy storage depot and 
as protection of organs. Nowadays adipose tissue is regarded to be involved in metabolic 
and inflammatory processes. Obesity is caused by an imbalance between energy intake and 
energy expenditure, resulting in a positive energy balance and associated weight gain.  
  The prevalence of overweight and obesity continues to rise and has globally 
reached epidemic proportions.2 World-wide about 1.6 billion people are overweight (BMI > 
25kg/m2) of which 400 million suffer from obesity (BMI>30kg/m2). In the Netherlands, the 
prevalence of overweight and obesity are 50% and 12% respectively among men and 63% 
and 15% respectively among women.3  
 Next to a sedentary lifestyle and 
physical inactivity, genetic components increase 
the risk for the development of obesity. About 
40% of the total variation in body weight between 
individuals can be explained by genetic 
differences.4 Due to genetic predisposition, 
individuals react differently to changes in energy 
balance or dietary factors. The contribution of 
genetic factors to overweight and obesity 
increases as the severity of the metabolic disorder increases.4   
A consequence of the increased incidence of obesity is a rise of metabolic and 
cardiovascular diseases. Overweight and obesity are major risk factors for cardiovascular 
disease and type 2 diabetes. Together with vascular dysfunction, insulin resistance, 
hypertension, dyslipidaemia, hyperglycemia, they are part of the metabolic syndrome (Fig1). 
Cardiovascular disease, mainly heart disease and stroke, is already the world’s number one 
cause of death and the incidence of type 2 diabetes will rapidly reach epidemic proportions.5 
Both cardiovascular disease and type 2 diabetes are associated with and even partly 
caused by disturbed vascular function and insulin resistance. Vascular dysfunction and in 
particular endothelial dysfunction is regarded as an important and early factor in the 
pathogenesis of vascular complications in diabetes and hypertension,6,7 while insulin 
resistance is characterized by impaired insulin signaling,8,9 impaired capillary recruitment6 
resulting in impaired glucose uptake in skeletal muscle.10,11 
 
 
 
 
 
 
 
Figure 1. Overview of connected disorders 
studied in this thesis. The metabolic 
syndrome is a combination of disorders (partly 
consisting of: obesity, insulin resistance, 
vascular dysfunction, and hypertension) that 
are strongly associated with each other and 
with cardio-vascular disease and type 2 
diabetes. Solid arrow depicts strongly related 
relations between 2 disorders, dashed lines 
depicts the role of vascular insulin resistance in 
type 2 diabetes and hypertension. 
 
Obesity Vascular insulin
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Type 2 
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Textbox 2. Different definitions of Resistance
Resistance: the force that opposes (relative) motion. 
 
Vacular resistance: the resistance to flow that must 
be overcome in order for blood to circulate through 
the body. 
 
Insulin resistance: the insensitivy to insulin of 
glucose uptake  in  (mainly) skeletal muscle. 
 
Vascular insulin resistance: decreased ability to 
respond to insulin vasodilator effects, resulting 
increased resistance to blood flow and decreased 
glucose delivery to tissues. 
Mircocirculation and Endothelial Function 
 
Obesity and insulin resistance are associated with changes in microvascular function. The 
microcirculation consists of resistance arteries, capillaries and venules. In this thesis the 
function of resistance arteries, also called arterioles, is described and investigated. A 
resistance artery has an intima consisting of endothelial cells and a media consisting of 
smooth muscle cells (Fig 2). The endothelial cells are in direct contact with blood and serum 
factors, like fatty acids, nutrients and hormones. The endothelial cells react to these factors 
through signal transduction cascades that regulate the production of vasoactive substances. 
These vasoactive substances influence calcium homeostasis in the smooth muscle cells 
and can either stimulate contraction, by 
raising smooth muscle concentrations or 
sensitivity of calcium, or relaxation by 
lowering concentrations or sensitivity of 
calcium.12 When contraction of vascular 
smooth muscle occurs, this results in a 
vasoconstriction and an increased 
resistance in the vasculature. When 
vascular smooth muscle cells relax, the 
vascular diameter becomes larger, resulting 
in vasodilation. 
Vasoconstriction and vasodilation induced by components in the blood are normally in 
equilibrium to maintain vascular tone in resistance arteries. The primary function of the 
microcirculation is to regulate blood pressure, blood flow and the exchange of substances 
between blood and tissue. Small changes in diameter of resistance arteries can have large 
effects on blood flow and blood pressure. According to Poiseuille’s law, a small change of 
10% in diameter of resistance arteries results in approximately 40% change in blood flow.  
Acute regulation of the vascular diameter is achieved by the production of 
vasodilator and vasoconstrictor factors by the endothelial cells of resistance arteries. Two 
important endothelial vasoregulatory factors discussed in this thesis are nitric oxide (NO) 
and endothelin-1 (ET-1). An important regulatory hormone is insulin, which is continuously 
present and adapts to the nutritional status, and which can induce the production of both NO 
and ET-1 by the endothelial cells. 
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Textbox 3. Insulin
Insulin is a hormone produced by the 
islets of Langerhans of the pancreas. 
The name comes from the latin word 
insula for “island.” 
 
Insulin has extensive effects on 
metabolism and vasoregulation. In 
skeletal muscle insulin stimulates 
glucose uptake as main energy 
source. In the vascular system, insulin 
regulates vascular diameter in 
resistance arteries. 
 
Insulin resistance: see textbox 2  
Vascular Insulin Signaling 
 
Insulin circulates in the vascular system and when it 
binds to its receptor on endothelial cells of a resistance 
artery, it activates a complex signaling network. The two 
most critical signaling branches downstream of the 
insulin receptor are mediated by the kinases 
phosphatidylinositol 3-kinase (PI3K)13 and extracellular 
signal-regulated kinase 1/2 (ERK1/2).14 PI3K activates 
Akt and endothelial NO synthase (eNOS),15 leading to 
the production of NO by the endothelial cells13 and as 
discussed stimulates vasodilation (Figure 2).16 ERK1/2 
activation results in the production of ET-1, which 
stimulates vasoconstriction17 (Figure 2). The ability of 
insulin to produce both factors that cause vasodilation and vasoconstriction and to keep 
these factors in balance makes this hormone an important vasoregulator.18  
Important proteins in the regulation of insulin signaling are the insulin receptor 
substrates (IRSs). IRS1 and IRS2 are the predominant isoforms in endothelial cells and 
mediate the vascular effects of insulin.19 The IRS proteins associate with the insulin receptor 
and act as a downstream regulator by binding signaling proteins that contain appropriate 
binding domains.19,20 In this way, IRS proteins are at the head of the signaling cascade of 
insulin and can influence all functional effects of insulin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endothelial   cells
Smooth muscle cells
Blood
Figure 2. Resistance artery and vascular insulin signaling. The resistance artery is composed of endothelial cell 
layer (yellow ovals) and a smooth muscle cell layer (pink).  Insulin signaling occurs in the endothelial cells, with the 
insulin receptor in direct contact with blood. The vasoregulatory properties of insulin are mediated by a complex 
signaling network leading to the production of nitric oxide (NO) and endothelin-1 (ET-1). The production of NO by 
endothelial cells induces a decrease in calcium in smooth muscle cells resulting in vasodilation. The production of ET-
1 by endothelial cells induces an increase in calcium in smooth muscle cells resulting in vasoconstriction.  
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Two effects of vascular insulin signaling are muscle perfusion and possibly also blood 
pressure regulation. Muscle perfusion contributes to the delivery of nutrients and insulin 
through the vasculature in muscle. In muscle, the delivery and uptake of glucose is the main 
determinant of energy generation. The amount of glucose that is delivered to the muscle 
depends on the perfusion of capillaries. Capillaries consist largely of a monolayer of 
endothelial cells, and the capillary bed reacts to shear forces induced by flowing blood from 
the supplying resistance arteries. The resistance arteries studied in this thesis are involved 
in muscle glucose uptake.21 When resistance arteries dilate, e.g. in response to exercise, 
more capillaries will be perfused (capillary recruitment). During recruitment of capillaries, the 
endothelial surface area is increased and diffusion of glucose from blood to tissue is 
enhanced.22 
Blood pressure is controlled by cardiac output, renal fluid resorption and vascular 
resistance. The resistance of arteries is determined by the vascular diameter. When the 
vascular diameter of resistance arteries is decreased, the heart needs more energy to pump 
the blood into the circulation. When the circulating blood volume (determined by renal 
absorption) and cardiac output are constant, the differences in blood pressure are entirely 
mediated by changes in vascular resistance. As insulin affects the production of vasodilator 
and vasoconstrictor factors, it possibly plays an important role in the regulation of vascular 
resistance. 
 
  
Vascular Insulin Resistance 
 
Insulin resistance is a condition in which cells become insensitive to the effects of insulin. 
This means that insulin can bind to its receptor but that intracellular insulin signaling is 
impaired. In vasoregulation, an impaired insulin signaling disturbs the production of NO or 
ET-1 leading to a shift in the balance of vasodilator and vasoconstrictor effects on resistance 
arteries. As a consequence, vasoconstriction of resistance arteries often occurs, leading to 
disturbed regulation of muscle perfusion,23 glucose uptake11 and blood pressure.24 Vascular 
insulin resistance contributes to general insulin resistance, by reducing the delivery of insulin 
and glucose towards muscle,25 resulting in decreased glucose uptake in the muscle.11,26  
Vascular insulin resistance can contributes to Type 2 diabetes by impairment of 
muscle perfusion. Disturbed vascular insulin signaling in type 2 diabetes is characterized by 
a decrease in insulin-mediated NO production and an increase in ET-1 production. This 
leads to insulin-mediated vasoconstriction in resistance arteries of muscle and probably 
results in less perfused capillaries. A consequence is that the surface area for nutrient 
exchange and therefore glucose uptake by muscle is decreased. Initially, the pancreas 
compensates for insulin resistance by increasing insulin production. However, insulin 
resistance leads to type 2 diabetes when pancreatic β-cells fail to compensate the increased 
amount of secreted insulin. As a result total blood glucose levels will increase. Vascular 
insulin resistance may contribute to Hypertension by the induction of vasoconstriction in 
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Textbox 4. Adipocyte  
Adipocytes are the primarily cells composing 
adipose tissue. The cells contain a single large fat 
droplet, which forces the nucleus to the 
cellmembrane. Adipocytes have an endocrine 
function by the production of adipokines. 
 
 
Lipid dropletNucleus
cyto
plas
m
Secretion of adipokines
resistance arteries.6,24  In hypertension, vascular dysfunction is characterized by a 
predominance of insulin’s constrictor effects through a decreased NO production and an 
increased ET-1 production.25,27 This vasoconstriction will lead to increased resistance to flow 
in the arteries and increases blood pressure when the heart functions normally and the 
blood volume is constant.21  
 
 
 
Fat in relation to Vascular Insulin Resistance 
 
An important risk factor for the development of vascular insulin resistance is fat. Fat, in this 
thesis comprises both adipose tissue and obesity in general, as well as the mutual 
interaction of the vasculature and surrounding tissue and adipose tissue derived factors, 
likes FFA. 
In Obesity, the composition of blood 
plasma is changed, which also activates 
endothelium and impairs vascular function. 
Adipose tissue secretes substances called 
adipokines. More than 50 different kinds of 
adipokines have been described, of which 
most of them are inflammatory cytokines, 
hormones or FFA. In obesity, the increased 
fat mass secretes more FFA and cytokines, 
which can negatively influence vascular 
function. For example, the increased levels of 
FFA are associated with impairment of 
vasodilator responses of resistance arteries 
and with the development of insulin resistance 
and hypertension. 
An important determinant of the risk of obesity to the development of metabolic 
disorders, is the location of fat. Especially adipose tissue around the waist (abdominal) and 
around the organs (visceral) are stronger risk factors than e.g. adipose tissue underneath 
the skin (subcutaneous). Interestingly, adipose tissue pads have been identified around 
resistance arteries, so called perivascular adipose tissue (PVAT).28 The PVAT pads are 
increased in obesity.29 The local secretion of adipokines next to the vascular wall may have 
adverse effects on vasoregulatory properties of arteries.30  
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Textbox 5. Adipose tissue
Adipose tissue (AT), also called body fat, is a loose connective tissue. In healthy people AT is mainly composed of 
adipocytes. In obese people, adipose tissue also contains inflammatory cells, like macrophages. The number of 
macrophages in adipose tissue is related to the severity to metabolic disorders (MD). 
 
Different kinds of (AT):   Description:             Severity to MD: 
Abdominal AT    Depots of AT in region between thorax and pelvis, also called belly fat        high 
Brown AT    Abundant in newborns and hibernating animals           low 
Ectopic AT    Refers at AT depots outside normal location            high 
Intramuscular AT   Depot of AT between muscle bundles            unknown 
Perivascular AT   Depot of AT accumulated round arteries            unknown 
Subcutaneous AT   Depot of AT under the skin             medium 
Paraosseal    Depot of AT in the interface between muscle and bone           unknown 
Visceral AT   Depots of AT round organs, including epididymal, mesenteric, perirenal      high 
White AT                        Used for energy storage, ~20-25% of body content (normal weight)             normal 
 
Adipose tissue is a highly vascularized tissue and the growth of adipose tissue requires 
continuous remodeling of the vascular network.  As adipose tissue mass increases during 
obesity, the perfusion is insufficient to maintain normal oxygen levels. In order to keep the 
fat mass growing, inflammation and the formation of new blood vessels are triggered. 
Increased perfusion of adipose tissue by adipose tissue resistance arteries creates a 
larger surface area to diffuse nutrients. Changes in the regulation of nutrient metabolism in 
obesity promote nutrient storage in adipose tissue. 
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Outline of the Thesis 
 
This thesis focuses on the relation of vascular insulin resistance and fat in a mouse study. 
Vascular insulin resistance was studied by the determination of the effect of insulin to induce 
vasodilation and vasoconstriction in isolated resistance arteries in a pressure myograph. 
Different aspects of fat were investigated. Fat in this study comprises both adipose tissue 
and obesity in general, as well as the mutual interaction of the vasculature and surrounding 
tissue and adipose tissue derived factors, likes FFA. First, an extensive introduction 
concerning the role of endothelial dysfunction and diabetes induced by impaired insulin 
signaling, obesity and perivascular adipose tissue is given in Chapter II.  
Polymorphisms and changes in phosphorylation of Insulin Receptor Substrates 
(IRSs) proteins have been described to contribute to impaired insulin signaling. IRS proteins 
are important mediators of insulin signaling but their exact role in vascular function is not 
known. In Chapter III and IV the role of IRS in insulin-mediated vasoreactivity and their 
physiologic effects on vascular function was investigated. Chapter III focuses on the role of 
IRS1 in insulin signaling and muscle vascularization. In mice with a genetic deletion of IRS1 
we examined whether IRS1 deficiency impairs insulin responses in muscle resistance 
arteries and whether this influences vascularization and growth of skeletal muscle. Chapter 
IV focuses on the role of IRS2 in insulin signaling and blood pressure regulation. Blood 
pressure is highly sensitive to stress. In order to overcome the effects of stress we studied 
blood pressure with the use of radiotelemetry in mice. The effects of IRS2 deletion on blood 
pressure and whether possible changes could be related to changes in insulin-mediated 
vasoreactivity were examined to better understand the role of disturbed insulin signaling in 
blood pressure regulation.  
In obesity, plasma levels of FFA are increased and are associated with impaired 
insulin signaling, impaired capillary recruitment and impaired insulin-mediated glucose 
uptake in muscle. The mechanisms of how FFAs affect insulin-mediated vasoreactivity were 
investigated in Chapter V and VI.  In Chapter V, the hypothesis that FFA activates PKCθ in 
muscle resistance arteries and thereby impairs insulin-mediated vasoreactivity was tested. 
The strong evidence of PKCθ activation in muscle resistance arteries by FFA was further 
investigated in resistance arteries of adipose tissue in Chapter VI. The study described in 
this chapter tested the hypothesis that PKCθ is specifically activated in resistance arteries of 
muscle, as opposed to resistance arteries from adipose tissue and whether this selective 
activation of PKCθ affects blood flow towards skeletal muscle and adipose tissue.  
The prelimary results of the effects of local secretion of adipokines on vascular 
function are described in Chapter VII. This chapter examines the effects of perivascular 
adipose tissue isolated from lean and obese/diabetic mice on insulin sensitivity and insulin-
mediated vasoreactivity of vessels of lean mice. 
Finally, Chapter VIII provides a general discussion of the findings presented in this 
thesis and place these findings in perspective.  
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ABSTRACT 
 
Endothelial dysfunction comprises a number of functional alterations in the vascular 
endothelium that are associated with diabetes and cardiovascular disease, including 
changes in vasoregulation, enhanced generation of reactive oxygen intermediates, 
inflammatory activation and altered barrier function. Hyperglycemia is a characteristic 
feature of type 1 and type 2 diabetes and plays a pivotal role in diabetes-associated 
microvascular complications. Although hyperglycemia also contributes to the occurrence 
and progression of macrovascular disease, the major cause of death in type 2 diabetes, 
other factors such as dyslipidemia, hyperinsulinemia and adipose tissue-derived factors play 
a more dominant role. A mutual interaction between these factors and endothelial 
dysfunction occurs during the progression of the disease. Special attention is given to the 
possible involvement of endopalsmatic reticulum stress (ER stress) and role of obesity and 
adipose-derived adipokines as contributors to endothelial dysfunction in type 2 diabetes. 
The close interaction of adipocytes of perivascular adipose tissue with arteries and arterioles 
facilitates the exposure of their endothelial cells to adipokines, particularly if inflammation 
activates the adipose tissue, and thus affects vasoregulation and capillary recruitment in 
skeletal muscle. Thus, an initial dysfunction of endothelial cells underlies metabolic and 
vascular alterations that contribute to the development of type 2 diabetes.   
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1. Introduction
Diabetes mellitus is a common metabolic disease with a high and growing prevalence 
affecting 4% of the population and worldwide affecting 171 million people worldwide in 2000 
and an expected  366 million in 2030.1 Type 1 diabetes is characterized by an absolute 
deficiency of insulin due to pancreatic insuffiency. In contrast, type 2 diabetes is 
characterized mainly by insulin resistance, a reduced response of glucose uptake rate 
during insulin exposure, and therefore represents a relative deficiency of insulin in spite of 
high plasma levels of insulin. By progressive dysfunction of the pancreatic ?-cells this 
eventually can also in type 2 diabetes lead to an absolute deficiency of insulin for tissue 
cells. Endothelial dysfunction comprises a number of functional alterations in the vascular 
endothelium, such as impaired vasodilation, angiogenesis and barrier function, inflammatory 
activation, and increased plasma levels of endothelial products, that are generally 
associated with cardiovascular disease. Endothelial dysfunction in type 1 diabetes is 
probably the consequence of the metabolic changes related to diabetes, in particular 
hyperglycemia. With age a number of microvascular complications develop in type 1 
diabetes patients, in particular retinopathy, nephropathy and the diabetic foot. In contrast, 
the relation between endothelial dysfunction and diabetes is much more complex in type 2 
diabetes and draws in particular a heavy burden on the patients by cardiovascular disease. 
In type 2 diabetes a common cause may underlie both endothelial dysfunction and the 
development of hyperglycemia, while other factors such as dyslipidemia additionally 
contribute to both. Endothelial dysfunction may thus play a primary role in the development 
of vascular complications of type 2 diabetes, that are aggravated by hyperglycemia, but are 
not primarily dependent on the development of hyperglycemia. 
 In the present survey we shall discuss the nature of endothelial dysfunction in type 
1 and 2 diabetes and how it relates to these condittions. After discussing the effects of 
hyperglycemia on endothelial functioning, we will discuss how in type 2 diabetes, obesity 
and fat-derived adipokines act locally on arteries and arterioles and can contribute to insulin 
resistance and reduced glucose uptake in muscle. Further insight into the interrelationship 
between endothelial/vascular (dys)functioning, type 1 and 2 diabetes and obesity may help 
to further improve treatment of these epidemically increasing metabolic disorders. 
2. Normal Endothelial Functions 
The endothelium of all blood vessels represents a diffuse organ of over 700 gram in the 
adult man.2 Although local differences exist in the endothelium of various types of conduit 
vessels, resistance vessels and tissue capillaries, a number of general functions are known 
that are crucial for proper functioning of the organism.3-5 In addition, the endothelium of 
many different organs have specialized functions as well.3 The endothelium can extend its 
repertoire of functions by adaptation to various stimuli, including mechanical stress, 
oxidative and metabolic stresses, inflammation, hypoxia and many other stresses.4,6
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2.1 General functions 
By its location the endothelium acts as a blood container, but in addition to that it actively 
regulates the passage of nutrients, hormones and macromolecules into the surrounding 
tissue.7 It is covered by a glycocalyx that contributes to the selectivity of the endothelial 
barrier function.8 Furthermore, the endothelium ensures the fluidity of blood by its 
contribution to hemostasis. Indeed, living endothelial cells are needed to prevent and limit 
blood coagulation and the formation of a platelet thrombus, and to produce fibrinolysis 
regulators.9  
The interaction between flowing blood and endothelium regards not only the 
interaction of blood constituents and cells with the endothelium, but also includes the 
sensing of mechanical forces in particular shear forces that are exerted by the flowing blood 
on the endothelium. This sensing enables the endothelial cell to respond by acute 
vasoregulation and by inducing chronic adaptation of the blood vessel. Acute vasoregulation 
is achieved by the production of vasodilator factors, such as nitric oxide (NO), endothelium-
derived hyperpolarization factor (EDHF) and prostaglandins (PGI2/PGE2), of which the 
relative contribution varies between different types of vessels.10 The endothelium not only 
responds to vasoactive agents with usually vasodilation, but is also involved in the 
catabolism, metabolism and synthesis of various vasoactive agents, particular in the lung.11 
Furthermore, in specific conditions the endothelium is also able to induce the 
potent vasoconstrictor endothelin-1. Insulin also acts as a regulator of vasoregulation, as it 
is able to induce nitric oxide and endothelin-1 release.12,13 Another important function of the 
endothelium lies in the regulation of a proper recruitment of leukocytes at sites of 
inflammation or an immune reaction. Again both acute responses and chronic adaptation 
can cause induction of leukocyte adhesion molecules and other gene products. 
Inflammatory activation of the endothelium can occur e.g. after exposure to bacterial 
lipopolysaccaride and inflammatory cytokines, of which the potent inducers IL-1 and tumor 
necrosis factor alpha (TNF?) have drawn the most attention. Inflammatory activation can 
also be induced by reactive oxygen intermediates (ROI), which can be generated by the 
inflammation process itself, as well as by disturbed metabolic conditions.14 
Finally, the endothelium is the major vector in angiogenesis, the formation of new 
microvessels. This is not only important in development, growth and tissue repair, but also in 
capillary perfusion of muscle. Furthermore, in a number of diseases an improper 
angiogenesis response causes unwanted growth, risk for local haemorrhage by immature 
vessels, or insufficient blood supply.15  
 
2.2 Endothelial function in glucose metabolism and insulin action 
Endothelial cells are metabolically very active cells with a high rate of protein synthesis. 
They can use both glucose and fatty acids as nutrients. Non-esterified fatty acids (NEFA) 
are liberated from triglyceride-rich lipoproteins by lipoprotein lipase that is bound to the 
endothelial glycocalyx or are taken up from the plasma. In endothelial cells, uptake of D-
glucose occurs via the Glut-1 glucose transporter, which is not influenced by insulin, in 
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contrast to Glut-4 in muscle cells. Therefore, glucose uptake in the endothelial cells reflects 
the glucose level in the blood independently of insulin sensitivity. However, most of the 
glucose that reaches the endothelium should not be catabolized, but delivered to the 
underlying tissue cells.   
As the endothelium forms a continuous sealing of the blood, it acts as the gateway 
for glucose and insulin delivery for tissue cells. Small molecules like glucose can pass 
through the interendothelial junctions, except for those in the endothelium of brain 
microvessels, which only allow transcellular receptor GLUT-1 mediated translocation.16 In 
principle, Glut-1 may also contribute to the exchange of D-glucose from the blood to the 
interstitium of other tissues, but its relative contribution is not systematically investigated and 
probably small. This contrasts to the exchange of proteins, like albumin, which pass 
endothelial cells transcellularly via shuttling of caveolar vesicles between the luminal to the 
abluminal side. These caveolae contain specific receptors facilitating the translocation.17,18 
Only in conditions of enhanced demand, e.g. during inflammation, in caveolin-1 deficient 
animals which have no functional caveolae, or in hypoxia, the junctions widen and allow 
paracellular exchange of proteins. Insulin is a small protein (6,000 Da), but nevertheless 
there is ample evidence that insulin-receptor-mediated binding and exchange determines its 
exchange from plasma and interstitial fluid19,20 and thus its availability to the insulin-sensitive 
tissues, like muscle, adipose tissue and brain (Fig 1).  
 
 
Figure 1. Delivery of insulin, D-glucose and acute insulin signaling in endothelial cells  Uptake of D-glucose 
occurs via the glucose transporter Glut-1, which, in contrast to Glut-4 in muscle, is not affected by insulin signaling. 
Exchange of glucose from the plasma to the interstitial fluid proceeds mainly via intercellular gaps/junctions. In 
contrast, insulin is shuttled over the endothelium via caveolae after binding to its receptor. In addition, insulin receptor 
signaling affects vasoregulation by endothelial cells. It has a rapid effect on the release of endothelin-1 (ET-1) and 
nitric oxide (NO). Activation of the insulin receptor phosphorylates insulin receptor substrates (IRS), of which IRS-1 
and IRS-2 have been demonstrated in endothelial cells. PI3 kinase complexes with the phosphorylated IRS-1, after 
which PKB/Akt and subsequently eNOS are activated by phosphorylations. The eNOS dimer generates NO. Activation 
of the insulin receptor also cause activation of MEK-1 and ERK1,2 and subsequently the activation and release of 
endothelin-1. In analogy with heart cells25 one may suggest that interaction of the activated IRS-2 with the adapter 
protein Shc causes phosphorylation of MEK and the subsequent activation steps.   
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Only the liver escapes this control, as it has fenestrated endothelial cells. As a 
consequence, the endothelium may affect the relative exposure of insulin-sensitive tissue 
cells to insulin after a glucose challenge.21,22 The deliveries of glucose and insulin to a 
specific tissue depend on the size of the perfused capillary bed (capillary recruitment) and 
their passage rates over the endothelium. The perfused capillary bed is determined by the 
pre-existing capillaries and in particular by the vasoregulation of the proximal resistance 
vessels. Insulin affects this regulation and thus glucose and insulin delivery. 
Insulin can dilate arteries and arterioles by a receptor-dependent stimulation of a 
pathway that involves IRS-1, PI3 kinase, Akt/PKB and eNOS and leads to generation of the 
potent vasodilator NO (Fig 1). In addition, insulin is also able to cause rapid induction of 
endothelin-1, which occurs via a pathway that involves activation of MEK, ERK1,2 and 
endothelin converting enzyme. Both effects occur via activation of the insulin receptor, which 
subsequently phosphorylates insulin receptor substrates (IRS), of which IRS-1 and IRS-2 
have been demonstrated in endothelial cells.23,24 Deficiency of IRS-1 impairs NO induction 
by insulin.24 However, the roles of IRS-1 and IRS-2 in endothelial cells and the balance of 
their expressions in various metabolic conditions are not completely understood. In analogy 
with (diabetic) heart cells25 one may suggest that interaction of the activated IRS-2 with the 
adapter protein Shc causes phosphorylation of MEK and the subsequent activation steps. In 
addition to the acute regulation, there are also effects on gene expression. Mice with a 
vascular endothelial cell-specific insulin receptor deficiency show normal growth and 
glucose metabolism, but display a reduction in ET-1 and eNOS mRNAs.26 
 
 
3. Endothelial Dysfunction and Diabetes  
 
3.1 Endothelial dysfunction 
The functioning of the endothelium is flexible and adapts to various types of metabolic, 
mechanical and inflammatory stress.4,6 However when this functioning becomes inadequate, 
e.g. loss of NO generation, or exaggerated, e.g. improper inflammatory activation, one 
speaks of endothelial dysfunction. From a mechanistic point of view there are as many 
endothelial dysfunctions as endothelial functions exist. They include changes in barrier 
function and hemostasis, reduced vasodilator responses, improper inflammatory activation 
and angiogenesis (Table 1). 
In the clinical context, endothelial dysfunction is regarded as an important and early 
factor in the pathogenesis of atherothrombosis14,27 and vascular complications of diabetes28 
and is associated with a number of traditional risk factors including hypercholesterolemia, 
smoking, hypertension, diabetes mellitus and insulin resistance and, recently, obesity.29 In 
this context it is often thought to represent a collection of simultaneously occurring 
alterations in endothelial functioning that occur early in arterial disease and are causal to 
subsequent changes in structure and function of affected blood vessels. However, although 
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accumulation of reactive oxygen intermediates, loss of NO bioavailability and inflammatory 
activation of the endothelium play a role in most clinical conditions including diabetes (see 
below), the exact nature and degree of endothelial dysfunction can vary with the nature of 
the noxious stimulus and the type of vessel involved.  
 
 
3.2 Endothelial dysfunction and vascular complications of diabetes 
Endothelial dysfunctions that are associated with the occurrence and severity of vascular 
complications in diabetes are summarized in Table 1. Some of them are mainly associated 
with hyperglycemia and 
microangiopathy, while others 
are induced by more complex 
metabolic alterations in type 2 
diabetes and particularly 
contribute to Macroangio-
pathy. After a discussion of 
various aspects of endothelial 
dysfunction in diabetes in 
general, we shall discuss in 
the subsequent chapters how 
hyperglycemia, and insulin-
resistance- and obesity-
associated factors contribute 
to these aspects of type 1 and 
2 diabetes. 
 
 
 
3.3 Structural changes in endothelial extracellular matrix and barrier dysfunction 
The endothelial cell is polarized and has as extracellular matrix a glycocalyx at its luminal 
side and a basement membrane at its abluminal side. In diabetes the basement membrane 
is thickened and altered in composition, due to enhanced synthesis of matrix proteins by 
transforming growth factor beta (TGF-?) activity and possibly by inadequate counter 
regulation of matrix protein synthesis by the defective matrix itself.30,31 Chondroitin sulphate- 
and dermatan sulphate- proteoglycans are increased at the expensive of heparan sulphate 
proteoglycans, which are markedly reduced in diabetes.32 At the same time, the thickness of 
the glycocalyx, which contains high amounts of heparan sulphate proteoglycans is markedly 
reduced.33,34 Loss of the glycocalyx leads to a wide spectrum of vascular abnormalities, 
which include adhesion of mononunuclear cells and platelets to the endothelial surface, 
attenuated NO availability and reduced binding of prothrombin and lipoprotein lipase in 
addition to increased vascular permeability.35 The altered composition of the basement 
membrane and glycocalyx are thought to cause a moderately increased leakage of 
Endothelia l dysfunction in Diabetes
Structural changes in endothelial barrie r and matrix
Increased ba sal membrane thickness
Reduced glycocalyx
AGE formation and improper matrix crosslinking
Microalbuminuria
Reduced vasodilator res ponse  (hypertension)
Reduced NO production
Increased en dothelin-1 synthesis
Increased inflammatory ac tivation
Increased expression of cell adhesion molecules an d leukocyte adhe sion
Increased pro duction of and response to circulating med iators, incl CRP
Altered hemostasis
Elevated plasma leve ls of vWF
Re duced TM, i ncreased PAI-1
Improper angiogenesis
Improper vessel gro wth in diabetic retinopathy
Re duced a ngiogenesis in wound healing and di abetic foo t
Table 1. Endothelial dysfunction associated with the occurrence  
and severity of vascular complications in diabetes. 
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macromolecules through the endothelium of many vessels in hyperglycemia and diabetes. 
This phenomenon might be the basis of the Steno Hypothesis,36 which proposed that 
microalbuminuria (see below) in diabetes reflects a systemic leakage of albumin and 
atherogenic lipoproteins over the endothelium, thus reflecting an enhanced risk for 
atherothrombosis and cardiovascular disease. Although this hypothesis may explain the 
more general localization of atherosclerosis in diabetes as compared to the more focused 
lesions in hypercholesterolemia,37 several studies were unable to demonstrate such 
association between the transcapillary leakage of albumin and microalbuminuria.38 This 
indicates that other additional factors determine the functioning of the endothelial barrier 
towards macromolecules in microalbuminuric patients.  
In vitro and animal studies have indicated hyperglycemia as an etiological factor of 
endothelial barrier injury, with microvascular hyperpermeability and plasma leakage as 
consequence.39,40 Hyperglycemia can stimulate crosslinking and modification of matrix 
proteins by glyco-oxidation, and advanced glycation end products (AGEs) which are 
generated in this process, have been reported to alter the synthesis of matrix proteins in 
animal experiments.41 The role of hyperinsulinemia as a contributor to capillary leakage is 
still controversial.39 Several studies suggested that the exchange of insulin in muscle 
capillaries is retarded, which can be either due to reduced permeability or to reduced 
perfusion of the muscle capillary bed.22,42 
 
 
3.4 Microalbuminuria 
Microalbuminuria, which is defined in humans as 30–300 mg urinary albumin excretion per 
24h,43,44 is generally considered as an indicator of early kidney damage and atherosclerosis 
in diabetes.45,46 Its origin is still incompletely understood. In the Steno Hypothesis36 leakage 
of albumin into the urine is a reflection of widespread vascular damage and thus predicts 
cardiovascular disease. Indeed, epidemiological and prospective studies show that 
microalbuminuria is predictive for cardiovascular disease in particular in patients with 
diabetes and hypertension, but also in the general population, independently of other 
classical risk markers.46  
Stehouwer et al.47 suggested that the close linkage between microalbuminuria and 
endothelial dysfunction in type 1 and 2 diabetes patients might explain the fact that 
microalbuminuria is a risk marker for atherosclerotic cardiovascular disease. The type of 
endothelial dysfunction appeared to be important in this aspect. In type 2 diabetes patients, 
these authors found that microalbuminuria, endothelial dysfunction as estimated from 
plasma von Willebrand factor levels, and low-grade inflammation, although tightly linked, 
were independently associated with risk for cardiovascular death.48 In constrast, in elderly 
individuals without and with diabetes, microalbuminuria was linearly associated with 
impaired endothelium-dependent, flow-mediated vasodilation, supporting the concept that 
impaired endothelial nitric oxide synthesis plays a role in the association of microalbuminuria 
with cardiovascular disease risk.49 Other investigators proposed that individual variation in 
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vascular function is simultaneously associated with a variable excretion of micro amounts of 
albumin and the susceptibility to develop cardiovascular disease subsequently.50
 Both changes in the hydrostatic pressure and the permselectivity of the glomeruli 
are thought to contribute to microalbuminuria. One may anticipate that changes in the local 
availability of growth factors, such as vascular endothelial growth factor (VEGF) and TGF?,
or unfavorable conditions, e.g. hyperglycemia, may affect the interaction between the 
podocyte foot ends and the glomerular endothelium and thus alter glomerular 
permselectivity, together with changes in the glomerular proteoglycans.51 In addition to 
increased glomerular leakage of albumin, decreased protein resorption in the renal tubuli will 
also contribute to the appearance of albumin in the urine.52
3.5 NO availability and dysfunctional vasoregulation 
A key feature of endothelial dysfunction is the inability of arteries and arterioles to dilate 
appropriately in response to stimuli. This limits the delivery of nutrients and hormones to the 
distal tissues. Two mechanisms play an important role. Dominant is a decreased 
bioavailability of the vasodilator nitric oxide (NO). In addition, increased synthesis of 
endothelin-1 by activated endothelial cells induces vasoconstriction. The bioavailability of 
NO is determined by a balance of NO production by endothelial NO synthase (eNOS, also 
called NOS-III) and reduction of active NO by quenching of NO by reactive oxygen 
intermediates (ROI), particularly the superoxide anion.53 The NO generation occurs in a 
tightly coupled sequence of reactions at the eNOS dimer, which is stabilized by BH4 and 
requires several cofactors.54 Uncoupling of eNOS causes the enzyme to produce 
superoxide rather than NO.55,56
Superoxide and other ROI inhibit NO bioavailability in several ways. First, 
superoxide reacts directly with NO and forms peroxynitrite. Peroxinitrite is a potential 
damaging agent and contributes by itself to eNOS uncoupling, thus aggravating reduced NO 
production. Second, ROI reduce the availability of tetrahydrobiopterin (BH4), a cofactor 
required for NO synthesis from eNOS. Loss of structural interaction of BH4 with eNOS 
results in eNOS uncoupling and production of superoxide instead of NO by eNOS.54,57
Infusion of BH4 partially counteracted the reduced acetylcholine-induced vasodilation in type 
2 diabetes patients, supporting the concept that eNOS uncoupling and reduced NO 
bioavailability contribute to endothelial dysfunction in diabetes.58 A third mechanism by 
which ROI reduce NO availability is by inhibition of the enzyme dimethylarginine 
dimethylaminohydrolase (DDAH).59 As DDAH converts the endogenous eNOS inhibitor 
Asymmetric dimethylarginine (ADMA), inhibition of DDAH causes accumulation of ADMA 
and suppression of NO production.59 Elevated plasma ADMA levels are a risk marker for 
cardiovascular events and diabetic kidney disease in patients with type 1 and type 2 
diabetes.60,61 Intensive treatement of type 2 diabetes patients reduced, amongst others, both 
ADMA levels and cardiovascular risk.62
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Besides ROI, an increase in arginase is another mechanism of reduced NO availability. 
Arginase metabolizes L-arginine to urea and ornithine. As enhanced arginase activity can 
decrease tissue and cellular arginine levels, L-arginine availability to eNOS is reduced,63 
which leads to a decreased NO production and increased superoxide generation.64 
Recently, it has been reported that increased arginase activity in diabetes contributes to 
vascular endothelial dysfunction by reduced L-arginine availability to NO synthase.65 A 
possible mechanism involved is the activation of RhoA by high glucose levels, which 
increases arginase activity, which in turn initiates a feed-forward cycle of diminished NO 
levels and further oxidative stress.65 Insulin suppresses the expression of genes from urea 
synthesis pathway, including arginase. As insulin signaling is disturbed in diabetes, diabetes 
induced increase in arginase activity might explain the decreased L-arginine levels reported 
in plasma from diabetic animals and patients66,67 and in vascular tissue of diabetic rats.66 
Insulin resistance and oxidative stress, such as induced by hyperglycemia, can 
both contribute to an increased production of the potent vasoconstrictor endothelin-1. As will 
be discussed below, the balance between NO en endothelin-1 dependent pathways plays a 
major role in the vasoregulation by insulin and the dysfunction of vasoregulation in diabetes 
and obesity. 
Other vasodilating factors such as endothelium-derived hyperpolarisation factor 
(EDHF) may also be altered in diabetic animals.68 The contribution of EDHF is most 
pronounced in smaller vessels, which limits a possible role for EDHF in diabetic endothelial 
dysfunction to the smaller resistance arteries and arterioles. Within the limited number of 
studies available, variable effects of diabetes on EDHF production (reduction, compensatory 
increase, no contribution) have been reported depending on the type of vessel studied and 
experimental setting.68,69 
 
 
3.6 Leukocyte adhesion and inflammation 
The generation of ROI also affects other functions of the endothelium. Either directly via ROI 
or via reduction of NO, the NF-?B pathway is activated with subsequently the activation of 
numerous genes involved in inflammation4,6,70 In particular the cell adhesion molecules 
VCAM, ICAM-1 and E-selectin have drawn much attention. As they represent major 
receptors controlling the influx of monocytes and other inflammatory cells into the arterial 
wall, their expression is considered as a hallmark in the etiology of atherosclerosis.14 Their 
importance is further underlined by the observation that the proper arterial shear forces 
exerted by the flowing blood on the endothelium have anti-atherogenic properties by 
reducing inflammatory activation of and expression of these leukocyte adhesion molecules 
by the endothelium.14,71,72 Many studies in experimental animals have shown increased 
expression of leukocytes adhesion molecules and low-grade inflammation of the 
endothelium in diabetes and their effects on the development and aggravation of 
atherosclerotic lesions. In humans the moderate elevation of C-reactive protein (CRP) in 
atherosclerosis, insulin resistance and diabetes has been interpreted as being the 
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consequence of a systemic low-grade inflammatory of the arteries.73-76 Furthermore, an 
increase of soluble forms of VCAM-1 and ICAM-1 has been observed in diabetes patients 
and was associated with an increase risk of developing cardiovascular disease.77,78
It has been reported that advanced glycation end products (AGEs) can activate NF-
?B in endothelial cells via activation of the receptor RAGE. This has been found in studies in 
vitro as well as in experimental animals.41,79 AGE/RAGE-mediated activation of NADPH 
oxidase was also reported.80 Further studies have shown that RAGE also has other ligands 
with a much higher affinity, such as S100 protein, which are also involved in inflammation 
too, and that other vascular cells, e.g. macrophages also contain RAGE.81 Hui et al.82
pointed out that radical generation by AGEs can be caused by the ability of AGEs to bind 
ROI-generating heavy metals. This may explain why considerable variation exists in reports 
on the effect of AGEs on endothelial cells.80,81,83,84
Hyperinsulinemia accelerates atherosclerosis by directly enhancing neutrophil 
transendothelial migration through increasing endothelial PECAM-1 expression via mitogen-
activated protein kinase activation.85
3.7 Decreased thromboresistance 
Several proteins involved in hemostasis have been evaluated as potential risk indicators of 
cardiovascular disease in diabetes.86 An increase in soluble thrombomodulin may point to a 
decreased ability to activate the anticoagulant protein C pathway, while a decrease in 
tissue-type plasminogen activator and increase of its inhibitor PAI-1 may point to a reduced 
fibrinolysis.47,49 Of particular interest is von Willebrand factor (vWF), which is both involved 
in the adhesion of platelets to collagen and complexes with coagulation factor VIII. 
Increases in plasma  vWF concentrations have consistently been associated with an 
increased risk of cardiovascular complications and death in diabetes patients.49,87 How vWF 
contributes to this risk is still uncertain. 
3.8 Altered angiogenesis and tissue repair 
The regeneration function of endothelial cells represented by angiogenesis is dysfunctional 
in hyperglycemia and diabetes. Diabetes patients have poor wound healing, impaired 
collateral formation after vascular occlusion or myocardial infarction, and an increased risk 
of rejection of transplanted organs.88 Impaired vascularization probably also contributes to 
diabetic neuropathy. In contrast, an excessive neovasularization is observed in the eyes of 
patients with diabetic retinopathy.89 Although this may look surprising, one has to realize 
that the cause of this excessive neovascularization is improper vascularization of the retina 
itself. Indeed, narrower retinal arteriolar caliber, before the onset of neovascularisation 
predicts the development of diabetes, providing further evidence that microvascular changes 
may contribute to the pathogenesis of diabetes.90 Because of the reduced blood supply, an 
additional layer of unstable vessels is growing in the vitreous fluid over the retina, thereby 
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increasing the risk for vascular leakage and bleeding into the eye. In patients with 
proliferative diabetic retinopathy huge levels of VEGF have been found in the eye fluid, 
indicating an important contribution of this angiogenic factor.91 Furthermore, the level of 
VEGF was less in diabetes patients treated with angiotensin-converting enzyme (ACE) 
inhibitors suggesting that angiotensin 2 also contributes.92 Either diabetes itself or the 
hypoxia that results from endothelial and vascular injury may induce these factors. 
Hyperglycemia is a major determinant of vessel damage in diabetic retinopathy with ROI, 
accumulation of glycolysis intermediates and AGEs as potential mediators. Reduction of the 
accumulation of glycolysis intermediates and blockage of AGE formation has been shown to 
be effective in an animal setting.93,94 Anti-VEGF antibodies have been shown to be effective 
in counteracting neovascularization in adult macular degeneration in the eye and are 
evaluated in patients with diabetic retinopathy.95 Finally, hyperinsulinemia and overactivation 
of insulin and IGF-1 receptors in the retinal microcirculation have been shown, in rodents, to 
contribute to VEGF expression and retinopathy associated with diabetes. 
Besides VEGF, the VEGF receptors can also be affected in diabetes. Chronic 
coronary heart disease in diabetic patients is accompanied by an increased VEGF 
myocardial expression and a decreased expression of its receptors along with a down-
regulation of its signal transduction. The latter could be partially responsible for the reduced 
neoangiogenesis in diabetic patients with ischemic cardiomyopathy.96 Furthermore, the 
neurotrophin p75 receptor, which is upregulated in the ischemic hindlimbs of the diabetic 
mice induce endothelial apoptosis and has angiogenic properties.97 
 
 
3. Hyperglycemia-related Endothelial Dysfunction in 
type 1 Diabetes 
 
Hyperglycemia is a feature of both type 1 and type 2 diabetes. There is ample evidence that 
intensified regulation of blood glucose markedly reduces the development and progression 
of microvascular complications.98,99 The UKPDS and subsequent studies showed that the 
efficacy of tight glucose control was less pronounced for macrovascular complications, 
particularly atherosclerosis and its sequels, in type 2 diabetes patients,100 and very stringent 
control could even aggravate the disease.101,102 This indicates that determinants other than 
hyperglycemia play a dominant role in the development of macrovascular disease as well.  
Notwithstanding this, hyperglycemia is still considered not only pivotal in diabetes-
associated microvascular complications, but also to contribute to worsening macrovascular 
complications. 
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4.1 Endothelial activation by hyperglycemia 
Major vascular defects in diabetes, in which hyperglycemia plays an important role, include 
increased arterial stiffness and reduced NO production in resistance arteries and arterioles, 
reduced glomerular function and microalbuminuria in the kidney, and inappropriate 
neovascularization in the eye.47 In nearly all of these cases it is thought that the 
hyperglycemic state affects endothelial functioning. A number of biochemical mechanisms 
has been observed, which Michael Brownlee unified in one mechanism.103,104 According to 
this mechanism (Fig 2), the production of reactive oxygen radicals generated in particular by 
mitochondrial uncoupling and the subsequent activation of PARP and inhibition of the 
glycolysis enzyme GAPDH caused accumulation of glycolysis pathway intermediates, which 
activated at least four biochemical pathways known to be altered in endothelial cells by 
hyperglycemia: PKC activation, generation of methylglyoxal and AGEs, activation of the 
hexosamine pathway, and reduction of the NADPH/NADP+ ratio by activation of the sorbitol 
pathway. 
 
 
Figure 2. Role of hyperglycemia on endothelial activation. The production of reactive oxygen radicals generated in 
particular by mitochondrial uncoupling and the subsequent activation of PARP and inhibition of the glycolysis enzyme 
GAPDH caused accumulation of glycolysis pathway intermediates, which activated at least four biochemical pathways 
known to be altered in endothelial cells by hyperglycemia: PKC activation, generation of methylglyoxal and AGEs, 
activation of the hexosamine pathway, and reduction of the NADPH/NADP+ ratio by activation of the sorbitol pathway. 
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The accumulation of glycolysis-derived triose-phosphates can activate PKC by their 
conversion to DAG, a known activator of PKCs. In particular the isoforms PKC-?2, and 
PKC? have received much attention, on the one hand because they increase the expression 
of genes that are enhanced in diabetes, such as plasminogen activator inhibitor-1 (PAI-1), 
endothelin-1, VEGF and TGF-?, on the other hand because of the efficacy of PKC-?2 
blockers in reducing diabetic microangiopathy in animals.105,106 However, the efficacy in man 
of these blockers is still unclear. 
Furthermore, the accumulated glycolysis-derived triose-phosphates can be 
converted into methylglyoxal, which can modify proteins intracellularly, forming advanced 
glycation end products within the cell. Methylglyoxal modification of heat-shock protein 
Hsp27107 and mSin3A, which enhances angiopoietin-2 transcription,108 have been reported 
in endothelial cells. An increase in cellular methylglyoxal has also been found to arrest cell 
growth, to induce apoptosis109,110 and to stimulate endocytosis of macromolecules 111. 
Intracellular methylglyoxal is degraded by glyoxylase. Overexpression of glyoxylase I in 
endothelial cells results in a decrease of the intracellular hyperglycemia-induced 
methylglyoxal concentration accompanied by normalization of endocytosis.111 High glucose 
levels also cause the formation of extracellular AGEs. As discussed above such AGEs may 
induce inflammatory activation of endothelial cells.79  
The ambient glucose concentration regulates the cellular concentration of uridine 
5’diphosphate N-acetylglucosamine (UDP-GlcNAc), which is generated from the glycolysis 
intermediate fructose-6-phosphate by glutamine:fructose-6-phosphate aminotransferase in 
the hexosamine pathway.112,113 UDP-Glc is a precursor for proteoglycans and O-linked 
GlcNAc (O-GlcNAc) addition to nuclear and cytoplasmic proteins.112 Increased O-
glycosylation of SP-1 causes increased activity of this transcription factor and a subsequent 
elevated gene transcription of PAI-1 and TGF-?.114 Furthermore, an increased flux of 
glucose through the hexosamine pathway has been associated with insulin resistance 
associated with defects in Akt activation in 3T3 L1 adipocytes115 and insulin resistance in 
skeletal muscle.116,117  
The sorbitol pathway is also stimulated by hyperglycemia and can contribute to 
hyperglycemic complications in animals, but its significance for endothelial dysfunction has 
been disputed as aldolase inhibitors have little effect in man and the sorbitol pathway is 
poorly active in endothelial cells.118  
Brownlee’s unifying mechanism for the pathobiology of hyperglycemia-induced 
diabetic complications104 thus proposes that hyperglycemia induces generation of 
superoxide, which subsequently results –via activation of PARP - in the inhibition of GAPDH 
and accumulation of glycolysis intermediates. Subsequent animal studies demonstrated that 
application of benfotiamine, which lowered the levels of glycolysis intermediates by 
stimulation of the pentose phosphate shunt, had a beneficial effect on endothelial survival 
and microvascular in the eye of rodents.93 Additional evidence for the importance of this 
mechanism was provided by studies that interfered with superoxide production in diabetic 
mice, which corrected defective ischemia-induced neovascularization.119 In the original 
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model uncoupling of mitochondria is indicated as a major source of superoxide generation. 
However, it should be kept in mind that in addition to uncoupled mitochondria several other 
mechanisms could generate reactive oxygen intermediates (ROI). In particular the activation 
of NADPH oxidases has been indicated as an important contributor to ROI stress,120,121
while also uncoupling of eNOS contributes to the generation of superoxide.122
4.2 Pseudohypoxia   
To explain various changes in hyperglycemia-exposed endothelial cells, such as enhanced 
TGF-? expression and collagen synthesis, Williamson et al.123 postulated that 
pseudohypoxia occurred in endothelial cells. In support of this concept, the transcription 
factor HIF-1? is increased when angiotensin II stimulates endothelial cells in the presence of 
high glucose concentrations.124 It is likely that superoxide and glycosylation do not affect 
HIF-1? itself, but enzymes that regulate its stability, in particular proline hydoxylases.125
Such mechanism may result in enhanced production of important factors in diabetes, such 
as VEGF and TGF-?.
4.3 Hyperglycemic memory 
A common feature of all above-mentioned pathways is their reversible nature, once 
hyperglycemia is corrected. However, the progression of microvascular complications after 
euglycemia was established again in dogs led to the hypothesis that the mechanisms 
associated with hyperglycemia have an irreversible nature causing persistence of vascular 
damage, the so-called hyperglycemic memory.126,127 This phenomenon has been confirmed 
in man.118,128 Two mechanisms have been hypothesized to explain this phenomenon. First, 
the generation of irreversible advanced AGEs, the products of non-enzymatic glycation of 
proteins and nucleotides. In addition to their aforementioned effects, AGE-mediated cross-
linking of collagens contributes to long-lasting arterial stiffness. As the visco-elastic artery 
dampens the pressure wave that is transferred to the periphery after every heart beat, 
arterial stiffness increases the force with which this pulse arrives in the microvessels of the 
extremities, with potential damaging effects in e.g. small resistance vessels in the legs. 
Second, enduring effects of oxidative stress induced by hyperglycemia have been proposed 
to induce enduring inflammatory activation.120,121,129 Recently Forbes et al.130 suggested that 
oxidative stress might also affect the methylation of specific proteins and thus contribute to 
hyperglycemic memory. 
 Taken together, hyperglycemia causes activation of endothelial cells by various 
pathways resulting in endothelial dysfunction and vascular disease, in particular 
microangiopathy and arterial stiffness. Normalization of glucose levels is necessary to 
counteract these effects, but hyperglycemic memory causes a delay in the effectiveness of 
this treatment in reducing variable dysfunctions and complications.  
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5.  Endothelial Dysfunction in type 2 Diabetes 
 
Type 2 diabetes can be characterized by insensitivity to insulin-mediated glucose uptake 
which in combination with impaired beta cell function increases circulating blood glucose. 
Blood vessels of patients with type 2 diabetes131 and diabetic mice132,133 show attenuated 
endothelium dependent vasodilatation, which is caused by attenuation of NO production and 
decreased NO sensitivity of the smooth muscle cells, enhanced breakdown of NO by 
reactive oxygen species, decreased Akt phosphorylation and enhanced vasoconstrictor 
tone.131 Although the precise origins of endothelial dysfunction in type 2 diabetes remain 
unclear, several studies have suggested that endothelial and vascular dysfunction initiates 
well before the occurrence of overt hyperglycemia. Impairment of endothelium-dependent 
vasodilation has been reported in first degree relatives of type 2 diabetes subjects134,135 and 
subjects with impaired glucose tolerance.134 
 
 
5.1 Dyslipidemia 
In addition to hyperglycemia, dyslipidemia and chronic inflammatory activation of adipose 
tissue and the arterial wall are hallmarks of type-2 diabetes and its vascular 
complications.136 Triglyceride-rich lipoproteins are usually elevated and contribute to 
increased levels of non-esterified fatty acids (NEFA) in the circulation. Remnants of 
triglyceride-rich lipoproteins can affect endothelial cells directly via activation of the receptor 
LOX-1, by which they stimulated NAD(P)H oxidase-dependent superoxide formation and 
induced cytokine release and apoptosis in endothelial cells in vitro.137 NEFA also can 
activate endothelial cells (see below). Furthermore, triglyceride-rich lipoproteins and their 
remnants, as well as (oxidized) cholesterol-delivering low density lipoproteins (LDL), can 
activate endothelial cells indirectly as they contribute to lipid accumulation in macrophages 
and subsequently the production of inflammatory cytokines and oxidized products138-140 LDL 
oxidation can occur within the oxidative milieu of an inflamed vessel wall, after which 
oxidized products can damage or activate vascular cells and induce expression of leukocyte 
adhesion molecules on the endothelium.139,141 As type 2 diabetes patients have smaller LDL 
particles, their passage through the arterial endothelium will be increased, by which they can 
contribute more to cholesterol delivery into the arterial wall. This accumulation is aggravated 
by a reduction in cholesterol-removing HDL particles, which is generally observed in the 
plasma of type 2 diabetes patients. In addition to effects on the arterial wall, the altered 
circulating lipids in type 2 diabetes contribute to lipid loading and inflammatory activation of 
adipose tissue and production of adipokines with subsequent vascular effects, as further 
explained below.  
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5.2 Genetic predisposition to the development of type II diabetes 
In “the thrifty gene” theory of Neel142 a genetic selection for food storing is suggested which 
in today’s western lifestyle predisposes to the development of obesity and diabetes. Studies 
with ob/ob mice with obesity due to leptin deficiency, and db/db, mice with type 2 diabetes 
and obesity due to a defective leptin receptor, support this hypothesis. Heterozygeous 
animals, ob/+ and db/+, survived longer during fasting.143 Mutations in the leptin receptor in 
humans have been described to be associated with the development of obesity144 and to be 
expressed in the vasculature.145 Leptin-deficient ob/ob mice have impaired endothelial 
dysfunction, which is restored after leptin administration through a mechanism in which 
leptin enhances NO release from the endothelium.146 Db/db mice147 and fa/fa zucker rats,148
both with defective leptin receptors, also showed endothelial dysfunction. Furthermore, the 
fa/fa rats show a selective resistance to insulin signaling, in particular a selective resistance 
to activation of PI3 kinase, which normally is involved in NO production.149 These data point 
to comparable mechanisms involved in endothelial dysfunction in type 2 diabetes and 
obesity. 
         Other interesting candidates in the genetic predisposition of endothelial function in 
type 2 diabetes are proteins from the insulin signaling pathway, e.g. insulin receptor 
substrates (IRS), eNOS but also newly discovered proteins present in the vascular 
endothelium like PKC? and PPAR?. Polymorphisms in IRS proteins are associated with 
insulin resistance150 and disrupted IRS phosphorylation in endothelial cells leading to 
decreased NO production.151 However the exact role of IRS in endothelial dysfunction in the 
microvasculature is not completely clear. PKC? has recently been discovered in the 
vascular endothelium of mice and humans, and is involved in disturbed insulin-mediated 
vasoreactivity induced by fatty acids.152 PKC? KO mice are protected from acute fatty acid-
induced insulin resistance153 and an overactive PKC? gene could be involved in endothelial 
dysfunction in type 2 diabetes. PPAR? has mostly been known for regulating adipogenesis 
and lipid metabolism,154 but has also been described to be present and active in vascular 
endothelium.155 Interference with PPAR? signaling produces endothelial dysfunction via a 
mechanism involving oxidative stress and causes vascular hypertrophy and inward 
remodelling.156 The observation of regulating insulin signaling by NEFA and PKC?
additionally points to a relation between fatty acid-induced activation of PKC? and 
endothelial dysfunction in obesity and diabetes. 
5.3 Impaired insulin signaling and ER stress 
Insulin resistance and reduced insulin signaling are associated with endothelial dysfunction. 
The defective insulin signaling causes inadequate production of NO and endothelin-1 (ET-
1). In the resting pre-prandial state, the vasodilator and vasoconstrictor effects of insulin are 
in balance and insulin adapts this balance to the demands of the the body to produce either 
more NO, causing vasodilatation, or more ET-1, causing vasoconstriction. However, in 
obese states the balance of vasodilatation and vasoconstriction is shifted towards 
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vasoconstriction. In obese rats, these signaling pathways are differently affected: insulin-
mediated activation of the Akt and NO pathway is impaired, but insulin-mediated activation 
of ERK1/2 and ET-1 is intact.149 Accordingly, we have recently found that insulin induced 
ET-1 dependent vasoconstriction in skeletal muscle arterioles of obese rats.148 Experimental 
studies in healthy rats demonstrate that ET-1 infusion in vivo severely blunted the increased 
capillary recruitment and limb blood flow caused by insulin.157 
       How insulin signaling becomes impaired in the vascular endothelium is still poorly 
understood. In type 2 diabetes, endoplasmic reticulum stress (ER stress) may be a plausible 
link between insulin resistance and endothelial dysfunction. 
               In non-endothelial cells (liver, adipose tissue, pancreas) and intact mice it has 
been reported that a so-called unfolded protein stress or ER stress is involved in disturbed 
insulin signalling.158 Increases in protein synthesis, enhanced generation of reactive oxygen 
intermediates and other aspects of metabolic stress can cause ER stress, which evokes a 
series of reactions that result in changes in the translation of proteins, activation of JNK (Jun 
kinase) and IKK (I?B kinase) and induction of new, often inflammation-related genes (see 
159,160 for reviews on ER stress). This results simultaneously in a reduction of IRS-1-
mediated insulin signaling and a state of low-degree inflammatory activation (Fig 3).158,161 
not only pointed to the potential role of ER stress as a link between obesity, insulin 
resistance and diabetes, but also demonstrated in mice that reduction of ER stress by 
chemical chaperones could restore glucose homeostasis in type 2 diabetes. Endothelial 
cells have a high protein synthesis capacity, are maximally exposed to elevations of 
nutrients in the blood, contain all the key proteins involved in ER stress,162 and have been 
shown indeed to display ER stress after exposure to oxidized phospholipids163 or 
homocysteine.164 Therefore, it is highly likely that ER stress contributes to reduced NO 
availability and increased expression of leukocyte adhesion molecules that accompany 
endothelial dysfunction.  
 
Figure 3. Simplified scheme of how ER stress can contribute to endothelial dysfunction in type 2 diabetes. In 
various cells the accumulation of unfolded proteins in the endoplasmic reticulum (ER stress) can activate the proteins 
(inositol-requiring 1?) IRE, (double-stranded RNA-dependent protein kinase (PKR)-like ER kinase) PERK and 
(activating transcription factor 6) ATF6 in the ER membrane and cause various effects resulting in altered gene 
induction, protein translation and cell signaling (see 159,160 for reviews). Activated by ER stress, IRE starts to 
phosphorylate Jun kinase (JNK), which induces a disturbed insulin signaling in endothelial cells by inhibiting IRS1 by 
phosphorylation at ser307, and I?B kinase (IKK), which leads to activation of NF?B and inflammatory activation. This 
causes a reduced NO production by endothelial cells.           
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Moreover, Eringa et al.165 showed that JNK can be activated by TNF? in the endothelium of 
skeletal muscle arterioles of rat and causes a reduced vasodilatory response to insulin. It is 
thought that JNK can phosphorylate serine-residues on IRS-1 and therewith reduce the 
ability of insulin to phosphorylate tyrosine residues on IRS-1, which becomes manifest as 
insulin resistance.166,167 As a consequence insulin-mediated AKT activation and NO 
production were impaired. As TNF? can induce ER stress in other cells,168 TNF?-induced 
activation of JNK in endothelial cells may also involve activation of the ER stress signaling 
pathway. Figure 4 shows a simplified scheme of how ER stress can affect endothelial cells, 
comparable to other cell types. The precise role of ER stress in endothelial dysfunction in 
type 2 diabetes is a challenging new field that needs to be further underpinned.  
           The involvement of ER-stress may be complex. Uncoupling of eNOS and subsequent 
generation of peroxynitrite as well as exposure to inflammatory mediators, such as TNF?,
can cause ER stress.168,169 However, ER stress may also facilitates eNOS impairment and 
TNF? generation. Therefore, it is likely that a mutual interaction exists between factors that 
cause ER stress and factors that are generated by ER stress. This can cause a type of cell 
activation that is self-perpetuating and therefore is difficult to normalize. Particularly the 
growth and displacement of adipose tissue and adipokines derived thereof can markedly 
enhance endothelial activation and dysfunction. 
5.4 Obesity and endothelial dysfunction 
Obesity is an independent risk factor for coronary170 and systemic29 endothelial dysfunction, 
which are detectable before the onset of diabetes.171 Impaired vasodilator responses at the 
level of the resistance vessels of  the nutritive capillary beds develops progressively along 
with an increase in adiposity.172-174 The close association between measures of adiposity 
and microvascular function suggests communicative pathways between adipose tissue and 
the microvasculature. Obesity, in particular visceral obesity, is strongly associated with 
insulin resistance.175 Therefore, the presence of endothelial dysfunction in obese subjects or 
animal models might be related to the insulin-resistant state. However, a possible role of
obesity in inducing endothelial dysfunction before the development of and independent of 
insulin resistance has been suggested in a rat model of diet-induced obesity.176 We recently 
hypothesized that perivascular fat has an important effect on endothelial vasoregulation in 
diabetes and obesity. To better understand the effect of perivascular fat on endothelial 
function and vasoregulation, we shall briefly survey inflammation and adipokine production 
by adipose tissue.  
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5.5 Obesity and inflammation 
Changes in the regulation of nutrient metabolism in obesity, promote nutrient storage in 
adipose tissue.177 This change in nutrient metabolism rather than steady-state glucose and 
insulin concentration causes a pro-inflammatory state in adipose tissue. Adipose tissue 
exhibits distinct secretory profiles that depend on adipose tissue mass. The secretion of a 
number of bioactive molecules such as NEFAs, TNF?, interleukin-6 (IL-6), 
angiotensinogen,178,179 and plasminogen activator inhibitor type 1,180,181 is significantly 
increased in adipose tissue from obese animals and humans. In contrast, the production of 
adiponectin, a hormone that increases fatty acid oxidation and inhibits hepatic glucose 
production, is diminished.182,183 Of note, weight loss as a result of lifestyle changes is 
associated with a reduction in the plasma levels of inflammatory markers such as IL-6, IL-
18, and C-reactive protein, as well as an increase in the circulating concentration of 
adiponectin.184 These observations strongly support the notion that the production of 
adipose-derived signals are regulated at least partly by the adipose tissue mass. 
Inflammation in adipose tissue, as observed in obesity, is characterized by an increased 
size and number of fat cells and predicts the number of macrophages in adipose tissue.185-
187 In obesity, 50% of adipose tissue consists of macrophages and the size of fat cells is 
approximately 120 ?m, compared to 5-10% macrophages and a fat cell size of 70 ?m in 
adipose tissue of lean mice.187-189  Inflammation in adipose tissue is probably initiated by the 
secretion of low amounts of TNF?, which stimulate pre-adipocytes to produce MCP-1 
resulting in recruitment of macrophages190,191 and a changed excretion profile (Fig 4). 
Figure 4. Inflammation of adipose tissue and altered secretion of adipokines. Inflammation in adipose tissue is 
probably initiated by the secretion low amounts of TNF?, as a consequence of e.g. changes in membrane-cholesterol 
of in size increased adipocytes. TNF? is able to regulate the secretion of other adipokines, by stimulating pre-
adipocytes to produce MCP-1 and subsequently the recruitment of macrophages.275,276 Subsequently, TNF? creates a 
hierarchy of cytokines within adipose tissue277,278 and will change the excretion profile of adipose tissue into a pro-
inflammatory state. This is indicated as increased letter size of the indicated adipokines in the figure. 
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5.6 Adipokines 
Adipose tissue secretes a variety of adipokines, such as fatty acids, TNF?, leptin, 
adiponectin (and likely many more)  that modulate vascular tone, nutritive blood flow and 
insulin sensitivity. These adipokines alter smooth muscle contractility both directly and 
indirectly, by interacting with endothelium-dependent vasodilation. 
 
Non-esterified fatty acids (NEFA) impair endothelium dependent vasodilation in conduit 
arteries192,193 as well as the microcirculation,194 insulin-mediated capillary recruitment and 
glucose uptake of humans and rats.194,195 Insulin-mediated nutritive blood flow is blunted by 
lipid infusion, and this effect correlates very well with inhibition of insulin-mediated muscle 
glucose uptake.195 While data from isolated rabbit femoral arteries has suggested that NEFA 
directly decrease eNOS activity,193 evidence from aortic endothelial cells has shown that  
NEFA also inhibit insulin-mediated activation of Akt and eNOS.196 Indeed, we have recently 
found in muscle resistance arteries that the fatty acid, palmitic acid, induce insulin-mediated 
vasoconstriction of muscle resistance arteries at concentrations observed in obesity, 
through the inhibition of insulin-mediated activation of Akt and eNOS.  PKC? plays an 
important role in this interaction.197 This study suggests a direct interaction between FFA 
and insulin in the muscle microcirculation, leading to vasoconstriction of muscle resistance 
arteries. We propose that NEFA shift the balance of insulin’s vasoactive effects towards 
insulin-mediated vasoconstriction in skeletal muscle arterioles (Fig 5), which causes a 
reduction in blood flow and capillary perfusion, which results in a decreased glucose delivery 
and uptake in muscle.  
Figure 5. Effect on insulin 
signaling by TNF? or 
NEFA. Normal insulin 
signaling is mediated by 
either insulin receptor 
substrate (IRS), Akt, eNOS 
and NO production leading 
to vasodilation or by 
ERK1/2 and ET-1 
production leading to 
vasoconstriction. TNF? and 
NEFA affect the insulin 
signaling pathway by the 
activation of JNK or PKC?, 
leading to impaired Akt 
activation induced by TNF? 
and NEFA, and increase in 
ERK1/2 activation by NEFA, 
which both leads to insulin-
mediated vasoconstriction 
in muscle resistance 
arteries. 
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TNF? release by adipose tissue is increased in obesity.198 Based on animal and in vitro 
data, TNF? has been proposed to reduce endothelial NO production, to impair insulin-
stimulated glucose uptake in skeletal muscle, impair capillary recruitment,199 impair insulin-
mediated vasodilation in muscle resistance arteries200 and reduction of NO production in 
aortic endothelial cells.201,202 Several proteins have been shown to mediate the interaction 
between TNF? and insulin, such as p38 mitogen-activated protein kinase,202 c-jun N-
terminal kinase (JNK)165 and I?B kinase (IKK).201 A new source of TNF? that has recently 
been identified is perivascular adipose around coronary arteries.203 This implies that TNF? 
is produced by tissue directly adjacent to the vascular wall and may mean that circulating 
levels of TNF?, which remain very low in obesity,204 underestimate the biologically relevant 
concentrations of this cytokine. 
 
Leptin was the first endocrine product of adipose tissue to be identified205 and has recently 
been found to regulate vascular function through local206,207 and central208 mechanisms. 
Leptin is a vasodilator in coronary arteries209 and in human forearm resistance arteries210 
through endothelium-dependent211 and endothelium-independent mechanisms.212 A direct 
interaction between leptin and insulin has been shown in aortic endothelium. In a synergistic 
mechanism, leptin and insulin were shown to enhance NO production by phosphorylation 
eNOS at Ser1177.213 In contrast to these vasodilator effects, leptin also increases 
sympathetic nerve activity214,215 and enhances ET-1 release from vascular endothelium.216 
Paradoxically, circulating leptin levels are elevated in obesity, apparently contradicting the 
beneficial effects of leptin described above. To explain this, recent studies have 
demonstrated impairment of leptin’s metabolic effects and to leptin-induced nitric oxide 
production, i.e. “leptin resistance”, in obesity217,218 and human hypertension.219 Leptin 
resistance may be caused by inflammatory mechanisms, as CRP impairs intracellular leptin 
signalling.220,221 Therefore, resistance to vasodilator effects of leptin may contribute to 
vascular dysfunction in obesity. 
 
Adiponectin has recently emerged as an adipose tissue-derived modulator of endothelial 
function. Adiponectin increases NO production in vascular endothelium by increasing 
phosphorylation of eNOS at Ser1177,222,223 inhibits endothelial cell activation222,224,225 and 
associates negatively with risk of a cardiovascular event.226 In obesity adiponectin levels are 
decreased,227 contributing to impaired vascular function.228 In the coronary circulation, 
adiponectin produced by epicardial adipose tissue regulates the cardiac flow reserve.229  
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5.7 Local versus systemic adipokine secretion 
Obesity related consequences, like insulin resistance and endothelial dysfunction, are 
dependent on the location of fat accumulation. For example, abdominal adipose tissue 
contains more monocytes and macrophages than the subcutaneous depots. Morphological 
studies revealed substantial differences between not-obese subcutaneous and intra-
abdominal fat depots. Macrophages were found in direct contact with matured adipocytes in 
abdominal AT.230 Moreover, adipose tissue from obese mice show adipocytes with an 
increased size and clusters of small nucleated cells compared to not-obese mice. These 
small nucleated cells form giant cells by fusion of multiple macrophages, which is also 
observed in instances of chronic inflammation.231 Furthermore, waist to hip ratio, a measure 
of abdominal fat accumulation, is correlated with CVD and inflammatory factors, like 
TNF?.232,233 In population studies, it has been proposed that an increased waist-to-hip ratio
may reflect a relative abundance of abdominal fat (increased waist circumference) and 
peripheral muscle atrophy (decreased hip circumference).234 The abundance of abdominal 
AT is associated with macrophage infiltration and cytokine production.235 The peripheral 
muscle atrophy is associated with a low glucose uptake in muscle and a decrease in insulin 
clearance.236
Local adipokine secretion causes a local high concentration of inflammatory 
products, which is often miscalculated due to inability to measure locally but predicts 
inflammation by systemic inflammation markers. However, increasing fat pads around 
insulin responsive organs like the vasculature, skeletal muscle and cardiac tissue cause 
local high concentrations of adipokines, which may have huge effects on insulin signaling.  
Perivascular adipose tissue (PAT) is present around all conduit arteries and in some 
microvascular beds, such as that of the mesentery.237 We observed that PAT round skeletal 
muscle arterioles is increased in a diabetic mouse model (Fig 6). Recent evidence has 
shown that the vascular adventitia and especially PAT regulate vascular tone238,239,
endothelium-dependent vasodilatation,240 vessel wall thickness,241 angiogenesis242,243  and 
inflammation.244-246  Skeletal muscle is responsible for the majority of whole-body insulin-
stimulated glucose disposal and therefore a relevant target tissue in obesity and type 2 
diabetes. The accumulation of adipose tissue interspersed within skeletal muscle and 
triglycerides within muscle cells are related to insulin resistance, at least in sedentary 
subjects. Healthy muscle is characterized by the capacity to utilize either lipid or 
carbohydrate fuels and to switch effectively between these fuels depending on the stimulus 
and the energy demands. The inflexibility of skeletal muscle to switch between fat and 
glucose fuels appears to be an important aspect of insulin resistance of skeletal muscle in 
obesity and type 2 diabetes.247
 Taken together, systemic measurements of circulating adipokines are likely a 
underestimation of the actual concentration and damaging effects of local produced 
adipokines.  
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5.8 Endothelial dysfunction, type 2 diabetes and hypertension 
Endothelial dysfunction and type 2 diabetesare accompanied by cardiovascular disorders, 
such as peripheral and coronary arterial disease due to atherosclerosis, hypertension and 
stroke. Endothelial injury reflected in endothelial dysfunction has been indicated as an early 
hallmark of the development of atherosclerosis27 as well as hypertension.248 It affects the 
development of type 2 diabetes, while the metabolic disturbances of type 2 diabetes in turn 
further aggravate the progression of these diseases. Similarly, obesity contributes to 
endothelial dysfunction and metabolic alterations that further accelerate the vascular 
diseases and occurrence of their clinical complications.  
Obese, hypertensive humans show an insulin-induced vasoconstriction249 as well as 
increased ET-1–dependent vasoconstrictor tone and decreased NO-dependent vasodilator 
tone at the level of the resistance arteries.250 In hypertension, the structure and function of 
the microcirculation are altered.251 Blood pressure is inversely related to insulin sensitivity 
and capillary recruitment, a consequence of reduced endothelium-dependent vasodilatation 
at the precapillary level.174 Infusion of endothelin-1 in vivo blunted capillary recruitment and 
limb blood flow caused by insulin157  and resulted in an increased blood pressure and 
reduced muscle glucose uptake. In addition, insulin resistance in spontaneously 
hypertensive rats is associated with endothelial dysfunction characterized by imbalance 
between NO and ET-1 production.252 
 
 
Figure 6. Increased 
local perivascular 
adipose tissue in 
skeletal muscle 
arterioles of Db/Db 
mice. After dissecting the 
gracilis muscle, the 
vasculature of the 
corresponding muscle in 
the control and Db/Db 
mice (b and e, with scale 
bar of 1mm) becomes 
visible. At a higher 
magnification the artery 
and vene can be 
distinguished (c and f, 
with scale bar 0f 0.25 
mm). The Db/Db mice (d-
f) contain more and larger 
fat cells surrounding the 
gracilis artery compared 
to control mice (a-d).  
A:artery, V:vene, F: 
femoral artery. 
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Conclusion 
Endothelial dysfunction contributes to the generation of insulin resistance and subsequent 
vascular complications of type 2 diabetes. The close interaction of adipocytes with arteries 
and arterioles facilitates the exposure of endothelial cells to adipokines, particularly when 
inflammation activates the adipose tissue, and thus affects vasoregulation and capillary 
recruitment in skeletal muscle.
6.  Does Endothelial Dysfunction precede Insulin        
     Resistance in type II Diabetes and Obesity? 
Dyslipidemia and circulating NEFA aggravate type 2 diabetes and its cardiovascular 
sequelae.136 Interestingly, several lines of evidence point to a causal role of endothelial 
function in insulin resistance, particularly in muscle. However, the discussion about the 
causal relation between type 2 diabetes and endothelial dysfunction is complicated on the 
one hand by the fact that various endothelial dysfunctions, namely reduced NO production 
and vasodilation, microalbuminuria, elevated plasma vWF, and low grade inflammatory 
activation accompanied by increased circulating VCAM and C-reactive protein, are 
independently associated with risk of cardiovascular complications in patients with diabetes 
and glucose intolerance.77 On the other hand, it is likely that endothelial dysfunction(s) and 
metabolic dysregulation in these patients act mutually on each other, so that the chicken 
and egg question will be difficult to solve. Notwithstanding, several arguments indicate that 
endothelial dysfunction as reflected by impaired vasoregulation indeed can contribute to 
reduced insulin sensitivity in skeletal muscle tissue.  
Muscle insulin resistance is the main contributor to impaired insulin actions and 
impaired glucose uptake and thereby increased blood glucose levels. Skeletal muscle 
accounts for  approximately 80% of the insulin-mediated glucose uptake (IMGU) after a 
meal253 and becomes resistant to insulin in type 2 diabetes and obesity.254 Interference with 
endothelial NO production results in an impaired insulin sensitivity in striated muscle in both 
mice and rats.255,256 Furthermore, in obesity, elevated plasma NEFA impair the ability of 
insulin to stimulate muscle glucose uptake.195 NEFA also have major effects on 
microvasculature. NEFA activate PKC? in the endothelium of resistance arteries and 
thereby induce insulin-mediated vasoconstriction.197 Other studies showed that lipid infusion 
impairs capillary recruitment194 and glucose uptake in muscle.195 So both NO production and 
response to NEFA by endothelial cells can cause a defect of muscle glucose uptake by an 
impairment of the microcirculation leading to vasoconstriction. There are several other 
reports showing a blunted endothelial response before the onset of type 2 diabetes and also 
reports showing a reversal effect of endothelial function after restoring insulin sensitivity in 
e.g. obesity-associated insulin resistance. One report showed that vascular reactivity 
(responses to acetylcholine and sodium nitroprusside) in both microcirculation and 
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macrocirculation were not only reduced in diabetic subjects, but also in insulin resistant 
subjects and relatives of diabetic subjects without increased levels of insulin or glucose. 
These data support the concept that endothelial dysfunction predicts the development of 
insulin resistance and diabetes. In addition, elevated plasma levels of biomarkers reflecting 
endothelial dysfunction, like E-selectin, ICAM-1, and VCAM-1 were powerful independent 
predictors of type 2 diabetes in initially healthy people.257  
The mechanisms by which endothelial dysfunction and sub-clinical inflammation 
may lead to the development of type 2 diabetes are not completely clear. It has been 
suggested that endothelial dysfunction may decrease insulin-mediated capillary recruitment 
and microvascular redistribution of skeletal muscle blood flow from non-nutritive to nutritive 
flow paths, limiting insulin availability to skeletal muscle as well as insulin delivery to the 
interstitium. Whatever the mechanism may be, the fact that an improvement in endothelial 
dysfunction can lead to a decrease in insulin resistance and perhaps to a reduction in the 
incidence of type 2 diabetes has already been appreciated in the secondary analyses of 
some trials using medications known to improve vascular function.258,259   
Taken together, both metabolic and vascular effects contribute to the development 
of type 2 diabetes. Notwithstanding a mutual interaction of these aspects during the etiology 
of diabetes, initial dysfunction of endothelium function contributes to this process, even prior 
to the increased hepatic glucose production (Fig 7). 
 
 
 
 
Figure 7. Endothelial 
dysfunction versus type 
2 diabetes.  Mutual inter-
action of metabolic and 
vascular effects contribute 
to the development of type 
2 diabetes, which can be 
initiated by either hyper-
glycemia, genetic factors, 
obesity or other unidentified 
factors. One possible route 
through which endothelial 
dysfunction result in type 2 
diabetes is showed in A-B-
C-D, in which impaired 
endothelial vasodilation 
results in impaired capillary 
recruitment, impaired glu-
cose uptake with increased 
levels of glucose as a 
result. A possible route in 
which type 2 diabetes 
result in endothelial 
dysfunction showed in 1-2-
3 is through the formation 
of reactive oxygen 
intermediates produced 
from the glycation pathway.   
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7.   Conclusion and Perspectives
From the foregoing discussion it will be clear that endothelial dysfunctions are associated 
and often causally related to the vascular complications of type 1 and/or 2 diabetes and 
insulin-resistance associated with obesity, in particular those related to improper generation 
of ROI, reduced availability of NO after stimulation by insulin and other vasoactive agents, 
and low-grade inflammatory activation of the endothelium, and altered composition of the 
extracellular matrix. 
Hyperglycemia 
Hyperglycemia is an important causal factor in endothelial dysfunction and plays a dominant 
role in the complications of type 1 diabetes, in particular the development of nephropathy, 
retinopathy, neuropathy associated with the diabetic foot, as well as in the occurrence of 
arterial stiffness. Part of the effects of hyperglycemia is long lasting, which give affected 
tissues some kind of hyperglycemic memory. Early detection of hyperglycemia and control 
of plasma glucose level are important for reducing hyperglycemia-induced vascular 
complications.  
While normalization of insulin secretion and improvement of the circulation glucose 
levels, by pharmacological treatment or pancreatic island transplantation, is the prime 
approach to reduce the complications of hyperglycemia, the inefficacy of current methods 
and the hyperglycemic memory urge to look for additional treatments. ROI overproduction 
from mitochondrial electron transport chains, serves as a causal link between elevated 
glucose and three major pathways responsible for hyperglycemic damage, namely 
activation of the hexosamine pathway, increased formation of AGE and activation of PKC 
isoforms. One possible way to reduce ROI is the detoxification of superoxide radicals by 
increasing superoxide dismutase (SOD). A recent study in mice with an overexpression of 
SOD in endothelial cells showed a suppression of the progression of diabetic retinopathy in 
vivo, by reducing expression of VEGF and fibronectin.260 Other ways of scavenging ROI or 
inhibiting ROI generating NADPH oxidase in vascular cells are presently evaluated. Another 
option to reduce hyperglycemia effects is reduction of gycolysis intermediates by 
bezotiamine, which appeared effective in the mouse eye, or by interfering with specific 
pathways in the endothelial cells. Inhibition of VEGF in the eye appears promising, while 
reduction of PKC activation and inhibitors targeted to AGE production reduce vascular 
complications in diabetic rodents, but have not been proven to be effective in man.  
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Impaired insulin signaling 
Although also important in type 2 diabetes, normalization of the plasma glucose 
concentration had only a relatively small effect on the reduction of cardiovascular disease 
(peripheral and coronary atherosclerosis, hypertension and stroke), suggesting that other 
factors have a larger impact. As outlined in chapters 5 and 6 improper functioning of the 
endothelium and blood supply to tissues, such as muscle, has a profound effect on insulin 
sensitivity of these tissues, and contributes to insulin resistance. In the subsequent chain of 
reactions that end with overt type 2 diabetes a mutual interaction between metabolic 
dysregulation and vascular dysfunction occurs, which is additionally fueled by genetic or 
acquired dyslipidemia. Normalization of metabolic control and endothelial/vascular function 
are therefore both required. Furthermore, we pointed to the importance of adipose tissue to 
vascular functioning. In particular, extension of perivascular fat directly adjacent to the 
arterioles and arteries and the enhanced production of adipokines by inflammation of this 
adipose tissue provide a new paracrine system with a high competence of inducing insulin 
resistance in the skeletal muscle. It will be of interest to know whether and how the extent 
and activity of this perivascular fat is influenced by diet and exercise, two important factors 
in influencing insulin sensitivity. 
Various drugs are used to improve insulin sensitivity. In addition to drugs that aim 
at restoring pancreatic function and normalization of blood glucose, ACE inhibitors and 
PPAR-? agonists, like thiazolidinediones (TZD), are regularly used to treat diabetes mellitus 
type II. ACE inhibitors reduce the conversion of angiotensin 1 into the potent angiotensin 2 
and simultaneously reduce the breakdown of the vasoactive agent bradykinin. These 
inhibitors have an improving effect on nephropathy and cardiovascular complications in all 
diabetes patients. The main beneficial effects of TZD are the improvement of insulin 
sensitivity and glucose tolerance, the generation of small insulin sensitive adipocytes and a 
decrease in inflammation markers.261,262 TZDs lead to an improvement in vascular function 
through either a direct effect on the vascular wall or by reducing the release of adipokines by 
adipose tissue.263 Statins, which in addition to lowering plasma LDL cholesterol, also reduce 
ROI production in endothelial cells and improve endothelial function, are also shown to 
reduce cardiovascular disease in diabetes patients.264  
Another way to improve insulin sensitivity is to inhibit the negative effects of 
adipokines on the induction of insulin-mediated vasoconstriction. In isolated arteries we 
showed that the insulin-mediated vasconstriction induced by either TNF? or free fatty acids 
can be abolished by the inhibition of JNK or PKC? activation respectively.165,197 
Furthermore, mice models with a genetic deletion of JNK or PKC? were protected from diet-
induced insulin resistance. This makes JNK and PKC? good targets to improve insulin 
sensitivity. 
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Obesity and endothelial dysfunction 
As obesity contributes to insulin resistance and endothelial dysfunction reduction of 
circulating NEFA and weight loss by diet and/or exercise, or surgery can be used to improve 
endothelial function in obesity. Overnight lowering of FFA in obese women improved 
capillary recruitment, independent from endothelial dependent vasodilation, whereas FFA 
elevation in lean subjects impaired both capillary recruitment and endothelial vasodilation.265
So only an acute reduction in FFA levels is not sufficient to improve endothelial function. In 
contrast, weight loss is associated with reduction of long-term total mortality of particularly 
deaths from diabetes and heart disease,266 an improvement of insulin sensitivity, decrease 
in insulin production267 and an improvement of flow mediated vasodilation.268 Most studies 
on the effect of weight loss by either a low caloric diet,269,270 diet and exercise,271 or diet and 
medication272 showed positive effects on endothelial dysfunction. Furthermore, Woo et al 
showed that improvement in arterial endothelial function was greater in the diet and exercise 
group compared with the diet alone group, due to an independent effect of exercise training 
on improved arterial function.273 That exercise has a positive effect on endothelial function 
has well been recognized and the additional improvement in endothelial function by diet and 
exercise is therefore not surprising.  Even in hyperglycaemic obese mice, which have total 
blunted endothelial response from birth, exercise reverses vascular endothelial 
dysfunction.274
Taken together, the effect of adipokines from adipose tissue adjacent to the vessel 
wall is an important contributor to endothelial dysfunction and the understanding of 
intervention at the level of adipocytes and/or endothelial cells may improve the treatment of 
metabolic disorders. 
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ABSTRACT 
 
Obesity is associated with insulin resistance, hypertension and cardiovascular disease, but 
the mechanisms underlying these associations are incompletely understood. Microvascular 
dysfunction may play an important role in the pathogenesis of both insulin resistance and 
hypertension in obesity. Adipose tissue-derived substances (adipokines) and especially 
inflammatory products of adipose tissue control insulin sensitivity and vascular function. 
Recently, adipose tissue associated with the arterial tree, called perivascular adipose tissue 
(PAT) has been shown to produce a variety of adipokines and to trigger vascular 
inflammation. This review summarizes the mechanisms linking adipose tissue to 
(micro)vascular function, inflammation and insulin resistance with a special focus on the role 
of PAT in the regulation of vascular tone, endothelial function, inflammation and insulin 
sensitivity. 
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1. Introduction 
 
Obesity is an increasingly common condition1 that is associated with insulin resistance,2 i.e. 
impairment of insulin-mediated glucose uptake, and endothelial dysfunction.2 The 
mechanisms underlying these associations are incompletely understood. Recent studies 
have suggested that endocrine products of adipose tissue regulate insulin-mediated glucose 
uptake and vascular function.4-7 These products, called adipokines (originally called 
adipocytokines or adipose tissue-derived cytokines), comprise a heterogeneous group of 
substances including non-esterified fatty acids (NEFA),8 cytokines (i.e. TNFα5,73 and IL-64), 
chemokines (i.e. IL-85 and MCP-111) and hormones (i.e. leptin12 and adiponectin13). 
Inflammation of adipose tissue, particularly abdominal adipose tissue, has been proposed to 
contribute to obesity-related insulin resistance and vascular dysfunction in obesity.5,14 We 
and others have proposed that microvascular dysfunction plays an important role in the 
development of insulin resistance as well as hypertension,6 as microvascular dysfunction will 
impair muscle blood flow and thereby muscle insulin sensitivity, but may also increase 
vascular resistance through vasoconstriction of resistance arteries.16 
In this review, we will discuss the regulation of vascular function by adipose tissue 
and its relevance to obesity-related vascular dysfunction and insulin resistance, with a 
special focus on perivascular adipose tissue. First, we will discuss the relationships between 
impairment of microvascular function, inflammation of adipose tissue and insulin resistance. 
Second, we will review the products of adipose tissue that regulate vascular function and 
inflammation. Finally, we will discuss regulation of vascular function and inflammation by 
perivascular adipose tissue.   
 
 
 
2. Regulation of Insulin Sensitivity and Inflammation 
by the Microcirculation 
 
Two functions of the microcirculation are relate to insulin resistance and vascular 
dysfunction in obesity: regulation of tissue perfusion17,18 and regulation of local 
inflammation.19,20 Local blood flow is regulated through vasodilatation and/or 
vasoconstriction of resistance arteries,7 whereas expression of adhesion molecules on 
vascular endothelium regulates local infiltration of inflammatory cells from the 
bloodstream.20,21 
Muscle perfusion is an important regulator of insulin-mediated muscle glucose 
uptake, the main determinant of whole-body insulin sensitivity.8 Insulin itself has been shown 
to increase muscle perfusion by acting directly on microvascular endothelium,9 and, in 
muscle, this effect contributes to insulin-mediated glucose uptake.10,11 In a series of elegant 
studies, the groups of Clark and Barrett have elucidated the mechanisms underlying the 
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relationship between muscle blood flow and muscle glucose uptake.18,26,27 They have shown 
that the distribution of blood flow between “nutritive” capillaries, i.e. capillaries that perfuse 
sites of high glucose uptake, and “non-nutritive” capillaries, i.e. capillaries that perfuse sites 
of low glucose uptake, regulates muscle glucose uptake.12-16 Insulin redistributes muscle 
blood flow towards nutritive capillaries and thus increases muscle glucose uptake17. This 
‘capillary recruitment’ is critically dependent on insulin-stimulated production of nitric oxide 
by the endothelial cells in the muscle microcirculation18 and is impaired by vasoconstrictor 
substances that constrict nutritive arterioles, such as serotonin.29,34  
We have shown that insulin directly increases NO activity in muscle resistance 
arteries, and that this effect of insulin is mediated by phosphatidylinositol 3-kinase (PI3-
kinase) and protein kinase B/Akt.19 In addition to this NO-dependent vasodilator effect, 
insulin increases the activity of ET-1, a process mediated by extracellular signal-regulated 
kinase 1/2 (ERK1/2).24 This balance of NO- and ET-1-dependent effects has also been 
demonstrated in the microcirculation of the human forearm.35 Importantly, insulin becomes a 
vasoconstrictor of muscle resistance arteries when insulin-stimulated NO production is 
blunted,20 mimicking the effect of serotonin.14,21 Thus, impairment of insulin-stimulated NO 
production in the muscle microcirculation results in insulin-mediated vasoconstriction, 
impairment of nutritive blood flow and lowering of insulin-mediated glucose uptake in 
muscle.  
The microcirculation of obese, insulin-resistant subjects is characterized by 
reduced production of vasodilator substances such as nitric oxide22,23,24 and endothelium-
derived hyperpolarizing factors, increased activity of vasoconstrictor substances such as 
endothelin-1 (ET-1)25 and structural narrowing of muscle resistance arteries.41 Insulin-
mediated capillary recruitment is blunted in obese, insulin-resistant rats26 and obese, insulin-
resistant human subjects,42 but the causes of impaired insulin-mediated capillary recruitment 
in muscle of obese subjects have not been elucidated. 
Key to understanding decreased nutritive blood flow in obesity may be the dual effects of 
insulin on vascular tone and its differential impairment in obesity. In insulin-resistant human 
subjects and in insulin-resistant rats, insulin-mediated activation of PI3-kinase, Akt and 
eNOS is impaired, while the activation of ERK1/2 and ET-1 by insulin is normal.27-29 
Moreover, insulin has been shown to constrict forearm resistance arteries in obese, 
hypertensive subjects,30 supporting a disturbed balance of NO and ET-1 in the muscle 
microcirculation. The causes of this impairment of insulin signaling in endothelium of obese 
subjects have not been identified.  
Obesity-related vascular dysfunction and insulin resistance may well be caused by 
altered signaling from adipose tissue to blood vessels and to muscle, as adipose tissue 
produces a large number of substances (adipokines) that affect vascular function and insulin 
sensitivity.  
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3. Regulation of Vascular Function and Insulin 
Sensitivity by Adipokines 
 
In the past years, several adipokines have been shown to alter vascular tone and vessel 
wall inflammation. These effects may be achieved by direct interaction with vascular 
endothelium, or indirectly, by enhancing monocyte infiltration into the vessel wall. Adipokines 
that act directly on vascular endothelium include TNFα,31 IL-6,48 NEFA,8,49 leptin50 and 
adiponectin,51 while MCP-1,11 IL-832 and resistin52,53 increase monocyte adhesion to 
vascular endothelium. 
The first identified cytokine secreted by adipose tissue was TNFα.5,54 Obese 
persons express markedly higher TNFα expression in adipose tissue compared to lean 
persons,5 and TNFα has been proposed to impair insulin-stimulated glucose uptake in 
skeletal muscle.33 TNFα associates with impaired capillary recruitment in man56 and directly 
inhibits insulin-mediated capillary recruitment and insulin-mediated glucose uptake in rat 
muscle.34 We have shown that TNFα directly impairs insulin’s vasodilator effects in muscle 
resistance arteries of the rat through activation of the c-jun N-terminal kinase (JNK) and 
inhibition of insulin signaling in microvascular endothelium.16 A new source of TNFα that has 
recently been identified is perivascular adipose around coronary arteries.57 This implies that 
TNFα is produced within one millimeter of the vascular endothelium and may mean that 
circulating levels of TNFα, which remain very low in obesity,5 underestimate the biologically 
relevant concentrations of this cytokine. 
Like TNFα, Non-Esterified Fatty Acids (NEFA) impair insulin-mediated capillary 
recruitment and glucose uptake of humans and rats.8,49 Insulin-mediated nutritive blood flow 
is blunted by lipid infusion, and this effect correlates very well with inhibition of insulin-
mediated muscle glucose uptake.49 Evidence from aortic endothelial cells has suggested 
that these effects of NEFA are achieved by direct inhibition of insulin-mediated activation of 
Akt and eNOS.58 Indeed, we have recently found that the fatty acid Palmitic Acid (PA) 
induce insulin-mediated vasoconstriction of muscle resistance arteries at concentrations 
observed in obesity, in which Protein Kinase C theta (PKCθ) plays an important role 
[unpublished data]. These studies suggest a direct interaction between FFA and insulin in 
the muscle microcirculation, leading to vasoconstriction of muscle resistance arteries. FFA 
shift the balance of insulin’s vasoactive effects towards insulin-mediated vasoconstriction in 
skeletal muscle arterioles, which causes a reduction in blood flow and capillary perfusion, 
which results in a decreased glucose delivery and uptake in muscle.  
IL-6 is the principal regulator of the production of C-reactive protein, an important 
marker of inflammation and established risk factor for cardiovascular disease.35 Although IL-
6 levels are related to vascular dysfunction in man,36 direct evidence demonstrating that IL-6 
impairs vascular function is scarce.60  Long term elevation of IL-6 in mice impairs endothelial 
function by increasing angiotensin-stimulated production of reactive oxygen species,60 and 
genetic deletion of IL-6 attenuates angiotensin-induced hypertension in mice.61 Other 
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studies, however, have suggested that IL-6 may be a marker rather than a cause of vascular 
dysfunction,62 and genetic deletion of IL-6 in mice does not affect insulin sensitivity.63  
Resistin has received a lot of attention for its proposed role in obesity-related 
insulin resistance.37 While this role has not been convincingly demonstrated in man,38 some 
recent evidence has suggested that resistin modulates vascular function. Circulating resistin 
levels are increased in obesity,39 resistin increases ET-1 release and expression of 
adhesion molecules in cultured endothelial cells40 and impairs endothelium-dependent 
vasodilatation to the endothelium-dependent vasodilator bradykinin in isolated arteries.67 In 
contrast, circulating resistin levels are not independently associated with coronary heart 
disease68 and do not relate to vascular reactivity.41 While the former studies imply that 
endothelial cells carry a receptor for resistin, further research will be needed to clarify the 
relationship between resistin and vascular function. 
Leptin was the first endocrine product of adipose tissue to be identified70 and has 
recently been found to regulate vascular function through local42 and central43 mechanisms. 
Leptin is a vasodilator in coronary arteries44 and in human forearm resistance arteries45 
through endothelium-dependent75 and endothelium-independent mechanisms.46 
Interestingly, a direct interaction between leptin and insulin has been shown in aortic 
endothelium. In a synergistic mechanism, leptin and insulin were shown to enhance NO 
production by phosphorylating eNOS at Ser1177.72 In contrast to these vasodilator effects, 
leptin also increases sympathetic nerve activity47 and enhances ET-1 release from vascular 
endothelium.48 Paradoxically, circulating leptin levels are elevated in obesity, apparently 
contradicting the beneficial effects of leptin described above. To explain this, recent studies 
have demonstrated impairment of leptin’s metabolic effects and to leptin-induced nitric oxide 
production, i.e. “leptin resistance”, in obesity76,78 and human hypertension.79 Leptin 
resistance may be caused by inflammatory mechanisms, as CRP impairs intracellular leptin 
signaling.49 Therefore, resistance to vasodilator effects of leptin may contribute to vascular 
dysfunction in obesity. 
Adiponectin has recently emerged as an adipose tissue-derived modulator of 
endothelial function. Adiponectin increases NO production in vascular endothelium by 
increasing Ser 1177 phosphorylation of eNOS,51,82 inhibits endothelial cell activation83-85 and 
associates negatively with risk of a cardiovascular event.86 In obesity adiponectin levels are 
decreased,13 contributing to impaired vascular function.87 In the coronary circulation, 
adiponectin produced by epicardial adipose tissue regulates the cardiac flow reserve.88 
In conclusion, adipose tissue secretes a variety of adipokines, such as fatty acids, 
TNFα, IL-6, leptin, adiponectin that modulate vascular tone, nutritive blood flow and insulin 
sensitivity. These adipokines alter smooth muscle contractility diretcly and indirectly, by 
interacting with endothelium-dependent vasodilatation.  
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4. Obesity, Inflammation of Adipose Tissue and Insulin 
Resistance 
 
In obesity, adipose tissue initiates inflammation by local production and secretion of 
cytokines and chemokines. As obesity increases, this inflammation becomes systemic.50  A 
central feature of inflammation in adipose tissue is accumulation of activated 
macrophages.51 Macrophages in adipose tissue are the main source of pro-inflammatory 
cytokines in this tissue,52 and recent evidence suggests that the expression of 
proinflammatory cytokines by macrophages cause obesity-related insulin resistance.91,92 An 
increase in adipocyte size triggers the production of monocyte chemoattractant protein-1 
(MCP-1), which attracts macrophages into adipose tissue.53,54 Immunohistochemical 
analysis of human subcutaneous adipose tissue showed that both BMI and adipocyte size 
were strong predictors of the percentage of CD68-expressing macrophages.55  
Morphological studies reveal substantial differences in inflammation between 
subcutaneous and intra-abdominal fat depots. Abdominal adipose tissue contains more 
monocytes and macrophages than the subcutaneous depots. Moreover, the release of the 
pro-inflammatory cytokines TNFα, is increased in abdominal adipose tissue, and is 
correlated with body mass index (BMI), and waist-to-hip ratio (WHR).11,93 It has been 
proposed that an increased WHR may reflect a relative abundance of abdominal fat 
(increased waist circumference) and peripheral muscle atrophy (decreased hip 
circumference).94  
The differences in inflammatory properties of different adipose tissue depots relates 
to microvascular function in obesity. De Jongh et al. have shown that increased abdominal 
adipose tissue is associated with impairment of capillary recruitment, and that this 
relationship is partially explained by increased production of inflammatory cytokines.95 
Consistent with this, the abundance of abdominal AT is associated with macrophage 
infiltration and cytokine production.11 This suggests that increased intra-abdominal adipose 
tissue is pro-inflammatory and associates with microvascular dysfunction and insulin 
resistance 
 
 
5. Location of Adipose Tissue as a Determinant of    
Insulin Resistance and Microvascular Function  
 
Apart from inflammatory activity within adipose tissue, another important determinant of 
insulin sensitivity and vascular function in obesity is its localization. In obese and in 
hypertensive subjects, accumulation of visceral adipose tissue is associated with insulin 
resistance,96 hypertension96 and impairment of endothelium-dependent vasodilatation.97 In 
recent years the hypothesis of ectopic fat has emerged as a possible cause of insulin 
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resistance. In man, accumulation of lipids inside myocytes relates to muscle insulin 
resistance,56 suggesting that increased exposure of muscles to lipids and/or altered lipid 
metabolism in myocytes is involved in the development of insulin resistance. In spite of 
these associations, intramyocellular lipid is not likely to cause muscle insulin resistance 
directly, as lipids also accumulate in the highly insulin-sensitive muscles of endurance-
trained athletes.100  
We101 and others102 have provided a possible solution to this paradox by showing that in 
obese, insulin-resistant rats, perivascular adipose tissue (PAT) forms around the arterioles 
in muscle and relates well to insulin resistance. While these intramuscular adipose tissue 
depots are very small, they may be the most relevant to muscle insulin resistance. 
 
 
6. Perivascular Adipose Tissue: Anatomy and Cellular 
Consistency 
 
Perivascular adipose tissue is present around all conduit arteries and in some microvascular 
beds, such as that of the mesentery.103 It may have organ-specific names such as epicardial 
adipose tissue57 (or “fat”), peri-aortic adipose tissue,104 mesenteric adipose tissue,105 
vascular stroma of adipose tissue,106 and intramuscular adipose tissue.90,101 As all of these 
adipose tissue depots are situated around the local vasculature, they will therefore be 
included in this review, although they may have different pathophysiological roles.  
PAT is essentially a differentiated form of the vascular adventitia.104,105 The 
adventitia of blood vessels consists of fibroblasts,107,108 fibroblast-like stem cells,109-111 
adipocytes,101 macrophages,112 and T-lymphocytes.112 In larger arteries such as the LAD 
and aorta, the vascular adventitia is connected to the endothelium and vessel lumen by the 
vasa vasorum.113 Interestingly, extension of the vasa vasorum precedes endothelial 
dysfunction in coronary arteries of hypercholesterolemic pigs,114 indicating that increased 
communication between adventitia and endothelium precedes endothelial dysfunction. 
A striking anatomical feature of the vascular adventitia is its plasticity. The resident 
fibroblast-like stem cells in the adventitia can differentiate into adipocytes or 
macrophages,111 but also to smooth muscle cells migrating to the media.110,115 The cellular 
consistency of the adventitia is not only determined by differentiation of resident stem 
cells,110 but also by infiltration of leukocytes116 and bone marrow-derived stem cells.117 After 
mechanical injury and hypoxic stress, immune cells and bone marrow-derived stem cells 
invade the adventitia.117 Given the potential of adventitial cells to differentiate to adipocytes, 
the increase in PAT volume throughout the vasculature observed in obesity118 may well 
originate from the adventitia.  
The physiological and (patho) physiological stimuli that regulate cellular 
differentiation and infiltration of inflammatory cells in the adventitia are largely unknown. A 
model for studying the differentiation of the adventitia to perivascular adipose tissue is the 
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rat cremaster muscle, which contains very little PAT in normal rats. In obesity, PAT develops 
in the cremaster muscle at the most proximal branching point of the muscle arterial tree101 
(around the proximal part of the first degree arteriole). Moreover, subjecting rats to four 
weeks of a high fat diet (as described by Ouwens et al.119) induces formation of PAT at this 
location (unpublished results). Interestingly, this diet does not result in hyperinsulinemia,119 
which is known to induce differentiation of fibroblasts to adipocytes.120 This suggests that the 
formation of intramuscular PAT depends on a combination of circulating factors, possibly 
lipids, and local stimuli. It is tempting to speculate that turbulent flow, which occurs at 
branching points in the vascular tree, is one of these local determinants of PAT formation. 
Studies on flow patterns in conduit arteries have shown that low shear stress and turbulent 
flow induce local accumulation of lipids and macrophages in the vessel wall.121 Therefore, 
the adventitial response to hyperlipidemia may be determined by the local flow pattern 
through increased penetration of lipids into the vessel wall.122   
 
 
7. Regulation of Vascular Function by PAT 
  
Traditionally, the vascular adventitia has been viewed as a tissue stabilizing the vessel 
wall.123 Aside from this function, recent evidence has shown that the vascular adventitia and 
especially PAT regulate vascular tone,124,125 endothelium-dependent vasodilatation,126 
vessel wall thickness,127 angiogenesis128,129 and inflamma-tion.57,116,130  
 
PAT and vascular tone 
Regulation of smooth muscle tone by perivascular adipose tissue was first demonstrated by 
Soltis and Cassis,125 further characterized by the groups of Gollasch105,131,132 and 
Fernandez-Alonso133 and has recently been confirmed in human conduit arteries.134 These 
groups demonstrated the release of an adipose tissue-derived relaxing factor from PAT of 
the aorta104,131 and mesenteric arteries,105,132 which hyperpolarizes vascular smooth 
muscle131 and inhibits adrenergic and depolarization-induced vasoconstriction.125 In an 
elegant series of experiments, Gollasch et al. showed that preincubation of culture medium 
with PAT resulted in a relaxing effect on arteries without PAT, demonstrating the production 
of an adventitia-derived relaxing factor (ADRF). Its release depends on extracellular calcium 
and its effect is mediated by intracellular tyrosine kinases and voltage-dependent smooth 
muscle K+ channels but not NO, P450 or prostaglandins.131 This factor is therefore an 
adventitia-derived hyperpolarizing factor that has yet to be identified. 
In obese Zucker rats the ADRF effect is not altered,104 but it may be in 
spontaneously hypertensive rats (SHR).132 Galvèz et al. have shown that the systemic 
vasodilator response to K+ channel blockade is attenuated in these rats and relates to the 
amount of PAT around mesenteric arteries.132 Furthermore, K+ channel blockade constricted 
isolated mesenteric arteries of normotensive rats, but not SHR, only in the presence of their 
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PAT. However, inhibition of vasoconstriction by PAT of mesenteric arteries was not altered 
at physiological pressures, precluding definitive conclusions.132 
In addition to the ADRF, known vasodilator products of adipose tissue may play a role. 
Epicardial adipose tissue, mesenteric adipose tissue and the stromal fraction of adipose 
tissue express leptin106,132,135 and adiponectin,88,135,136 but the role of these hormones in 
effects of PAT on vascular tone has not been investigated. 
Aside from vasodilator products, PAT has also been shown to secrete 
vasoconstrictor peptides. First, An et al. have shown that periaortic adipose tissue secretes 
ET-1 upon stimulation by angiotensin II (AngII).107 Whether periaortic PAT releases ET-1 
without Ang II stimulation is unclear, as this PAT decreases, rather than increases, vascular 
tone in isolated experimental setups.131 Second, PAT of conduit arteries synthesizes 
angiotensinogen.137 Moreover, the presence of angiotensin-converting enzyme (ACE)138 has 
been demonstrated in periaortic PAT, suggesting a functional renin-angiotensin 
system.137,139 In support, ACE inhibitors have been shown to inhibit ACE in PAT with similar 
potency as their inhibiting effect on circulating Ang II levels.139 These data suggest that PAT 
is capable of synthesizing the potent vasoconstrictor peptides Ang II and ET-1, but it 
remains to be determined if this is the case for PAT at other locations. 
In addition to its direct effects on smooth muscle tone, PAT may influence vascular tone by 
impairment of endothelium-dependent vasodilatation.126,133 Angiotensin enhances the 
generation of reactive oxygen species by aortic and mesenteric PAT140 through activation of 
p91 phox in mice,141 and ROS from PAT impair endothelium-dependent vasodilatation.126 
PAT releases other adipokines, such as NEFA142-144 and TNFα,57,145 known inhibitors of 
endothelium-dependent vasodilatation.57 
 
Regulation of inflammation by PAT 
Macrophage accumulation in adipose tissue and muscle is a crucial step in the development 
of obesity-related insulin resistance91,92 and accumulating evidence suggests that PAT 
controls this process. PAT of mouse aortas,146 rat mesentery,147 vascular stroma of adipose 
tissue148 and human coronary arteries57 has been shown to produce the chemokines MCP-1 
and IL-8, and supernatant from peri-aortic adipose tissue of mice fed a high-fat diet induces 
chemotaxis of monocytes and T-lymphocytes across the endothelial cell layer.146 Similar 
effects have been demonstrated in the vascular stroma of adipose tissue.106 These 
chemotactic effects of PAT respond to its local environment, as attraction of leukocytes by 
PAT is induced by a lipid-rich diet.130 However, only 5% of cells found in PAT are 
macrophages, suggesting that adipocytes themselves produce chemokines and cytokines 
production in the presence of infiltrated immune cells.146 Indeed, synergistic production of 
cytokines by adipocytes and macrophages has been shown in co-culture experiments.144 
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8. PAT in the Metabolic Syndrome: the Vasocrine  
Hypothesis 
 
Obesity-related insulin resistance of muscle is associated with impairment of insulin-
mediated nutritive blood flow42, reduction of endothelium-dependent vasodilatation and NO 
synthesis,149-151 ectopic disposition of lipids58 and infiltration of macrophages.59 To unite all 
of these different elements of the pathophysiology of obesity-related insulin resistance, we 
have recently hypothesized that intramuscular PAT causes muscle insulin resistance.101 We 
propose that ectopic lipid deposition in the vascular adventitia induces formation of 
intramuscular PAT around arterioles that regulate nutritive blood flow. This newly formed 
PAT secretes NEFA, cytokines and chemokines, which trigger the infiltration of monocytes 
and differentiation to macrophages. Adipocytes and macrophages in PAT then secrete 
NEFA as well as cytokines, which impair endothelium-dependent vasodilatation and insulin-
mediated nutritive muscle blood flow, resulting in a reduction of insulin-mediated glucose 
uptake. A summary of these proposed mechanisms is provided in Figure 1. 
 
 
 
 
The mechanism of impairment of capillary recruitment in muscle by PAT requires 
downstream signaling from larger arterioles to precapillary arterioles, as intramuscular PAT 
associates with larger arterioles and capillary recruitment is mediated by vasodilatation of 
precapillary arterioles. We have termed this vessel-to-vessel-signaling “vasocrine”.101 We 
hypothesize that this intramuscular vasocrine signaling reduces insulin-mediated muscle 
glucose uptake and effectively induces a redistribution of substrates to adipose tissue, which 
has been demonstrated in mice with a specific impairment in muscle insulin signaling.60 
Insulin
PI3K
Akt
eNOS
ERK
Cytokines
Fatty acids
ET-1
NO
?Nutritive blood flow ? Insulin resistance
Macrophage
Perivascular 
adipocyte
Figure 1. Proposed 
mechanism involved in the 
regulation of endothelial 
function and insulin-mediated 
glucose uptake bij PVA.T  
EC: Endothelial Cell; VSMC: 
Vascular Smooth muscle cell; 
eNOS: endothelial Nitric Oxide 
Synthase; PI3K: 
Phospatidylinositol-3-kinase; 
ERK: Extracellular signal-
Regulated protein Kinase; ET-1: 
Endothelin-1. Adapted form 
Yudkin et al.101 
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The evidence available from human and experimental obesity supports the 
vasocrine hypothesis. In muscle, PAT around resistance arteries may impair insulin-
mediated nutritive blood flow and muscle glucose uptake.101 Insulin-mediated capillary 
recruitment in muscle regulates insulin-mediated muscle glucose uptake and is impaired in 
muscle of obese Zucker rats,61 and we have observed accumulation of intramuscular PAT in 
these rats.101 Consistent with a role for PAT in human insulin resistance, increased amounts 
of epicardial adipose tissue153 as well as cytokine expression in this tissue associate with 
insulin resistance in man.154 This hypothesis remains to be tested in future research.  
Around resistance arteries such as those of the mesentery, PAT may be involved in 
the regulation of vascular resistance and blood pressure, but the evidence available is 
inconsistent. On the one hand, a decreased amount of PAT in the mesentery is related to 
reduced blood pressure-elevating and vasoconstrictor effects of K+ channel blockade in 
hypertensive rats.132 On the other hand, PAT is not present around resistance arteries of 
other tissues, such as muscle, in normal rats.101 Furthermore, the amount of epicardial fat 
positively associates with peripheral resistance in man.155 Whether and how PAT regulates 
vascular resistance needs to be clarified in subsequent studies.  
In the coronary circulation, increases in PAT associate with decreases in cardiac flow 
reserve88 and local inflammation.57,135,156 The latter may be involved in accelerated 
atherosclerosis in coronary arteries, as has been previously shown for PAT around the 
aorta.130 Peri-aortic adipose tissue plays a critical role in vessel wall inflammation and 
atherosclerosis in mice.92,115,130,157 PAT-induced oxidative stress and endothelial 
dysfunction, as described above, may also contribute to accelerated atherosclerosis in 
obesity.  
Diverse as the proposed pathophysiological effects of PAT are, it can be questioned 
whether properties of PAT are specific for their respective locations or that gene expression 
in mesenteric adipose tissue is predictive of, for example, epicardial adipose tissue. While 
the humoral factors to which PAT at different locations is exposed may be similar, local 
metabolism and mechanics may vary widely. Although expression of inflammatory genes 
has been demonstrated in intramuscular, mesenteric, peri-aortic and epicardial PAT, no 
studies have compared gene expression in different PAT depots, preventing definitive 
conclusions on similarities and differences between depots of PAT.  
 Obesity-related factors regulating formation of PAT and altered adipokine expression in it 
have not been identified, but may involve increased levels of low-density lipoprotein (LDL). 
Adventitial fibroblasts act as scavengers of LDL,158 and a lipid-rich diet induces macrophage 
infiltration in PAT.130 As information on this topic is scarce, further studies are clearly 
needed. 
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Perspectives 
Despite the recent rise of interest in physiological functions of PAT, the evidence available is 
inconclusive. Furthermore, we do not know what factors mediate the formation, cellular 
composition and secretion pattern of PAT. To address these questions, it will be necessary 
to manipulate the amount of PAT, its cellular composition and its pattern of gene expression. 
Complete removal of PAT may not always be the best way, as blood vessels are capable of 
new adventitial tissue.159 Transfection of the vascular adventitia has proved possible in 
recent years,160,161 opening possibilities to investigate PAT function at specific locations as 
well as gene therapy at specific locations and directed at specific cell types present in PAT. 
Future research will elucidate the mechanisms involved in regulation of vascular function 
and insulin sensitivity by PAT.  
 
Conclusions 
In the context of the worldwide increase of obesity and its cardiovascular and metabolic 
complications, perivascular adipose tissue presents an exciting new field of research for 
obesity-related vascular disease and type 2 diabetes. Perivascular adipose tissue expresses 
a broad range of vasoactive substances that trigger local inflammation and modulate 
vascular function, which relate to abdominal obesity and insulin resistance. Future research 
will further clarify the physiological functions and therapeutical potential of this tissue.   
 
 
 
Table 1. Products of PAT 
involved in regulation of 
vascular function.  
NEFA, non-esterified fatty 
acids; ROS, reactive oxygen 
species; IL-6, interleukin-6; 
TNFα, tumour necrosis 
factor alpha; IL-1β, 
interleukin-1 beta; MCP-1, 
monocyte chemoattractant 
protein-1; IL-8, interleukin-8; 
ADRF, adventitia-derived 
relaxing factor; ADGF, 
adventitia-derived growth 
factor. 
 
 
 
 
Periaortic Mesenteric Epicardial SVF
NEFA X X X
ROS X X
IL-6 X X
TNFα X X X
IL-1β X
MCP-1 X X X X
IL-8 X X X
ADRF X X
Endothelin X
Angiotensinogen X X
Leptin X X X
Adiponectin X X
Resistin X
ADGF X
References: 104, 105, 123, 129, 132, 135, 138, 57, 67, 88, 137,  90, 103, 128, 139, 
133-134, 143 140, 142, 144 141, 150 145
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ABSTRACT 
 
Objective: Insulin resistance is characterized by reduced expression and activity of insulin 
receptor substrates (IRSs) and is partly caused by impaired perfusion of skeletal muscle. 
This study examined whether IRS1 deficiency impairs insulin responses in muscle arterioles 
and whether this influences vascularization and growth of skeletal muscle. 
 
Research design and methods:  To determine the role of IRS1 in regulating microvascular 
function and muscle growth, IRS1+/+ and IRS1-/- mice (aged 5 and 10 weeks) were studied. 
Subsequently, structural and functional properties of the muscle microcirculation were 
determined by myography of isolated arterioles and histology of gastrocnemius muscles.  
 
Results: IRS1-/- mice showed a reduced body weight, muscle mass and myocyte size. The 
maximal diameter of arterioles and capillary ratio in skeletal muscle were structurally 
reduced in IRS1-/- mice. Unexpectedly, insulin induced vasodilation in arterioles of IRS1-/- 
mice, despite a reduced insulin-mediated Akt activation. This vasodilation was caused by 
reduced sensitivity to ET-1 and a reduced ET-1-mediated vasoconstriction and was 
associated with reduced media thickness, which limited contractile function. These 
functional changes were independent from vasodilation responses to acetylcholine and 
sodium nitroprusside, which were not altered in arterioles from IRS1-/- mice. 
 
Conclusion:  IRS1 deficiency leads to insulin-mediated vasodilation caused by reduced 
endothelin-1-dependent vasoconstriction in muscle arterioles, despite impaired insulin-
mediated Akt activation. These changes were accompanied by structural narrowing of 
arteries and reduced capillary ratio in skeletal muscle.  Our data show that reduced IRS-1 
expression may partly explain microvascular dysfunction associated with insulin resistance. 
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INTRODUCTION 
 
Deficiencies in Insulin Receptor Substrate 1 (IRS1) expression and function in target tissues 
of insulin, such as skeletal muscle, are associated with insulin resistance and type 2 
diabetes in man.1 Insulin plays a key role in glucose uptake in skeletal muscle as well as in 
vascular delivery of glucose into skeletal muscle.2 In muscle this will lead to an increase of 
muscle size by induction of myogenesis3 and an increase in nutrient supply by vasodilation 
of small arteries and recruitment of capillaries.4,5 IRS1 can be activated by insulin and 
IGF1,6 but its exact role in microvascular function has not been investigated.  
  Mice that are homozygous for targeted deletion of the IRS1 gene are growth 
retarded at birth and remain growth retarded into adulthood.7,8 Furthermore, these IRS1-
deficient mice show impaired glucose tolerance and a decrease in insulin- or IGF1-mediated 
glucose uptake, but do not develop diabetes.7,8 The insulin resistance of IRS1-deficient mice 
occurs at the level of skeletal muscle, due to a decrease in the activation of PI3K/Akt and 
glucose transport.9 Glucose disposal is dependent on the ability of myocytes to take up 
glucose and on the delivery of glucose and insulin to muscle tissue, which is limited by the 
degree of perfusion of the skeletal muscle.5,10 Insulin regulates skeletal muscle perfusion 
chronically by inducing formation of new blood vessels and acutely by increasing perfusion 
of already existent capillaries.11,12 Capillary density in skeletal muscle is correlated with 
insulin-mediated glucose uptake.13 In muscle arterioles, insulin regulates vascular diameter 
and muscle perfusion by the induction of both vasodilation (mediated by PI3K/Akt/pathway 
leading to NO production4,14) and vasoconstriction (mediated by ERK1/2 pathway leading to 
ET-1 production).15,16 These two pathways are in balance or result in net vasodilation in 
healthy conditions and respond to physiological needs of insulin sensitive tissues, such as 
skeletal muscle.  
In insulin resistance, the balance of insulin-mediated vasoreactivity is shifted towards 
vasoconstriction in arterioles, due to reduced Akt and eNOS activity17-19 and normal to 
enhanced endothelin-1 activity.17,20 Furthermore, this functional change is characterized by 
inward remodeling of arterioles21 and reduced capillary-to-muscle ratio in skeletal muscle.22 
IRS1 deficient mice are insulin resistant, but the role of IRS1 in the functioning of arterioles 
and insulin-mediated vasoreactivity is unclear. IRS1 activates the pathway of PI3K/Akt upon 
stimulation by insulin or IGF1 and influences both muscle growth3 and blood flow.11 
Presently, the effects of IRS1 in the vasculature have been mainly described in the context 
of the NO pathway of endothelial cells in-vitro,23,24 but the exact role of IRS1 in  
microvascular function and the effect of IRS1 on muscle vascularization and growth is still 
poorly understood.  
The present study aimed to assess whether IRS1 deficiency impairs microvascular 
responses to insulin in skeletal muscle, and whether it affects vascularization and growth of 
skeletal muscle. IRS1 deficient mice were used to characterize capillary-to-muscle ratio and 
density in skeletal muscle, as well as functional responses of arterioles to insulin, and to 
evaluate whether the observed changes were associated with differences in myocyte size 
and skeletal muscle mass. 
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RESEARCH DESIGN AND METHODS 
 
Animals: The investigation conformed to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH publication No 85 to 23, revised 1996). The local 
ethics committee for animal experiments approved the procedures. Male and female IRS1-/- mice and 
their WT littermates of 5 and 10 weeks of age were obtained by heterozygous breeding (heterozygous 
breeding couple was kindly provided by the laboratory of C.R. Kahn, Boston, USA) and genotypes were 
determined with PCR. Mice were sacrificed with an overdose of isoflurane. Organs, including 
gastrocnemius muscles, were isolated, weighed, frozen in liquid nitrogen and stored in –80ºC until 
further analysis. Arteries (femoral artery and gracilis artery) were dissected from surrounding tissue and 
studied in a pressure myograph.  
 
Immunohistochemistry: Sections of 5 μm from the gastrocnemius muscle were either stained with 
hematoxylin-eosin to determine myocyte size or with endothelial-selective glycocalyx stain Lectin 
(Lycopersicon esculentum Lectin, FITC-conjugate, Sigma-Aldrich) to determine the number of 
capillaries. Images of muscle samples were visualized with Leica DMRB light microscope using 20x 
objective and myocyte size was determined with NIH-ImageJ software. Capillaries were visualized with 
a ZEISS Axiovert 200 Marianas inverted digital imaging microscope workstation using Slidebook 
software (Slidebook version 4.1; 3l Intelligent Imaging Innovations, Inc). The number of capillaries was 
expressed as capillary ratio per muscle cell and number of capillaries per mm2. 
 
Vasoreactivity experiments: Artery segments of the femoral and gracilis artery were dissected and 
placed in a pressure myograph with corresponding in vivo pressure (100 and 80 mmHg, respectively) to 
measure maximal diameters.25 To study changes in response to insulin in arterioles, segments of the 
gracilis artery were preconstricted to ~50% of the maximal diameter with 25mM KCl, as described 
before.26 To determine vasodilator and vasoconstrictor effect of the arteries, dose-response relations 
with both acetylcholine or sodium nitroprusside and ET-1 were performed. Acute effects of insulin (Novo 
Nordisk, Alphen a/d Rijn, the Netherlands), at four concentrations (0.02, 0.2, 2 and 20nM) on the 
diameter of the gracilis artery were studied and each concentration was recorded for 30 minutes.25 The 
role of ET-1 in insulin-mediated vasoreactivity was assessed by pre-treatment with a non-selective ET-1 
receptor antagonist (PD142893, 10μM) for 30 minutes.  
 
Chemicals: MOPS-buffer consisted of (in mM) 145 NaCl, 4.7 KCl, 2.5 CaCl2, 1.0 MgSO4, 1.2 NaH2PO4, 
2.0 pyruvate, 0.02 EDTA, 3.0 MOPS (3-(N-morpholino) propanesulfonic acid), 5.5 glucose and 0.1% 
bovine serum albumin (BSA), and was set at a pH of 7.4.  BSA, and acetylcholine (ACh) were obtained 
from Sigma (St. Louis, MO) and human insulin (Actrapid®) was obtained from Novo Nordisk (Alphen a/d 
Rijn, the Netherlands).  
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Protein analysis: Protein analyses were performed by western blotting, as described before.26 
Segments of gracilis arteries from the same mouse (3 mm in length) were exposed to solvent (controls) 
or to insulin (2nM) for 15 minutes at 37ºC. Differences in phosphorylated protein of Akt at ser 473 were 
adjusted for differences in the total Akt protein staining (antibodies obtained from Cell Signaling 
Technology, Boston, MA).  
 
Statistics: Values are expressed as mean±SEM. Statistical analyses for differences between IRS1+/+ 
and IRS1-/- mice were performed by student t-test. Differences in insulin responses were determined by 
one-way ANOVA with Bonferroni post hoc test. Differences in probability values of p<0.05 were 
considered statistically significant. 
 
 
 
RESULTS 
 
General characteristics of IRS1-/- mice 
The body weight and the weight of several organs (heart, kidney and spleen) of 10-week-old 
IRS1-/- mice were 20-40% less than those in control mice (Table 1). In contrast, the tibia 
length, an often used parameter of body growth, was reduced by only 12%. Similar to other 
organs, the muscle mass as well as the cross sectional area of single myocytes was 
decreased by 36-38% in IRS1-/- mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: General characteristics of 10-week-old IRS1+/+ and IRS1-/- mice. Data are mean±SEM. Organs weights 
and diameter GA: IRS2+/+ n=14, IRS2-/- n=12. CSA, diameter FA, cap ratio and Cap/mm2: IRS2+/+ n=6, IRS2-/- n=6. 
CSA: Cross Sectional Area muscle myocytes, FA: Femoral Artery, GA: Gracilis Artery, Cap: Capillaries. 
 
Characteristics IRS1+/+ IRS1-/- N p % change
BW (gr) 22.6±0.8 14.2±0.5 12 <0.0001 -38%
Tibia (mm) 16.2±0.2 14.5±0.2 12 <0.0001 -12%
Heart (mg) 13.8±0.7 9.6±0.9 12 <0.001 -30%
Liver (mg) 96.5±11.6 74.1±4.1 12 =0.14 -23%
Kidney (mg) 14.8±1.0 11.9±0.5 12 <0.01 -20%
Spleen (mg) 9.4±0.6 5.7±0.3 12 <0.0001 -39%
Muscle mass (mg) 14.2±0.9 8.0±0.4 12 <0.05 -36%
CSA (μm2) 2082±187 1304±88 6 <0.005 -38%
Diameter FA (μm) 313.3±19.7 281.3±14 6 <0.05 -15%
Diameter GA (μm) 130.1±2.4 97.3±3.4 12 <0.0001 -25%
Cap ratio (#/cell) 1.60±0.1 1.21±0.1 6 <0.01 -24%
Cap/mm2 746±79 949±98 6 P=0.14 +21%
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Microvascular characteristics of IRS1-/- mice: reduced diameter of arterioles and 
reduced capillary-to-muscle cell ratio in skeletal muscle  
We further focused on the role of IRS1 in skeletal muscle and the muscle vasculature in 10-
week-old IRS1+/+ and IRS1-/- mice. A conduit artery (femoral artery: FA) and muscle 
microvasculature, in particular the resistance gracilis artery (GA) and capillaries, were 
investigated. The maximal diameter of conduit and arterioles were reduced in the IRS1-/- 
mice by 15% and 25%, respectively, as compared to their control counterparts. The number 
of capillaries expressed as number of capillaries per myocyte was reduced by 24%. 
However, the capillary density (capillaries/mm2) in muscle was not significantly changed in 
IRS1-/- mice. 
One may anticipate that the structural changes in skeletal muscle and vasculature 
are influenced by the growth deficit. Therefore, muscle and vascular parameters were 
corrected for physical length and growth delay. Correction for physical length was achieved 
by dividing muscle and vascular parameters by tibia length. Table 2 compares these data for 
10 weeks old IRS1+/+ and IRS1-/- mice, and shows that after tibia correction only the 
difference in the diameter of the conduit femoral artery was normalized. Muscle mass, 
myocyte size, diameter of arterioles and capillary-to-muscle cell ratio remained significantly 
different after correction for tibia length (Table 2).  
 
 
 
 
 
 
 
 
 
Table 2: Muscle and vascular characteristics corrected for tibia length in 10-week-old IRS1+/+ and IRS1-/- 
mice. Data are mean±SEM for at least 6 mice. CSA: Cross Sectional Area muscle myocytes, FA: Femoral Artery, GA: 
Gracilis Artery, Cap: Capillaries. 
 
 
The growth of resistance artery diameter is impaired during growth between 5 and 10 
weeks in IRS1-/- mice 
As the body weight of 5-week-old IRS1+/+ mice (Table 3) is comparable to that of 10-week-
old IRS1-/- mice (Table 1), we investigated IRS1+/+ and IRS1-/- mice of 5 and 10 weeks of 
age to determine whether a possible postnatal growth delay might explain our results. The 
general characteristics of 5-week-old IRS1-/- mice (Table 3) showed similar muscle and 
vascular defects as the 10-week-old IRS1-/- mice (Table 1). 
Correction tibia length IRS1+/+ IRS1-/- N p % change
Muscle mass / tibia (mg/mm) 0.87±0.05 0.55±0.02 9 <0.0001 -37%
CSA / tibia  (μm2/mm) 125.9±10.4 90.3±6.1 5 <0.05 -28%
FA / tiba (μm/mm) 19.3±1.1 19.7±0.6 6 =0.77 2%
GA / tibia (μm/mm) 8.0±0.2 6.7±0.2 12 <0.0005 -16%
Cap ratio / tibia  (#/cell/mm) 0.097±0.005 0.084±0.004 5 <0.05 -13%
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Table 3: General characteristics of 5-week-old IRS1+/+ and IRS1-/- mice. Data are mean±SEM for at least 6 mice. 
CSA: Cross Sectional Area muscle myocytes, FA: Femoral Artery, GA: Gracilis Artery, Cap: Capillaries. 
 
  Comparison of the muscle characteristics of 5-week-old IRS1+/+ mice with 10-
week-old IRS1-/- mice (dashed lines in Fig 1A-B) revealed that muscle weight (Fig 1A) and 
myocyte size (Fig 1B) of 10-week-old IRS1-/- mice are comparable to that of 5-week-old 
IRS1+/+ mice. Furthermore, the increase in muscle mass (Fig 1A) and myocyte size (Fig 
1B) is in the same range in IRS1+/+ and IRS1-/- mice during the growth period from 5 till 10 
weeks of age. This suggests that although postnatal muscle growth still occurred, IRS1-/- 
mice have a persistent delay in muscle growth. 
Comparison of the vascular characteristics of 5-week-old IRS1+/+ mice with 10-
week-old mice IRS1-/- mice (dashed lines in Fig 2A-B) revealed that capillary-to-muscle (Fig 
2A) and capillary density (Fig 2B) of 10-week-old IRS1-/- mice are comparable to that of 5-
week-old IRS1+/+ mice. Furthermore, the increase in capillary-to-muscle ratio (Fig 2A) is in 
the same range as that in IRS1+/+ mice, whereas the difference in capillary density (Fig 2B) 
becomes relatively smaller during the growth period of 5-10 weeks in IRS1-/- mice. This 
suggests that although the number of capillaries still increases postnatally, IRS1-/- mice 
keep a persistent reduction in capillary-to-muscle ratio. 
In contrast, the diameter of the resistance artery is smaller in 10-week-old IRS1-/- 
mice than in 5-week-old IRS1+/+ mice (dashed line in Fig 2C). Furthermore, the increase in 
diameter was lower in IRS1-/- mice during the growth period from 5 till 10 weeks of age (Fig 
2C).  Thus, the reduction in diameter of arterioles in IRS1-/- becomes more severe during 
the growth period of 5-10 weeks compared to IRS1+/+ mice. 
 
 
Characteristics IRS1+/+ IRS1-/- N p % change
BW (gr) 16.0±1.9 9.8±0.3 6 <0.0001 -39%
Tibia (mm) 13.0±0.4 12.0±0.1 6 <0.001 -8%
Heart (mg) 9.8±0.6 6.4±0.2 6 <0.001 -35%
Liver (mg) 71.6±11.3 55.9±3.0 6 =0.28 -22%
Kidney (mg) 11.2±0.7 8.7±0.4 6 <0.05 -22%
Spleen (mg) 7.1±0.7 3.4±0.1 6 <0.001 -52%
Muscle mass (mg) 8.0±0.6 3.9±0.1 6 <0.0001 -51%
CSA (μm2) 1494±158 695±22 6 <0.005 -53%
FA (μm) 252.9±10.1 228.4±6.2 6 =0.29 -10%
GA (μm) 111.8±2.4 78.7±3.2 6 <0.0001 -30%
Cap ratio (# / cell) 1.32±0.1 0.85±0.1 6 <0.01 -36%
Cap/mm2 916±63 1474±34 6 <0.05 +37%
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Figure 2. Vascular characteristics in 5 
and 10 week old IRS1+/+ (○) and IRS1-
/- mice (●). (A) Capillary-to-muscle ratio, 
(B) capillary density and (C) diameter of 
gracilis artery (GA) of 5 and 10 week old 
IRS1+/+ and IRS1-/- mice. Dashed line in 
A-C compares IRS1+/+ of 5 weeks, with 
IRS1-/- of 10 weeks of age. (D) 
Representative capillary staining with 
Lectin of cross sections of the 
gastrocnemius muscle of IRS1+/+ and 
IRS1-/- mice of 5 and 10 weeks of age. 
White arrows point to an example of one 
typical capillary counted for quantification. 
Scale bar:100μm. 
 
Figure 1. Muscle characteristics in 5 
and 10 week old IRS1+/+ (○) and 
IRS1-/- mice (●). (A) Skeletal muscle 
mass and (B) cross sectional area 
(CSA) of gastrocnemius muscle of 5 
and 10 week old IRS1+/+ and IRS1-/- 
mice. Dashed line in A and B 
compares IRS1+/+ of 5 weeks, with 
IRS1-/- of 10 weeks of age. (C) 
Representative HE staining of cross 
sections of gastrocnemius muscle of 
IRS1+/+ and IRS1-/- mice of 5 and 10 
weeks of age. Scale bar:100μm. 
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Insulin induces vasodilation in arterioles of IRS1-/- mice due to a reduced ET-1 
mediated vasoconstriction 
Subsequently, functional parameters of the arterioles were determined with specific 
emphasis on their responsiveness to insulin. To that end, the responsiveness to insulin was 
evaluated in isolated gracilis arteries from IRS1+/+ and IRS1-/- mice of both 5 and 10 weeks 
of age. 
Prior to the insulin experiments, general vasodilatory function was determined by 
the responses to acetylcholine (ACh) and sodium nitroprusside (SNP). Arterial segments of 
IRS1+/+ and IRS1-/- had similar responses both to ACh (Fig 3A) and SNP (Fig 3B). This 
indicates that both endothelium-dependent and -independent vasodilation was not affected 
by the deficiency of IRS1 in these arteries.  
 
 
 
 
In IRS1+/+ mice, the addition of insulin alone induced in arterioles a vasoconstriction under 
physiological conditions, which is more pronounced in 10-week-old mice than in 5-week-old 
mice (Fig 4A). In IRS1-/- mice, the sole addition of insulin did not change the arterial 
diameter in 5-week-old mice. However, in 10-week-old IRS1-/- mice, insulin induced 
vasodilation (Fig 4B). In contrast, insulin-mediated Akt phosphorylation was significantly 
increased in arteries of IRS1+/+ mice, but not significantly increased in arteries of IRS1-/- 
mice (Fig 4C). 
Previous studies indicated that the vasoregulatory response of insulin in arterioles 
is largely determined by a balance between Akt/NO-mediated vasodilation and ERK/ET-1-
mediated vasoconstriction.25,26 An increase in NO production in arteries from IRS1-/- mice 
as a explanation for the insulin-mediated vasodilation  (Fig 4B) is not likely, because 
Montagnani et al noted that IRS1 is required for insulin-mediated NO production in 
endothelial cells.23 Furthermore, protein analysis of insulin-mediated Akt phosphorylation 
showed a decrease in arteries from IRS1-/- compared to IRS1+/+ mice (Fig 4C), suggesting 
a decrease rather than increase in NO production.  
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Figure 3. Vasodilator 
response in IRS1+/+ (○) 
and IRS1-/- mice (●) was 
determined by (A) dose 
response to endothelium-
dependent vasodilator 
acethylcholine (ACh) and 
(B) dose response to 
endothelium-independent 
vasodilator sodium 
nitroprusside (SNP).  
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Therefore, we investigated whether the difference in insulin response of the IRS1-/- mice 
was caused by changes in the response to ET-1-mediated vasoconstriction. Fig 5A shows 
the different insulin responses in 5- and 10-week-old IRS1+/+ and IRS1-/- mice at a 
concentration of 2nM. The insulin-mediated vasoconstriction in 10-week-old IRS1+/+ mice 
was inhibited with a non-selective ET-1 receptor antagonist (Fig 5B), whereas the non-
selective ET-1 receptor antagonist had no effect on the insulin-mediated vasodilation in 10-
week-old IRS1-/- mice (Fig 5C). 
In addition, we studied the sensitivity of arterioles to ET-1 by the addition of 
different concentrations of exogenous ET-1 to arterioles. The sensitivity of ET-1 was 
reduced in IRS1-/- mice of 10 weeks of age compared to IRS1+/+ of 10 weeks. Fig 5D 
shows vasoconstriction at a concentration 0.1μM of ET-1. The reduced ET-1 constriction 
was not present in 5-weeks-old IRS1-/- mice, suggesting an adaptation of ET-1 sensitivity in 
the arterial wall of developing IRS1-/- mice. Furthermore, this adaptation of ET-1 sensitivity 
in the 10 week-old IRS1-/- mice can explain the vasodilation to insulin as observed in the 10-
week-old IRS1-/- mice (Fig 5A). To elucidate whether ET-1 sensitivity was caused by 
structural changes in the vascular wall, media thickness in cross sections of the femoral 
artery were determined (Fig 5E). Arteries of 10-week-old IRS1-/- mice showed a reduced 
media thickness compared to IRS1+/+ mice (Fig 5F), suggesting a reduced degree of 
smooth muscle contraction. In addition, 5-week-old IRS1+/+ mice showed a similar media 
thickness as 10-week-old IRS1-/- mice. (data not shown) 
Taken together, IRS1 deficiency did not alter endothelium-dependent vasodilation 
in arterioles. However, IRS1 deficiency altered insulin responses by a reduction in ET-1 
sensitivity in the arterial wall, which resulted in an insulin-mediated vasodilation. This 
adaptive response to insulin might explain why muscle arterioles with a reduced diameter in 
IRS1-/- mice can still supply the increased number of postnatal muscle capillaries to a 
similar extent as IRS1+/+ mice (Fig 2).  
 
Figure 4. Responsiveness to insulin of arterioles of 5 and 10 week old IRS1+/+ (○,∆) and IRS1-/- mice (●,▲). 
Insulin-mediated vasoreactivity is depicted as percentile change from preconstricted diameter in 5 (∆,▲) and 10 (○,●) 
week old IRS1+/+ (A) and IRS1-/- mice (B). Response to insulin in 10 week old IRS1-/- mice is significantly different 
from IRS1-/- mice of 5 weeks and from IRS1+/+ mice of both 5 and 10 weeks of age, # p<0.01. (C) Insulin-mediated 
phosphorylation of Akt at ser473 was determined in control and insulin (2nM) stimulated conditions in femoral arteries 
of IRS1+/+ and IRS1-/- mice. *p<0.05 after insulin stimulation in IRS1+/+ mice. 
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Figure 5. Reduced sensitivity and activation of ET-1 leading to insulin-mediated vasodilation in arterioles 
of IRS1-/- mice.  A) Response to insulin at 2nM response is depicted as percentile change from starting diameter 
in IRS1+/+ and IRS1 -/- mice of 5 (white bars) and 10 (black bars) weeks of age.  B-C) Response to insulin (2nM) 
without (○, ●) and with an non-selective ET-1 receptor blocker PD142893, 10μM (□, ■) in 10-week-old (B) IRS1+/+ 
and (C) IRS1-/- mice. D) Responses to ET-1 (0.1μM) is depicted as percentile change from starting diameter in 
IRS1+/+ and IRS1 -/- mice of 5 (white bars) and 10 (black bars) weeks of age.  E-F) Cross sections of femoral 
artery stained with elastin to distinguish (E) media thickness depicted (F) with green line in the vascular wall of 10-
week-old IRS1+/+ and IRS1-/- mice. Data represent mean±SEM. *p<0.05 
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DISCUSSION 
 
This study demonstrates that IRS1 deficiency results in a reduced diameter of arterioles, but 
does not alter endothelium-dependent vasodilation. However, insulin responses in arterioles 
were changed in IRS1 deficient mice, resulting in insulin-mediated vasodilation caused by a 
reduced ET-1 mediated vasoconstriction and ET-1 sensitivity. This functional change in 
arterioles was associated with structural narrowing of arteries and reduced capillary-to-
muscle ratio in skeletal muscle.  
 
The role of IRS1 in vascular insulin signaling  
This study showed for the first time that IRS1 is not only involved in the NO pathway,6,23 but 
also in the ET-1 pathway of insulin. Unexpectedly, our study showed an insulin-mediated 
vasodilatation in arterioles of IRS1-/- mice, which was caused by a reduced sensitivity and 
ET-1 mediated vasoconstriction. The reduction in ET-1 sensitivity could be caused by the 
reduced ability of the smooth muscle cells in the arterial wall to contract. In the femoral 
artery, media thickness was reduced in IRS1-/- mice. Although we were not able to 
investigate media thickness in arterioles, due to their small size, it is plausible to assume a 
reduction of media thickness in arterioles, resulting in reduced capability to contract to 
vasoconstrictors, like ET-1. As ET-1 also has hypertrophic properties,27 the reduced media 
thickness could be a consequence of reduced ET-1 activation and the resulting reduced 
contractile response in IRS1-/- mice. 
ET-1 activation is mediated by ERK1/2.  One other study suggests the involvement 
of IRS1 in ET-1 pathway and showed that IRS1 deletion reduces insulin-mediated ERK1/2 
activation in cultured myocytes.28 Although we could not determine ERK1/2 activation in 
arterioles of IRS1-/- mice due to detection limitation, the inhibition of ET-1 with an ET-1 
receptor blocker inhibited insulin-mediated vasoconstriction in IRS1+/+ mice, while it had no 
effect in IRS1-/- mice. Taken together, our study shows the involvement of IRS1 in 
ERK1/2/ET-1 pathway of insulin, implying a more prominent role of IRS1 in insulin signaling 
than only its involvement in NO pathway. 
In general, the mouse strain used in our study appears to have stronger reactivity 
to ET-1 than to NO. This became evident from the induction of insulin-mediated 
vasoconstriction in WT mice (Fig 4A). The vasoconstriction was abolished by the inhibition 
of ET-1, but did not lead to NO-mediated vasodilation (Fig 5B), suggesting we could not 
detect NO responses to insulin in these isolated arterioles. It has to be taken into account 
that these findings cannot immediately be translated to the in vivo or human situation, 
because an underestimated role of NO in our mouse model cannot be excluded. In this 
study, we determined insulin-mediated vasoreactivity in isolated arteries and showed no or a 
small role for NO. Akt activation, upstream of NO, was detectable, and was reduced in  
IRS1-/- mice. However, in vivo the role of IRS1 in NO production is probably more 
pronounced, due to the presence of flow.  
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One logical explanation of the partly remaining insulin-mediated Akt phosphorylation and 
insulin-mediated vasodilatation in muscle arterioles of IRS1-/- mice is a compensated IRS2 
expression. Although IRS2 is more expressed in arterial tissue than IRS1, IRS2 gene 
expression was not increased in arteries of IRS1-/- mice.29 However, it should be taken into 
account that a decrease in protein expression does not necessary mean a reduced 
functionality of the protein. In agreement with this, 
insulin-mediated tyrosine-phosphorylation of IRS2 is enhanced in muscles of IRS1-/- 
mice.9,30 This suggests that IRS2 may partly compensate for defects of IRS1 in arteries, 
which would explain the ability of arterioles with IRS1 deletions to activate Akt and 
vasodilate to insulin .  
To our knowledge two other studies investigated vascular function in IRS1-/- 
mice,29,31 but this is the first study that investigated IRS1 in the microcirculation. The present 
study shows that endothelium-dependent vasodilation was not altered in arterioles from 10-
week-old IRS1-/- mice. In agreement to our study, Kubota et al showed no difference in 
acetylcholine response in aortic rings of 20 week old IRS1-/- mice.29 In contrast, Abe et al 
showed in aortic rings from very old specify IRS1-/- mice an impaired endothelium-
dependent vasodilation to acetylcholine.31 However, our study focused on the function of 
arterioles and we used mice of 10 weeks of age, making it difficult to compare these data 
directly. 
  
The role of IRS1 in regulation of muscle vascularization 
Despite an adaptive response to insulin in muscle arterioles and the ability of the muscles 
and capillaries to grow, IRS1-/- mice had a persistent decrease in muscle growth and 
capillary-to-muscle ratio. IRS1 can activate Akt upon receptor stimulation by insulin or IGF1 
and Akt regulates both the muscle growth3 and increased perfusion11 by inducing an 
enlarged capillary network.12 Akt activation in myocytes with an deletion for IRS1 is 
decreased,28 suggesting an impaired muscle development and decreased capillary network 
in muscles of IRS1-/- mice. Pete et al showed that the gastrocnemius muscle mass was 
reduced in IRS1-/- mice due to an impaired IGF1-dependent growth of the skeletal muscle. 
However, IGF1 overexpression could not overcome this body weight and muscle mass 
deficit that resulted from absolute IRS1 deficiency. This suggests that IGF1-stimulated 
muscle growth is impaired in IRS1-/- mice, and implies that an additional mechanism 
preserves postnatal muscle growth, possible by an adaptation of vascular responses of 
insulin. In agreement with this, we showed that IRS1-/- mice have a different vascular 
response to insulin, as shown by comparing 5 and 10-week-old mice, which depends on ET-
1 activation and is associated with muscle growth. Furthermore, this study shows that Akt 
can be activated in arterioles from IRS1-/- mice, although probably to a lesser degree, which 
might contribute to both the observed insulin-mediated vasodilation, and ability of muscles 
and capillaries to grow.  
Capillary-to-muscle ratio correlates with in-vivo insulin-mediated glucose uptake,32 but 
glucose uptake also depends on the number of capillaries perfused.11 In IRS1-/- mice, the 
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capillary ratio was structurally reduced. However, the number of perfused versus non-
perfused capillaries cannot be distinguished by the lectin staining used in this study. In 
IRS1+/+ mice the capillary ratio is higher, but not all capillaries are necessarily perfused, 
while in the IRS1-/- mice all capillaries may be perfused, despite the lower capillary ratio. 
This may imply that the muscle perfusion of IRS1+/+ and IRS1-/- is not or less different than 
expected on the basis of the capillary-to-muscle ratio. In favor of such compensatory 
mechanism we observed an insulin-mediated vasodilation in arterioles from IRS1-/- mice 
and not in IRS1+/+ mice.  
 
Perspectives 
Structural and functional alterations of the muscle microcirculation have been proposed to 
contribute to insulin resistance.33 These alterations comprise reduced insulin-mediated 
activation of Akt, reduced eNOS activity,17-19 normal to enhanced endothelin activity,17,20 
inward remodeling of arterioles21 and a reduced capillary-to-muscle ratio in skeletal 
muscle.22 The present study was undertaken to investigate whether decreased IRS1 
expression contributes to these structural and functional changes. 
Our data show that decreased IRS1 expression contributes to impaired Akt 
activation, inward remodeling of arterioles and a reduction of capillary to myocyte ratio. 
However, reduced IRS1 expression does not explain the impaired endothelium-dependent 
vasodilatation or enhanced ET-1 activity observed in insulin resistance.17,20 Interestingly, this 
study shows a novel additional role of IRS1 in the insulin-mediated vasoconstriction through 
ET-1. Its significance for impaired insulin signaling in insulin resistant subjects requires 
further clinical evaluation. 
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IV.3
IV.  IRS2 Deficiency decreases Blood Pressure  
      by Impairment of Insulin-mediated  
      Endothelin-1 activation in Muscle Arterioles 
 
 
Wineke Bakker, Caro-Lynn A.F. Alta, Ronald Vlasblom, Pieter Sipkema, Coen D.A. 
Stehouwer, Victor W.M. van Hinsbergh, Etto C. Eringa. 
 
 
 
ABSTRACT 
 
Objective: In type 2 diabetes, dysfunctional insulin receptor substrates (IRS) cause 
impaired insulin signaling, which is often associated with an increase in blood pressure. In 
part, insulin regulates blood pressure by controlling vasodilation (mediated by NO) as well 
as vasoconstriction (mediated by endothelin-1). IRS2 is necessary for insulin signaling; 
however, the involvement of IRS2 in blood pressure regulation is not known. The aim of this 
study is to investigate whether deletion of IRS2 alters blood pressure by changes in insulin-
mediated vasoreactivity and cardiac output.  
 
Research design and results: Radiotelemetry transmitters were implanted in IRS2-/- mice 
and their wildtype littermates for continuous blood pressure measurements without stress.  
The IRS2-/- mice showed a lower mean arterial pressure (MAP) than their wildtype 
counterparts (96±6 vs. 111±2 mmHg respectively, p<0.0001), due to mainly a decrease in 
vascular resistance and partly by decrease in cardiac output.  To further study vascular 
function, arterioles were isolated to study insulin-mediated vasoreactivity ex-vivo. Compared 
to IRS2+/+, IRS2-/- mice showed an impaired insulin-mediated ERK1/2 and endothelin-1 
activation, leading to insulin-mediated vasodilation. The sensitivity to endothelin-1 was not 
different between IRS2-/- and wildtype in arterioles.  
 
Conclusion: IRS2-deficiency lowers blood pressure, which is caused by a decrease in 
cardiac output and a decrease in vascular resistance by a specific impairment of insulin’s 
vasoconstrictor effects in arterioles. These data suggest that IRS2 plays a more important 
role in the ERK1/2/endothelin-1 pathway than in the Akt/NO pathway of insulin in arterioles.   
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INTRODUCTION 
 
Hypertension is associated with impaired insulin signaling, which is reflected by an 
prevalence of ~50% of insulin resistance in patients with hypertension.1 Impaired insulin 
signaling can be caused by environmental or genetic factors. Obesity is a frequent cause of 
impaired insulin signaling, in which changes in the function of insulin receptor substrates 
(IRSs) play an important role. Genetic mutations have been found in two IRS proteins, IRS1 
and IRS2, which have been reported to be associated with insulin resistance and/or type 2 
diabetes.2,3 However, the exact role of IRS proteins in blood pressure regulation is unknown. 
Blood pressure is controlled by cardiac output and by arterioles.4,5 Insulin plays an 
important regulatory role in these arteries.6 It determines vascular properties that contribute 
to blood pressure regulation by stimulating both vasodilation (through Akt activation and NO 
production)7,8  and vasoconstriction (through ERK1/2 activation and endothelin-1 (ET-1) 
production)9,10 in arterioles. In hypertension, vascular dysfunction is characterized by a 
predominance of insulin’s vasoconstrictor effects through decreased NO production and 
increased ET-1 production.11,12 This raises susceptibility to increased vascular peripheral 
resistance and hypertension.  
IRS proteins are essential to insulin signaling, but their exact role in blood pressure 
regulation and vasoreactivity is unknown. The IRS isoforms IRS1 and IRS2 are involved in 
the regulation of insulin-stimulated glucose disposal. Both IRS1-/- and IRS2-/- mice show 
endothelial dysfunction in aortic rings.13 How IRS proteins function in arterioles and thereby 
blood pressure regulation has not yet been studied. Whereas IRS1 has received more 
attention, and IRS1 and IRS2 are homologous proteins, yet IRS2 is more abundantly 
expressed in the vascular endothelium.13 Furthermore, the metabolic phenotype of IRS2-/- 
mice is more severe. IRS2-/- mice are hyperinsulinemic and become hyperglycemic later in 
life,14 whereas IRS1-/- mice stay in a hyperinsulinemic, but normoglycemic state.15,16  
In cultured endothelial cells, IRS1 is mainly described to function in insulin-
mediated NO production17 through Akt dependent eNOS phosphorylation.  IRS2 has been 
identified as an IRS1-independent pathway of insulin signaling.18-20 Furthermore, an 
increased IRS2 expression under hyperinsulinemia is accompanied by increased Akt and 
eNOS expression and decreased ERK2 expression in rat aortas.21 Of note, activity of 
ERK1/2 in arterioles regulates their diameter and therefore susceptibility to hypertension.22 
In addition, in a metabolic study, Kubota et al mentioned that systolic blood pressure is 
increased in IRS2-/- mice, as determined by tail cuff. In contrast, Bouzakri et al shows that 
IRS2 is mainly involved in the activation of ERK1/2 in muscle myoblasts.18 Thus, IRS2 might 
be an interesting determinant of endothelial function, but its exact role in insulin signaling in 
arterioles and its role in blood pressure regulation is not clear.  
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The aim of this study was to investigate whether deletion of IRS2 will affect blood 
pressure and whether this is mediated by shifting the balance of insulin-mediated 
vasoreactivity in arterioles. With the use of radiotelemetry, blood pressure was measured in 
IRS2-/- and IRS2+/+ mice. Resistance artery function and cardiac output were used as 
determinants of diastolic and systolic blood pressure. 
 
 
 
RESEARCH DESIGN AND METHODS  
 
Animals: The investigation conformed to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH publication No 85 to 23, revised 1996). The local 
ethics committee for animal experiments approved the procedures. Male and female IRS2-/- mice and 
their WT littermates, on a hybrid background of the C57Bl/6 and SV129 mice strain, (Jackson 
Laboratories, Maine, USA) were obtained by heterozygous breeding.  PCR was used to distinguish 
genotypes between IRS2+/+ and IRS2-/- mice. To check whether differences in genetic background 
affect insulin responses, C57Bl6 (Harlan, Horst, the Netherlands) and Sv129 mice (Jackson 
laboratories, Maine, USA) were used.  
 
Blood glucose and insulin (non fasting): Blood glucose was measured from tail blood samples using 
a glucose analyzer (HemoCue, Angelholm, Sweden). Plasma insulin was measured using ELISA 
(EZRMI-13K; Linco Research, St Charles, MO, USA). 
 
Blood pressure measurements: The radiotelemetry transmitters (TA 11 PA-C10, Data Science 
International, St. Paul, MN) were implanted under 3.0% isoflurane anesthesia (in a mixture of O2 and 
air) in 8-week-old mice. The pressure-sensing catheter-tip was placed through the left carotid artery into 
the aortic arch and the transmitter was placed in a subcutaneous pocket along the right flank. After a 
recovery period of 10 days, data of systolic (SBP), diastolic (DBP) and mean arterial pressure (MAP), 
heart rate (HR) and activity were collected every 5 min for 10 sec during 72 hours. The data was 
collected using the Dataquest ART software system, version 4.0 (Data Sciences International). This 
allowed us to detect, collect, and analyze signals from several animals simultaneously. For statistical 
analyses, we used mean values of 3 days for data analyses.  
To determine peripheral vascular resistance, the time constant tau was used to describe the 
individual diastolic pressure decay. The last third of the diastolic pressure decay was sampled (2 msec 
interval) and the individual coordinate points (t,P) were plotted on a semilogarithmic scale. This results 
in a nearly straight line with negative slope. The reciprocal of the slope is the time constant tau for that 
diastolic decay and can be used as an index of peripheral vascular resistance when the arterial 
compliance does not change.23,24 For each mouse, an average value was taken of at least 10 arterial 
waveforms.  
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Echocardiography: Non-invasive transthoracic echocardiograms were recorded in mice anesthetized 
with 1.2% isoflurane in a mixture of N2O/O2 (1/2, vol/vol) by an Aloka echo-machine (ProSound SSD-
4000) using a 13-MHz linear array transducer. Aortic diameter and aortic outflow (using Doppler in 
apical 5 chamber view) were measured and were used to determine stroke volume (SV: cross sectional 
area of the aorta * Velocity time integral of the aorta). Cardiac output (CO) was calculated by multiplying 
HR with SV. End-diastolic and end-systolic diameters (EDD and ESD, respectively) of the left ventricle 
were measured perpendicularly to the interventricular septum at midseptal level. EDD and ESD were 
used to calculate fractional shortening with the following formula: fractional shortening = [(EDD – 
ESD)/EDD] x 100%. 
 
Vasoreactivity: Mice were sacrificed with an overdose of isoflurane and arteries (aorta, femoral, 
mesenteric and gracilis artery) were dissected, placed in a pressure myograph and pressurized to their 
corresponding in vivo pressures (125, 100, 100 and 80 mmHg, respectively) to measure maximal 
diameters25. Compliance is defined as the slope of the pressure-volume relation (C=dV/dP) and is 
obtained by expanding a vessel by a known volume and measuring the change in pressure at steady-
state. The compliance (C) of the femoral artery was determined by the change in diameter (dD) divided 
by the change in pressure (dP), and multiplied with (π*D/2). dP/dD  was estimated by curve fitting of the 
diameter-pressure relation.  dP/dD and  the femoral diameter (D) were then determined at in-vivo 
pressure of the mouse (formula: C= (π*D*dD)/(2*dP)). 
To study changes in response to insulin in arterioles, segments of the gracilis artery were 
preconstricted to ~50% of the maximal diameter with 25 mM KCl in MOPS buffer, as described before26. 
Endothelial integrity was determined by measuring vasodilator response to acetylcholine (ACh: 
0.1μMol/l) before and after experiments. Acute effects of insulin (Human insulin (Actrapid®), Novo 
Nordisk, Alphen a/d Rijn, the Netherlands) on the diameter of the gracilis artery were studied at four 
concentrations of insulin (0.02, 0.2, 2 and 20nM) and diameter changes at each concentration were 
recorded for 30 minutes25. The role of ET-1 in insulin-mediated vasoreactivity was assessed by pre-
treatment for 30 minutes with the non-selective ET-1 receptor antagonist (PD142893: 10μM, Kordia, 
Leiden, the Netherlands) before the addition of insulin. Dose-relation responses with both acetylcholine 
or sodium nitroprusside and ET-1 were performed to check endothelial or smooth muscle integrity of the 
vessel wall.  
 
Protein analysis: Protein analyses was performed by western blotting, as described before.26 
Segments of gracilis arteries were exposed to solvent (controls) or to insulin (2nM) for 15 minutes at 
37ºC.  Differences in phosphorylated Akt at ser 473 were adjusted for differences in total Akt protein 
staining. Antibodies were obtained from Cell Signaling Technology. 
 
Statistics: Values are expressed as mean±SEM. Statistical analyses for differences in blood pressure 
were performed by Student’s t-test and differences in protein activation by column t-test with 
standardized mean. Differences in insulin responses were analyzed by one-way ANOVA and post hoc 
analysis was performed with the Bonferroni method. Differences in Probability values of <0.05 were 
considered statistically significant.  
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RESULTS 
 
Table 1 shows the general characteristics of IRS2-/- mice and WT littermates. IRS2-/- mice 
had similar body weights and higher levels of insulin and glucose than the IRS2+/+ mice. 
The diameters of both gracilis artery (resistance artery) and femoral artery (conduit artery) 
were reduced in IRS2-/- mice (Table 1). 
 
Blood pressure is decreased in IRS2-/- mice 
Blood pressure was measured continuously in conscious mice using radiotelemetry. Figure 
1A shows an example of the circadian rhythm of blood pressure in IRS2+/+ and IRS2-/- 
mice. The continuously measured mean arterial pressure (MAP) over 48 hours shows a 
decrease in IRS2-/- compared to IRS2+/+ mice (Fig 1B: 111±2 mm Hg vs. 96±6 mm Hg, 
p<0.01). The lower blood pressure in IRS2-/- mice was observed during the entire circadian 
cycle (Fig 1A). Both systolic and diastolic blood pressure are decreased by 10%, however 
due to large variation in the systolic blood pressure data, only the decrease in diastolic blood 
pressure was significant (Table 2).  The heart rate in conscious animals was not significantly 
different in IRS2-/- compared to IRS2+/+ mice (Table 2).  
 
The cardiac output is decreased in IRS2-/- mice 
To further explore the decrease in blood pressure of the IRS2-/- mice, determinants for both 
systolic and diastolic blood pressure were determined. Determinants for systolic blood 
pressure are the cardiac output and the compliance of the conduit arteries.  In this study 
cardiac output was determined by echocardiography under isoflurane anesthesia in both 
type of mice. Because isoflurane anesthesia influences blood pressure and heart rate, we 
measured both the arterial pressure by radiotelemetry and subsequently the cardiac output 
by echocardiography during one anesthetic period using a constant concentration of 
isoflurane (Table 3). The cardiac output was lower in the IRS2-/- mice compared to IRS2+/+ 
mice (Table 3), which was mainly determined by a decrease in stroke volume (Table 3). The 
fractional shortening, as indicator of the systolic heart function, was determined by end 
systolic and end diastolic lumen diameters and was not changed in IRS2-/- mice (Table 3).  
Changes in the compliance of the wall of conduit arteries were estimated from the 
pressure-diameter-relationships in isolated femoral arteries at pressures ranging from 25 till 
100 mmHg. The curve of the pressure-diameter-relation (Fig 2A) and the calculated 
compliance (Fig 2B) did not significantly differ between the femoral arteries from IRS2-/- 
mice and their IRS2+/+ counterparts.  We assume that possible changes in compliance of 
the femoral artery are representative for the total arterial compliance. 
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General characteristics IRS2+/+ IRS2-/- P
Body weight (g) 23±1 24±1 0.84
Fasting Blood Glucose (mMol/l) 5.3±0.5 12.6±2.7 <0.05
Non-fasting Blood Glucose (mMol/l) 8.7±0.8 12.2±0.9 <0.01
Non-fasting Blood Insulin (μU/ml) 9±1 20±2 <0.01
Diameters arteries
Gracilis artery (μm) 127±5  111±6   <0.05
Femoral artery (μm) 298±8 244±10  <0.05
Mesenteric artery (μm) 201±14 197±10 0.51
Aorta (μm) 1342±5 1283±6 0.09
Characteristics IRS2+/+ IRS2-/- P
Heart weight (mg) 116±1 118±1 0.87
Mean arterial pressure (MAP: mmHg) 69.7±7.3 46.0±4.8 <0.05
Heart rate (HR: bpm) 444±16 428±45 0.71
Stroke volume (SV: ml) 0.048±0.004 0.032 ±0.004 <0.05
Cardiac output (HR*SV: ml/min) 21.5±2.2 13.3±2.1 <0.05
Total peripheral resistance (mmHg/ml/min) 3.6±0.7 4.1±1.1 0.69
End Diastolic Lumen Diameter (EDD: μm) 3.1±0.2 2.8±0.2 0.12
End Systolic Lumen Diameter (ESD: μm) 1.2 ±0.1 1.2±0.1 0.60
Fractional shortening (%) 60.9±2.8 57.7±3.2 0.45
Table 3.  Cardiac 
characteristics involving 
blood pressure regulation 
under 1.2% isoflurane 
anesthetics Cardiac Output 
(CO) was determined by 
HR*SV. Peripheral Vascular 
Resistance was determined by 
MAP/CO. Fractional shortening 
was determined by (EDD-
ESD/EDD)*100%.  
Table 2. Blood pressure 
characteristics of conscious 
IRS2+/+ and IRS2-/- mice  All 
variables are an average of 
collected data of 5 seconds 
every 5 minutes for a period of 
72 hours. IRS2+/+ n=15,    
IRS2-/- n=8 
Table 1. General 
 characteristics and artery 
diameters of IRS2-/- mice.  
Data represent mean±sem, 
IRS2+/+ n=10, IRS2-/- n=7. 
General characteristics IRS2+/+ IRS2-/- P
Mean arterial pressure (MAP) (mmHg) 111±2 96±6 <0.01
Systolic pressure (mmHg) 115±8 104±6 0.36
Diastolic pressure (mmHg) 101±2 90±4 <0.01
Pulse pressure (mmHg) 21±2 15±3 <0.05
Heart Rate (bpm) 589±11 553±19 0.08
Activity (moves / 5 seconds) 7 ±1 5 ±1 0.11
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Figure 3. Decreased peripheral vascular resistance, determined by time constant tau of the diastolic 
pressure decay, in IRS2-/- mice.  (A) Continuous recording of arterial waveform in IRS2+/+ (○) and IRS2-/- 
mice (●) . (B) Time constant tau of the diastolic pressure decay as an index for peripheral vascular resistance 
in IRS2+/+ (n=9) and IRS2-/- (n=8), * p<0.05. 
Figure 1. Decreased blood pressure in IRS2-/- mice.  (A) Representative day and night rhythm of a 
continuous blood pressure registration for 2 nights and 2 days in one representative IRS2+/+ (○) and one 
representative IRS2-/- mouse (●). (B) Mean arterial pressure (MAP), an average of diastolic and systolic 
pressure averaged over 48h was decreased in IRS2-/- (n=8) compared to IRS2+/+ (n=15), * p<0.01.  
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Estimated peripheral vascular resistance is decreased in IRS2-/- mice 
Besides compliance, vascular resistance is the major determinant of diastolic blood 
pressure, which can be determined in conscious mice by analyzing the diastolic pressure 
decay from the arterial waveforms obtained by the radiotelemetry recordings. Figure 3 
shows a typical arterial waveform from IRS2+/+ and IRS2-/- mice (Fig 3A). One third of the 
diastolic pressure decay was used to determine the time constant tau (gray surface in Fig 
3A), which was decreased in IRS2-/- mice compared to IRS2+/+ mice (Fig 3B). As 
compliance of the vessel wall of conduit arteries was similar between IRS2+/+ and IRS2-/- 
mice, this implicates that the peripheral vascular resistance (PVR) in IRS2-/- mice is 
decreased, because the time constant is the product of the PVR and the compliance. 
 
Insulin-mediated ET-1 and ERK1/2 activation is impaired in arterioles from IRS2-/- 
mice 
To study whether changes in vascular resistance in IRS2-/- mice could be explained by 
changes in vascular function and protein expression, arterioles from IRS2+/+ and IRS2-/- 
mice were isolated.  
Arterioles of IRS2-/- mice showed normal endothelial function, as reflected by 
acetylcholine-induced vasodilation (Fig 4A), which is completely NO-dependent in these 
arteries.26 The sensitivity to respond to NO and ET-1 was not changed in IRS2-/- mice, as 
became evident from the dose response curves with the NO donor sodium nitroprusside and 
exogenous ET-1 (Fig 4B and 4C). This shows that the arterioles from IRS2-/- mice were 
able to produce NO and to respond to NO and ET-1 in the absence of insulin. 
In IRS2+/+ mice, insulin induced vasoconstriction, which was abolished after 
preincubation with a non-selective ET-1 receptor antagonist (Fig 5A). This shows that the 
vasoconstriction in the arterioles of IRS2 +/+ mice was completely dependent on insulin-
mediated ET-1 activity in the arterioles of IRS2+/+ mice.  The vasoconstriction to insulin in 
IRS2+/+ mice was different than in previous studies in C57Bl/6 mice, in which we found no 
change in diameter in response to insulin in arterioles.26 In contrast to that study, the IRS2 
mice used in this study are inbred from two mice strains, C57Bl/6 and Sv129.  We isolated 
arteries from both strains and subjected them to insulin, to investigate whether insulin has 
different effects on arterioles from different strains of mice. Insulin induced a 
vasoconstriction in arteries from Sv129 mice, while it had no net effect on the diameter in 
arteries from C57Bl/6 mice (Fig 6A). Endothelial function (response to acetylcholine-
mediated vasodilation) was not different between both mouse strains (Fig 6B). This shows 
that arteries from different mouse strains display different responses to insulin and 
underlines the importance of using littermates in the current study.  
 In the IRS2-/- mice, insulin levels are higher than IRS2+/+ mice in-vivo (Table 1). 
However, insulin induced no change in vascular diameter at all concentrations and 
preincubation with an ET-1 receptor antagonist had no effect (Fig 5B). As the 
responsiveness to ET-1 was equal (Fig 4C), this indicates that the ET-1 mediated 
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vasoconstriction induced by insulin is blunted in arterioles from IRS2-/- mice. In line with this, 
the phosphorylation of ERK1/2 is impaired in response to insulin in arterioles (Fig 7A).  
As the induction of NO by insulin is regulated by the phosphorylation of Akt,27  we 
further investigated whether also the NO pathway is affected in arterioles of the IRS2-/- mice 
by determine the phosphorylation of Akt. The phosphorylations of Akt at ser473 (Fig 7B) and 
thr308 (data not shown) in response to insulin were similar in arterioles from IRS2+/+ and 
IRS2-/- mice. 
Taken together, these data strongly suggest that a specific defect in insulin-
mediated ET-1 activity exists in the arterioles from IRS2-/- mice, which contributes to the 
decreased vascular resistance and decreased blood pressure in-vivo. 
Figure 5: Impaired insulin-mediated vasoreactivity in IRS2-/- mice. Responses to insulin in IRS2+/+ 
(A) and IRS2-/- mice (B) with ( ∆, ▲) and without (○, ●) pretreatment of ET-1 receptor antagonist, 
PD142893 (10μM) in IRS2+/+ (n=5) and IRS2-/- (n=4), * p<0.01).  
Figure 4: Vasoregulatory responses in arterioles in IRS2-/- mice . Acetylcholine, ACh (A); sodium 
nitroprus-side, SNP (B) and ET-1 (C) were comparable in IRS2+/+ (○, n=5) and IRS2-/- mice (●, n=6).   
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Figure 7: Decreased Phosphorylation ERK1/2, but not of Akt to insulin in arterioles of IRS2-/- mice. 
Insulin (2nM) stimulation (black bars) was compared to control situation (white bars) in the phosphorylation 
of ERK1/2 in (A) and in the phosphorylation of Akt at ser473 (B) in segments of the gracilis from IRS2+/+ 
(n=8) and IRS2-/- (n=9) mice, * p<0.05; # p<0.01.  
Figure 6: Insulin-mediated vasoreactivity (A) and endothelial function (B) in arterioles of different 
mouse strains. Response to different concentrations of insulin in arterioles of C57Bl/6 and Sv129 mice 
(n=6, *P<0.001) (A). Response to different concentrations of acetylcholine (ACh) in arterioles of C57Bl/6 and 
Sv129 mice (n=4) (B). 
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DISCUSSION 
 
This study demonstrates for the first time that IRS2 deficiency lowers blood pressure, which 
is accompanied by a decrease in cardiac output and a decrease in vascular resistance by a 
specific impairment of insulin’s vasoconstrictor effects in arterioles. Furthermore, this study 
shows that IRS2 is more involved in the ERK1/2-ET-1 pathway than in the Akt/NO pathway 
of insulin signalling in arterioles. 
To our knowledge, one other study measured blood pressure in IRS2-/- mice, and 
demonstrated, with the tail-cuff method, that systolic blood pressure in IRS2-/- mice is 
increased.13 In contrast, the present study shows a decrease in mean arterial pressure in 
IRS2-/- mice, mainly due to a decrease in diastolic blood pressure. Explanations for these 
different results may be the difference in the method to measure blood pressure and a 
difference in genetic background of the IRS2 mice. The tail cuff method measures the blood 
pressure in restrained and stressed mice, which influences the blood pressure. The use of 
radiotelemetry in the present study overcomes the induction of stress. Furthermore, it 
determines an averaged central blood pressure for 72 hours in a normal environment, 
instead of a determination of peripheral blood pressure for a short time period in a restrained 
condition.  
Systolic blood pressure was not significantly decreased in IRS2-/- mice (Table 1). 
However, a determinant of systolic blood pressure, cardiac output, was decreased in IRS2-/- 
mice. Cardiac output was determined under isoflurane anasthesia, which also has 
cardiodepressive28 and vasodilator effects29,30 and may influence cardiac output and blood 
pressure.31 However, under these anesthesia conditions, blood pressure and heart rate 
decreased in both IRS2+/+ and IRS2-/- mice in the same extent (comparing table 2 and 
table 3). This suggests that the isoflurane anesthesia had no extra effect in IRS2-/- mice on 
blood pressure regulation. 
The decrease in mean arterial pressure observed in IRS2-/- mice is partly 
determined by a decrease in diastolic pressure (Fig 1 and Table 2), a decrease in vascular 
resistance and an impaired insulin-mediated ET-1 activation (Fig 5). Diastolic blood pressure 
is largely regulated by adaptations in the vascular system. The diastolic pressure decay is 
caused by the drainage of blood from the large arteries through the peripheral arterioles and 
can be used as a determinant for vascular resistance, if compliance does not change.23,24 
The time constant tau of the diastolic pressure decay was decreased in IRS2-/- mice (Fig 3), 
which implicates a decrease in vascular resistance, because the compliance did not change 
in the IRS2-/- mice. In these arterioles, insulin plays an important role in regulating vascular 
diameter, by inducing either vasoconstriction or vasodilation. This study points out that 
deletion of IRS2 impairs the capability of arterioles to activate the potent vasoconstrictor ET-
1 in response to insulin, resulting in a vasodilation. This impairment could be a reasonable 
explanation for the decreased vascular resistance and decreased diastolic blood pressure in 
IRS2-/- mice.  
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IRS2 in insulin signaling has been described to participate in the activation of the ERK1/2 
pathway in myoblasts,31,32 but also in the activation of the Akt pathway upon stimulation with 
insulin in fibroblasts.33 These data, however, were obtained in-vitro and in non-vascular cell 
types. To our knowledge, this is the first study that investigated the functional role of IRS2 in 
insulin responses in the vascular wall. Our functional data showed that IRS2 is involved in 
insulin-mediated vasoconstriction by activation of ET-1. Whereas IRS2 is structurally 
homologous to IRS1,19 it appears that these protein isoforms are functionally different. IRS1 
is mainly described in the activation of Akt upon insulin stimulation,17 whereas this study 
shows that IRS2 is not involved in activation of Akt in the vascular endothelium.  IRS2 
appears to be more involved in insulin induced MAPK-activation, insulin-mediated 
vasoconstriction and thereby negatively regulates blood pressure.  
In the human microcirculation, insulin induces a net vasodilation, which is NO 
dependent.8 However, in this study, insulin’s vasodilator effects in arterioles were not 
functionally present in these types of mice. Insulin induces a vasoconstriction in arteries 
from IRS2+/+ mice, and did not show a vasodilation by blocking insulin’s vasoconstrictor 
component. Insulin’s differential effects in different mice strain can explain this discrepancy 
between human and mice studies.  It appears that arteries from certain mouse strains, 
particular the Sv-strains, are less sensitive to insulin-mediated NO production in the vascular 
wall (See Fig 6A). This reduced NO production results in vasoconstriction in arterioles, 
which were crossbred on a Sv-hybrid background, like the IRS2 mice. However, by 
constantly comparing the IRS2-/- with WT littermates these differences in strain effects do 
not influence our conclusion. 
 
Perspectives 
The relationship between insulin resistance and hypertension is poorly understood, as not all 
insulin-resistant subjects are hypertensive. Our finding that IRS2 deficiency decreases blood 
pressure sheds new light on the relationship between insulin resistance and hypertension. 
The majority of studies on relationships between insulin signalling and hypertension have 
focused on IRS1, which mainly regulates NO activity in vascular endothelium.17 Our results 
suggest that decreased IRS2 activity protects against hypertension. We propose that not a 
general decrease in expression of IRS1 and IRS2, but a predominance of IRS2 over IRS1 
activity in vascular endothelium increases an individual’s risk of developing hypertension. 
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V.  PKC-theta Activation induces Insulin-  
     mediated Constriction of Muscle Arterioles  
                          
Wineke Bakker, Pieter Sipkema, Coen D.A. Stehouwer, Erik H. Serne, Yvo M. 
Smulders,  Victor W.M. van Hinsbergh, Etto C. Eringa. 
 
 
 
ABSTRACT 
 
Objective:PKCθ-activation is associated with insulin resistance and obesity, but the 
underlying mechanisms have not been fully elucidated. Impairment of insulin-mediated 
vasoreactivity in muscle contributes to insulin resistance, but it is unknown whether PKCθ is 
involved. In this study, we investigated whether PKCθ-activation impairs insulin-mediated 
vasoreactivity and insulin signaling in muscle arterioles. 
 
Research Design and Methods: Vasoreactivity of isolated arterioles of mouse gracilis 
muscles to insulin (0.02-20nM) was studied in a pressure myograph with or without PKCθ 
activation by palmitic acid (PA, 100μM). 
 
Results: In the absence of PKCθ activation, insulin did not alter arterial diameter, which was 
caused by a balance of NO-dependent vasodilator and endothelin-dependent 
vasoconstrictor effects. Using three-dimensional microscopy and Western blotting of muscle 
arterioles, we found that PKCθ is abundantly expressed in endothelium of muscle arterioles 
of both mice and humans and is activated by pathophysiological levels of PA, as indicated 
by phosphorylation at Thr-538 in mouse arterioles. In the presence of PA, insulin induced 
vasoconstriction (21±6% at 2nM insulin), which was abolished by pharmacological or 
genetic inactivation of PKCθ. Analysis of intracellular signaling in muscle arterioles showed 
that PKCθ activation reduced insulin-mediated Akt phosphorylation (Ser473) and increased 
ERK1/2 phosphorylation. Inhibition of PKCθ restored insulin-mediated vasoreactivity and 
insulin-mediated activation of Akt and ERK1/2 in presence of PA.  
 
Conclusions: PKCθ activation induces insulin-mediated vasoconstriction by inhibition of Akt 
and stimulation of ERK1/2 in muscle arterioles. This provides a new mechanism linking 
PKCθ activation to insulin resistance. 
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INTRODUCTION 
Obesity is associated with disturbed insulin signaling1 leading to muscle insulin resistance, 
i.e. impaired insulin-mediated glucose uptake in muscle.2 Insulin resistance increases the 
risk for development of type 2 diabetes and hypertension.3 The impairment of vasoactive 
responses to insulin in the microcirculation4 has been described to contribute to insulin 
resistance by reducing appropriate delivery of insulin to skeletal muscle myocytes. However, 
the exact mechanism behind impaired vascular insulin responses leading to insulin 
resistance remains to be elucidated. 
Impairment of insulin-mediated vasoreactivity in the muscle microcirculation is 
characterized by an imbalance between insulin-mediated NO and endothelin-1 (ET-1) 
production. In the microcirculation, insulin regulates vasoactive responses by stimulating 
both vasodilator and vasoconstrictor effects. Insulin has been shown to induce 
vasodilatation by activation of Akt, which enhances Ser1177 phosphorylation and activity of 
eNOS.5 This vasodilator effect regulates nutritive muscle blood flow and, consequently, 
contributes to insulin-mediated glucose uptake in muscle.6 Vasoconstrictor effects of insulin 
are critically dependent on the activation of ERK1/2, which controls ET-1 release by the 
endothelium.7-9 Increased ET-1 activity, as observed in insulin resistant states, has been 
shown to impair blood flow and glucose uptake.10 In microvessels of insulin-resistant 
animals, it has been observed that insulin-mediated Akt activation is selectively impaired, 
whereas ERK1/2 activation is not altered.11  
PKCθ activation impairs insulin signaling and may be responsible for impaired 
capillary recruitment in muscle leading to a decrease in glucose uptake. PKCθ, one of the 
novel Ca2+-independent PKC isoforms,12 can be activated by  lipid infusion,13,14 a high-fat 
diet15 or direct stimulation with saturated fatty acids.16,17 PKCθ activation, induced by fatty 
acids, has been shown to impair insulin-mediated glucose uptake in skeletal muscle 
myocytes and in adipocytes by the inhibition of Akt in in-vitro studies.16-18 As outlined above, 
however, impaired glucose uptake in muscle is also caused by impaired nutritive blood flow, 
which is critically dependent on activation of Akt.19 It has been reported that fatty acids 
directly impair insulin-mediated nutritive muscle blood flow and cause insulin resistance.20
Moreover, mice lacking PKCθ are protected from acute fatty acid-induced insulin 
resistance21 and PKCθ activity is increased in skeletal muscle from obese diabetic 
patients.22 However, whether PKCθ activation impairs insulin’s vasoactive effects and 
thereby contributes to the development of insulin resistance is unknown. 
We hypothesize that PKCθ activation impairs insulin-mediated vasoreactivity in 
skeletal muscle arterioles, by interfering in the insulin signaling pathway. To study the 
vasoactive effects of insulin and PKCθ activation on arterioles, we used arterioles of gracilis 
muscles from wild type and PKCθ-knockout (PKCθ-KO) mice.  
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RESEARCH DESIGN AND METHODS 
 
Animals: The investigation conformed to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH publication No 85 to 23, revised 1996). The local 
ethics committee for animal experiments approved the procedures. Male C57Bl6 mice (Harlan; Zeist, 
the Netherlands) and male PKCθ-KO mice (Jackson Laboratories, Maine, USA, stock: 005711) 
weighing between 25 and 30g were sacrificed by CO2 inhalation and first order arterioles of the gracilis 
muscle were isolated. PKCθ-KO mice were generated by inactivation of gene encoding PKCθ by 
replacing the exon encoding the ATP-binding site of its kinase domain (amino acid residues 396-451) 
with the neomycin resistance gene23. PCR was used to confirm the inactive PKCθ in these mice with 
primers: 5'-TTGGTTCTCTTGAACTCTGC-3', 5'-ACTGCATCTGCGTGTTCGAA-3', 5'- 
TAAGAGTAATCTTCCAGAGC-3'.   
 
Patients:  Human skeletal muscle biopsies were kindly provided by Dr. HW Niessen. Participants gave 
informed consent for participation in the study. The study was undertaken with approval of the local 
ethics committee and performed in accordance with the Declaration of Helsinki. 
 
Chemicals:  MOPS-buffer consisted of (in mM) 145 NaCl, 4.7 KCl, 2.5 CaCl2, 1.0 MgSO4, 1.2 
NaH2PO4, 2.0 pyruvate, 0.02 EDTA, 3.0 MOPS (3-(N-morpholino) propanesulfonic acid), 5.5 glucose 
and 0.1% bovine serum albumin, at pH 7.4.  Palmitic acid (PA, C16:0, 10mM) was dissolved in 0.1M 
NaOH, coupled to 10% bovine albumin serum (BSA) as described by Kim et al.24 and diluted to a final 
concentration of 100 μM PA/0.1% BSA in MOPS-buffer (pH 7.4). Palmitic acid, BSA, L-NA, papaverine 
and acetylcholine (ACh) were obtained from Sigma (St. Louis, MO). The PKCθ inhibitor (Biosource, 
Carmarillo, USA), an isoform-specific pseudosubstrate (H2N-Leu-His-Gln-Arg-Arg-Gly-Ala-Ile-Lys-Gln-
Ala-Lys-Val-His-His-Val-Lys-Cys-NH2), inhibits the activity of PKCθ by binding to the substrate site in its 
regulatory C1-domain.12,25-28   
 
Vasoreactivity experiments: After dissection, the gracilis artery was placed in a pressure myograph 
and studied at a pressure of 80 mmHg and a temperature of 37°C in MOPS-buffer as described.7 The 
arteries were preconstricted to approximately 50% of the maximal diameter with 25 mM KCl. Endothelial 
integrity was determined by measuring vasodilator response to acetylcholine (ACh: 0.1μM) before and 
after experiments. Acute effects of insulin (Novo Nordisk, Alphen a/d Rijn, the Netherlands) on the 
diameter of the gracilis artery were studied at four concentrations of insulin (0.02, 0.2, 2 and 20nM) and 
diameter changes at each concentration were recorded for 30 minutes.7 The roles of NO and ET-1 in 
insulin-mediated vasoreactivity were assessed by pre-treatment for 30 minutes with the non-selective 
ET-1 receptor antagonist (PD142893: 10μM, Kordia, Leiden, the Netherlands) or an inhibitor of NO 
synthase (N-Nitro-L-arginine (L-NA): 0.1mM) before addition of insulin. To study the interaction between 
PKCθ and insulin in arterioles, artery segments were pre-treated with PA (100μM) for 30 minutes to 
activate PKCθ and were thereafter subjected to insulin. To inhibit PKCθ activity, artery segments were 
either pretreated with PKCθ-pseudosubstrate (PKCθi: 1μM, Biosource) before adding PA and insulin or 
by the isolation of gracilis artery segments from PKCθ-KO mice. 
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Figure 2. Effects of PA on insulin responses in mouse arterioles. A: Effects of physiological concentrations of 
Palmitate (PA; 10-600 μM) on arterial diameter, in the absence (white circles) and presence of insulin (black 
circles) (I: 2nM). **P<0.01; # P <0.001, n=3. B: Vasoactive effects of insulin alone (black squares), with PA (black 
circles) (100μM), and with PA and PKCθ inhibition by a pseudosubstrate (black triangles) (PKCθi, 1μM). 
Responses are given as percent change from the baseline diameter. * P < 0.05; ** P <0.01; # P <0.001, insulin vs 
insulin + PA; insulin + PA vs insulin + PA + PKCθ inhibition, n=5.
Figure 1. Effects of insulin on 
the diameter of mouse 
arterioles. Vasoactive effects of 
insulin (I) alone (black squares) 
and during inhibition of NO 
(black diamonds) (LNA, 0.1mM), 
or ET-1 (black triangles) 
(PD142893, 10μM). Responses 
are given as percent change 
from the baseline diameter. * 
P<0.05, # P<0.001 vs. insulin, 
n=5.  
General characteristics WT PKCθ-KO P
A.  Passive Diameter  (μm) 127±4 132±4 0.48
B.  Basal Diameter (μm) 69±4 69±3 0.92
C. Active Response (%)* 55±3 49±2 0.29
D. Diameter after Acetylcholine (μm) 99±4 97±5 0.86
E.  Diameter change after Acethylcholine (%)** 57±5 44±5 0.17
Table 1. General characteristics of diameter from gracilis arteries of wild type and PKCθ-KO 
mice. Basal diameter was determined after preconstriction with KCl (25mM). NS: not significant, WT 
n=20, PKCθ-KO n=6, data expressed as mean ± SEM. * Basal arterial tone was calculated by ((A-
B)/A)*100%,   ** Diameter change after ACh was calculated by ((D-B)/A-B))*100%.
A B
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Western blot experiments: Western blot analysis was performed as described.8 Segments of gracilis 
arteries from the same mouse (3 mm in length, n=4) were exposed to solvent, insulin, insulin with PA or 
insulin with PA and PKCθ pseudosubstrate for 15 minutes at 37ºC. The protein lysates of different 
arterial segments were stained with a specific primary antibody against phosphorylated Akt (60 kDa), 
phosphorylated ERK1/2 (44/42 kDa), phosphorylated PKCθ (79 kDa), total Akt and total ERK1/2 
(Antibodies obtained from Cell signaling technology, Boston, MA) and were visualized with a 
chemiluminescence kit (Amersham).  Differences in phosphorylated protein, were adjusted for 
differences in the corresponding total protein staining or Actin (50 kDa). 
 
Immunohistochemistry: PKCθ was stained in endothelium and smooth muscle of arterial segments, 
and in human arteries in skeletal muscle biopsies using a primary antibody against total-PKCθ (1:50, 
New England Biosource) and a fluorescein isothiocyanate- (FITC-) labeled secondary antibody. DAPI 
was used as nuclear counterstain.29 3D images of arterial segments were obtained using a ZEISS 
Axiovert 200 Marianas inverted digital imaging microscope workstation using Slidebook software 
(Slidebook version 4.1; 3 Intelligent Imaging Innovations, Inc). 
 
Statistics: Steady-state responses are reported as mean changes in diameter from baseline (in 
percent) ± SEM. The basal diameter was defined as the arteriolar diameter just before addition of the 
first concentration insulin. Differences between means at each concentration and differences in 
phosphorylation by western blot were assessed by one-way ANOVA with Bonferroni post hoc tests. 
Data were expressed as relative to unstimulated controls (C), assigning a value of 1 to the control. 
Differences were considered statistically significant if P < 0.05.  
 
 
 
RESULTS 
 
General characteristics of arterioles were similar in the PKCθ-KO and the WT mice (Table1). 
Preconstriction with KCl (25mM) induced arterial tone, reducing the diameter of these 
arteries to 55±2% and 49±2% in WT and PKC KO mice, respectively. All arterial segments 
dilated more than 25% in response to the endothelium dependent vasodilator ACh (0.1μM) 
at the start of the experiment. Palmitic Acid (PA) was used to activate PKCθ in this study. 
 
Insulin exerts NO-dependent vasodilator and ET-1-dependent vasoconstrictor effects 
 We first characterized, in wild type (WT) mice, the vasoactive effects of insulin in muscle 
arterioles and the role of NO and ET-1 activity therein. Insulin alone had no acute effect on 
the diameter of these arteries due to a balance of vasoconstrictor and vasodilator effects 
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Figure 4 
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Figure 3. PKCθ localization in mouse and human arterioles and PKCθ activation by PA. A-
F: Presence of PKCθ in the endothelial cell layer (A-C) and not in the smooth muscle cell layer 
(D-F) of mouse arterioles with immunohistochemistry at x63 magnification. EC endothelial cell 
layer, SMC=smooth muscle cell layer. G-K: Presence of PKCθ in small arteries in human 
quadriceps muscle of with co-staining of endothelial marker CD31 with fluorescence (G-I) and 
with bright light (J-K) at 40x magnification. L: PKCθ activation measured by the phosphorylation 
of PKCθ at Thr538 (n=4), * P<0.05. C= control, I=insulin (2nM), PA= Palmitic acid (100μM). 
Western blots shown are representative of four independent experiments.
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(Fig 1). This balance became apparent after inhibition of either insulin’s vasodilator effects, 
by blocking the NO production (LNA), or insulin’s vasoconstrictor effects, by adding the ET-1 
receptor blocker PD142893 (Fig 1). In the absence of insulin, the inhibitors of NO and ET-1 
had no significant effect on the arterial diameter (-4.2±3.5% and 1.3±2.1%, respectively). 
Thus, the vasodilator effects of insulin are NO-dependent and the vasoconstrictor effects of 
insulin are ET-1-dependent in muscle arterioles of WT mice.  
 
PA induces insulin-mediated vasoconstriction  
PA was used to study the effects of activation of PKCθ in arterioles of WT mice. PA induced 
a slight dose-dependent vasoconstriction in the absence of insulin and this vasoconstriction 
was enhanced in the presence of insulin (Fig 2A). Physiological levels of PA (10-50 μM)30 
induced no vasoconstriction in the presence of insulin (2nM), whereas pathophysiological 
levels of PA (100-600μM)31 induced a dose-dependent vasoconstriction to insulin (2nM) 
(Fig2A). 
Fig 2B shows that in the presence of PA, at a concentration that PA itself had no 
significant effect (100μM), insulin induced a dose dependent vasoconstriction (for example, 
vasoconstriction of 21%±6% at 2nM insulin). Inhibition of PKCθ with a pseudosubstrate 
(1μM) abolished the insulin-mediated vasoconstriction in the presence of PA and restored 
the balance of insulin’s vasodilator and its vasoconstrictor effect. In the absence of PA, the 
PKCθ inhibitor itself had no significant effect on arterial diameter (8±6%). In contrast, 2nM 
insulin induced vasoconstriction (-16±2%) during inhibition of PKCθ (data not shown). This 
suggests that basal activity of PKCθ is needed for normal insulin-mediated vasoreactivity in 
the absence of fatty acids. 
 
PKCθ is present in endothelium of arterioles of both mice and humans and is 
activated by PA 
To further clarify the effects of PKCθ on insulin responses, we first investigated whether 
PKCθ is present and whether PKCθ can be activated in muscle arterioles of the mouse. The 
presence of PKCθ was demonstrated by staining PKCθ in mouse arterial segments. Figure 
3A-C shows that PKCθ is abundantly expressed in the endothelial cells, but is almost absent 
in smooth muscle (Fig 3 D-F) of mouse gracilis arterioles. PKCθ is also present in small 
arteries of human skeletal muscle. Fig 3 G-K shows a co-staining of PKCθ with the 
endothelium-specific marker CD31.  
The activation of PKCθ by PA in the arterial segments was demonstrated by measuring the 
phosphorylation of PKCθ at Thr538, which reflects catalytically active PKCθ.32,33 Figure 3L 
shows that patho-physiological levels of PA (100μM), alone or in combination with 
physiological levels insulin (2nM) increased the phosphorylation of PKCθ at Thr538 in these 
arterioles.  
Taken together, these data show that vascular PKCθ is present predominantly in 
the endothelium and is more than additionally activated by PA, insulin and the combination 
of both. 
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Figure 6. Effect of ET-1 inhibition on 
insulin-mediated vasoreactivity in 
WT and PKCθ-KO mice. Insulin-
mediated vasoreactivity was studied 
with or without PA or ET-1 inhibition.
Responses are given as percent 
change from the baseline diameter and 
bars in the graph correspond to table 
below. ** P<0.01. WT: n=5; PKCθ-KO: 
n=6 (I; I+PA) and n=2 (I+ET-1 
inhibition).  PA= Palmitic acid. 
Figure 4. PKCθ-KO mice induce 
insulin-mediated vasoconstriction 
independent from PA in arterioles. 
Vasoactive effects of insulin alone 
(black squares) with PA (black circles) 
(100μM), and with PA and PKCθ
inhibition (black triangles) by a 
pseudosubstrate (PKCθi, 1μM) in 
PKCθ-KO mice. Responses are given 
as percent change (±SE) from the 
baseline diameter.  
Figure 5. Effect of PKCθ
activation on intracellular 
signaling of insulin. A: Insulin-
mediated Akt phosphorylation at 
Ser-473 in WT mice, n=5. B: Effect 
of ERK1/2 phosphorylation at 
Thr202/Tyr204 in WT mice, n=5. C:
Effect of Akt phosphorylation in 
PKCθ-KO mice, n=6. D: Effect of 
ERK1/2 phosphorylation in PKCθ-
KO mice, n=5. C=control, I=insulin 
(2nM), PA=Palmitic acid (100μM), 
PKCθi=PKCθ pseudosubstrate 
(1μM). * P < 0.05; ** P <0.01. PKCθ-KO mice PKCθ-KO mice
  Wild Type mice   Wild Type mice 
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PKCθ-KO mice are protected from insulin-mediated vasoconstriction induced by PA 
To further explore whether PKCθ activation impairs insulin responses, we subsequently 
studied insulin-mediated vasoreactivity in gracilis arteries of mice, in which PKCθ was 
functionally inactivated (further indicated as PKCθ-KO mice). Arterioles of PKCθ-KO mice 
had normal basal arterial tone and slightly attenuated vasodilator effects to ACh (0.1μM) 
(Table 1). Figure 4 shows that insulin induced a vasoconstriction, independent from PA, in 
PKCθ-KO mice. Furthermore, the addition of either PA (100μM) or the combination of PA 
and the PKCθ pseudosubstrate (1μM) did not induce additional effects.  
 
PKCθ activation inhibits insulin-mediated Akt activation and enhances insulin-
mediated ERK1/2 activation in muscle arterioles 
The vasodilator and vasoconstrictor effects of insulin in muscle arterioles require the 
activation of Akt and ERK1/2, respectively. To establish which of these signal transduction 
pathways of insulin were affected by PKCθ activation, western blot analyses of Akt (Ser-
473) and ERK1/2 (Thr202/Tyr204) phosphorylation were performed. Gracilis arterioles of 
WT and PKCθ-KO mice were exposed to insulin, insulin with PA, and insulin with PA with a 
PKCθ inhibitor. In WT mice, the exposure of gracilis arterioles to PA reduced the insulin-
mediated Akt activation and caused an increase in insulin-mediated ERK1/2 phosphorylation 
(fig 5A+B). PA alone had no significant effect on the phosphorylation of Akt and ERK1/2 
(data not shown). Treatment with a PKCθ pseudosubstrate (1μM) restored the disrupted 
insulin-mediated activation of Akt and ERK1/2 in gracilis arteries of wild type mice in the 
presence of PA (fig 5A+B). In PKCθ-KO mice, insulin-mediated activation of Akt and ERK1/2 
was not affected by either PA (100μM) or the combination of PA with a PKCθ 
pseudosubstrate (1μM) (Fig 5C+D). 
Taken together, these data show that activated PKCθ interferes in insulin signaling in 
muscle arterioles by inhibiting Akt activation and enhancing of ERK1/2 activation, and shows 
that both vasodilator and vasoconstrictor effects of insulin are affected.  
 
Insulin-mediated vasoconstriction during PKCθ activation is ET-1 dependent  
PKCθ activation shifts the balance of insulin-mediated vasoreactivity towards 
vasoconstriction in WT mice (Fig 2B), whereas in PKCθ-KO mice insulin also induces 
vasoconstriction (Fig 4). To verify whether this vasoconstriction is indeed ET-1 dependent, 
arteries from WT and PKCθ-KO mice were pretreated with an ET-1 receptor antagonist 
(PD142893, 10μM). In the presence of PA, ET-1 receptor antagonist abolished the insulin-
mediated vasoconstriction induced by PA/PKCθ activation in WT mice (Fig 6). In PKCθ-KO  
mice, ET-1 receptor antagonist also abolished insulin-mediated vasoconstriction and even 
caused vasodilation (Fig 6), indicating that both vasodilator and vasoconstrictor effects of 
insulin are present. 
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DISCUSSION 
This study demonstrates for the first time that PKCθ is present in the endothelium of muscle 
arterioles of both mice and humans and is activated by physiological levels of insulin and 
patho-physiological levels of palmitic acid. By genetic and pharmacological inhibition of 
PKCθ activity in mice we demonstrated that activated PKCθ induces insulin-mediated 
vasoconstriction by (A) the inhibition of insulin-mediated Akt activation, which results in a 
reduction of vasodilation, and (B) the stimulation of insulin-mediated ERK1/2 activation 
resulting in enhanced ET-1-dependent vasoconstriction.    
Insulin alone had no effect on the arterial diameter of muscle arterioles, due to a 
balance of vasodilator and vasoconstrictor effects. Previously others and we have shown 
that insulin’s vasodilator and vasoconstrictor effects require the activation of Akt and NO, 
and ERK1/2 and ET-1, respectively.5,8 Inhibition of NOS in our study resulted in insulin-
mediated vasoconstriction and inhibition of ET-1 activity resulted in insulin-mediated 
vasodilation. Our findings are in agreement with studies in rat arterioles and in the human 
forearm, which have shown that insulin-mediated production of NO and ET-1 and their 
effects are either balanced or result in net vasodilation.7,34 This suggests that the model 
used for this study is representative for the human microcirculation34 with respect to studying 
vasoactive effects of insulin. Figure 7 shows a schematic overview of the main findings of 
this study in the context of Akt-mediated NO production and ERK1/2-mediated ET-1 release, 
which have been reported earlier.8,9
Figure 7. Schematic 
overview of the effects 
of FFA in insulin 
signaling in gracilis 
arterioles of the 
mouse. PKCθ
activation impairs 
activation of Akt and 
enhances activation of 
ERK1/2, shifting the 
balance of insulin-
mediated vasoreactivity 
to vasoconstriction.  (A 
and B correspond with 
the numbers mentioned 
in first paragraph of the 
discussion) EC= 
endothelial cell, SMC = 
smooth muscle cell, 
FFA= free fatty acids.
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In this study we used isolated first-order gracilis arterioles as a model for skeletal muscle 
arterioles during preconstriction with KCl. All experiments in the present study were 
performed during preconstriction with KCl. Potassium influences the Ca2+ handling by 
depolarization of the cell-membrane of smooth muscle cells in the arterial wall, resulting in 
vasoconstriction. This simulation of arterial tone is commonly used in other studies on 
arterial vasoregulation.35-37 It is unlikely that the induced state of tone will bear impact on the 
results of insulin-mediated vasoreactivity and PKCθ activation, because we found in that 
insulin-mediated vasodilation is NO-dependent, insulin-mediated vasoconstriction is ET-1-
dependent. Another difference between studies on insulin-mediated vasoreactivity in vivo 
and ex vivo is the presence of shear forces in vivo. As shear is a well-known stimulator of 
endothelial NO production38 and NO inhibits insulin’s vasoconstrictor effects,7 this may 
explain the predominance of insulin’s vasodilator effects in vivo. In spite of this, 
vasoconstrictor effects of insulin have been demonstrated in a number of in vivo studies.34,39 
An interesting novel observation of our study is that PKCθ is abundantly expressed 
in the endothelium of muscle arterioles of both mouse and man. PKCθ was until now mainly 
described in skeletal muscle samples,13-15 fibroblasts17 or cultured skeletal muscle 
myocytes16 and T-cells.12 Moreover, PKCθ was encountered in cultured aortic endothelial 
cells,40 cultured human umbilical vein endothelial cells41,42  and small amounts have 
occasionally found in homogenates of tracheal43 and aortic44 smooth muscle cells of 
rodents. However, the present study shows for the first time the presence and localization of 
PKCθ in situ in the vascular system of skeletal muscle of both mice and humans and 
particularly in the endothelial cell layer, in which the insulin-mediated production of NO and 
endothelin-1 occurs. 
PKCθ activation interferes in insulin-mediated vasoreactivity by the inhibition of Akt 
and stimulation of ERK, resulting in insulin-mediated vasoconstriction (Fig 2B). In the 
present study, PKCθ activation by PA and insulin in muscle arterioles was determined by the 
phosphorylation of PKCθ at Thr-538. This phosphorylation-site is most important in PKCθ 
activation and mutations in this site inhibit the catalytical activity of PKCθ.13 We showed that 
activated PKCθ inhibits insulin-mediated Akt activation, thereby reducing vasodilation. 
Simultaneously, it stimulates insulin-mediated ERK1/2, thereby enhancing vasoconstriction 
effects of insulin. In cultured fibroblasts, PKCθ activation is associated with the inhibition of 
Akt activation17 and PKCθ was described as an upstream activator of the MAPK/ERK 
cascade.16,17 Furthermore, PKCθ can directly phosphorylate IRS1 at Ser-30717 and Ser-
1101,18 and IRS1 in turn is described to be involved in both the activation of Akt18,45 as well 
as the stimulation the MAPK/ERK pathway by insulin.46 It is possible that PKCθ can also 
influence IRS1 function in muscle arterioles directly, by specific phosphorylation and thereby 
influence insulin signaling. This results in the reduced Akt activation, which causes reduced 
vasodilation, and increased ERK1/2 activation, resulting in enhanced vasoconstriction. Thus, 
PKCθ can be a key player in shifting insulin-mediated vasoreactivity towards 
vasoconstriction by modulating IRS1 phosphorylation. 
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Surprisingly, insulin induced vasoconstriction in WT mice during inhibition of PKCθ in the 
absence of PA and in PKCθ-KO mice (figure 4). As acetylcholine-mediated vasodilatation 
was also slightly attenuated in PKCθ-KO mice (table 1), this effect may be caused by a 
positive effect of constitutional PKCθ activity on eNOS activity in absence of fatty acids. This 
may involve direct phosphorylation of eNOS by PKCθ at a serine residue that positively 
regulates its activation, such as Ser 114, Ser 615 or Ser 633.47 This effect was absent in WT 
arterioles in the presence of PA (figure 2B), suggesting that (PA-induced) hyperactivity of 
PKCθ has predominantly unfavorable vasoconstrictive effects. More studies are required to 
unravel this possible dual role of PKCθ. 
Our data support the hypothesis that PKCθ activation in muscle arterioles 
contributes to fatty acid-induced insulin resistance. Clerk et al.20 described that fatty acid-
induced insulin resistance in muscle is partially caused by impairment of insulin-mediated 
nutritive muscle blood flow,20 which is dependent on activation of PI3-kinase/Akt in muscle 
arterioles.19 These authors suggest a possible role for PKCθ in the impairment of insulin 
signaling in muscle arterioles.20 This suggestion is supported by the observation that mice 
lacking PKCθ are protected from acute fatty acid-induced insulin resistance.21 Indeed, this 
can be explained with our data, which show that fatty acids activate PKCθ in endothelium of 
muscle arterioles, resulting in impaired insulin-mediated activation of Akt and a shift in 
insulin-mediated vasoreactivity to vasoconstriction. We propose that fatty acids, in addition 
to other metabolic effects, induce muscle insulin resistance by activation of PKCθ in 
endothelium of muscle arterioles, which leads to reduction of insulin-mediated nutritive 
muscle blood flow. The findings in studies on muscle-specific PKCθ knockout mice are 
consistent with this hypothesis. Serra et al. have recently shown that specific expression of 
dominant-negative PKCθ in skeletal muscle myocytes reduces, rather than enhances, 
insulin sensitivity.48 Therefore, the insulin-sensitizing effect of blocking PKCθ shown by Kim 
et al.21 cannot be explained by a direct effect on myocellular glucose uptake, but must be 
caused by other mechanisms, such as improved nutritive blood flow. 
In summary, PKCθ activation by palmitic acid induces insulin-mediated 
vasoconstriction in muscle arterioles, which can explain how fatty acids cause a decrease in 
nutritive blood flow and impaired glucose uptake in muscle. This provides new mechanistic 
evidence of how PKCθ activation results in insulin resistance and suggest that PKCθ is 
promising novel target for improvement of vascular function in obesity. 
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VI.    Selective PKCθ Activation in Muscle  
        Opposed to Adipose Tissue Arterioles.  
        Consequences for tissue perfusion 
 
Wineke Bakker, Caro-Lynn A.F. Alta, Pieter Sipkema, Coen D.A. Stehouwer, Victor W.M. 
van Hinsbergh, Etto C. Eringa. 
 
ABSTRACT 
 
Objective: Obesity is characterized by increased levels of fatty acids, decreased glucose 
uptake in skeletal muscle and impairment of microvascular responses to insulin. Previously 
we have shown that PKCθ activation by fatty acids induces insulin-mediated 
vasoconstriction in muscle arterioles. The aim of this study was to investigate the 
contribution of PKCθ activation in muscle and adipose tissue arterioles on insulin-mediated 
vasoreactivity and blood flow in skeletal muscle and adipose tissue during obesity. 
 
Research design and methods: Skeletal muscle and adipose tissue of lean and obese 
Db/Db mice were characterized for mass and structure, function and PKCθ-activation of 
their microcirculation.  
 
Results: Skeletal muscle mass, myocyte size, diameter of muscle arterioles, and capillary 
ratio per myocyte were reduced in obese Db/Db mice. In contrast, adipose tissue mass, 
adipocyte size, diameter of adipose tissue arterioles and capillary ratio per adipocyte were 
increased in obese Db/Db mice. We identified and isolated arterioles that branched from a 
common artery but nourished either muscle or adipose tissue. Palmitic acid (PA,100μmol/l) 
activated PKCθ only in muscle arterioles but not in adipose tissue arterioles of lean mice. In 
muscle arterioles, this led to insulin-mediated vasoconstriction (30±6%, p<0.01) associated 
with a decreased Akt-activation. In adipose tissue arterioles, it resulted in a moderate 
insulin-mediated vasodilation, due to increased Akt-activation. In obese Db/Db mice, PKCθ 
was activated in muscle arterioles and not in adipose tissue arterioles. In obese Db/Db mice, 
this led to insulin-mediated vasoconstriction of muscle arterioles and was associated with an 
increased blood flow to adipose tissue compared to blood flow to skeletal muscle. 
 
Conclusion: Muscle and adipose tissue have functionally distinct vasculatures.  PKCθ is 
selectively activated by palmitic acid and in muscle arterioles from obese Db/Db mice, but 
not in adipose tissue arterioles. This was associated with insulin-mediated vasoconstriction 
in muscle and increased blood flow to adipose tissue, and may promote increased nutrient 
storage in adipose tissue. 
V
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INTRODUCTION 
 
Obesity is characterized by an increased fat mass, and is associated with microvascular 
dysfunction and decreased insulin-mediated glucose uptake in skeletal muscle.1 The 
obesity-dependent impairment of microvascular responses to insulin in obesity is thought to 
contribute to insulin resistance by reducing perfusion and appropriate delivery of insulin and 
glucose to skeletal muscle.2 However, it is unknown whether and how disturbed muscle 
perfusion and adipose tissue expansion are related in obesity.   
In skeletal muscle, the vasodilation of arterioles by insulin and the recruitment of 
capillaries increases muscle glucose uptake, by increasing microvascular volume.3 Arteriolar 
diameter is regulated by insulin’s vasodilator (mediated through Akt/NO pathway) and 
vasoconstrictor effects (mediated by ERK1/2/ET-1 pathway).4 These two pathways are in 
balance or result in net vasodilation in healthy conditions, and the balance is shifted towards 
vasoconstriction in obesity.5,6 Both obesity and lipid infusion are characterized by reduced 
muscle perfusion, inhibition of insulin-mediated muscle glucose uptake7 and impaired 
insulin-mediated capillary recruitment.7,8 Furthermore,  in a previous study we have shown 
that free fatty acids (FFA), activates PKCθ in muscle arterioles, which results in insulin-
mediated vasoconstriction.9 This suggests PKCθ activation as a new mechanism in the 
reduction of muscle perfusion.9 
In obesity, increased adipose tissue mass is characterized by adipocyte 
hyperplasia, adipocyte hypertrophy, and a proinflammatory state.10,11 The growth of adipose 
tissue is dependent on neovascularization and remodeling of existing capillaries.12 
Postprandial adipose tissue blood flow is positively correlated with insulin sensitivity13 and is 
attenuated in obesity.14 However, regulation of adipose tissue arteriolar function in the 
context of obesity has not been studied yet, and it is unclear whether blood flow to adipose 
tissue is linked to vascular responses in muscle.             
We hypothesized that muscle and adipose tissue have functionally distinct 
vasculatures; that PKCθ is selectively activated in muscle arterioles; and that this is 
associated with an increased blood flow to adipose tissue. To investigate PKCθ activation 
and vasoactive responses, muscle and adipose tissue arterioles from lean mice were 
subjected to the free fatty acid palmitic acid (PA) and insulin. In addition, arterioles were 
isolated from obese Db/Db mice and responses to insulin were compared to those of lean 
mice. Different vascular responses of muscle and adipose tissue arterioles were observed, 
which revealed structural and functional changes in capillary density, arteriolar diameter and 
blood flow of muscle and adipose tissue. 
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RESEARCH DESIGN AND METHODS 
 
Mice: The investigation conformed to the Guide for the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (NIH publication No 85 to 23, revised 1996). The local ethics 
committee for animal experiments approved the procedures. Male C57Bl6 and Obese  Db/Db mice 
(Harlan; Zeist, the Netherlands) of 10 weeks were sacrificed by overdose of isoflurane inhalation. Obese 
Db/Db mice have a mutation in their leptin receptor and are characterized by increased body weight, 
hyperglycemia, hyperinsulimia and hyperlipidemia.15 Body weight (40.6±0.8 vs. 24.8±0.4 g), fasting 
blood glucose (10.3±0.6 vs. 5.4±0.2 mM) and non-fasting blood glucose (25.4±1.5 vs. 12.4±0.1 mM) 
were higher in obese Db/Db mice than in lean mice (10 vs14 animals; P<0.0001 for all parameters) with 
a similar genetic background (C57Bl/6). Gastrocnemius muscle, subcutaneous adipose tissue and 
corresponding arterioles were isolated to analyze structural and functional characteristics. 
 
Immunochemistry:  Muscle samples were snap frozen at -80°C and adipose tissue samples were 
embedded in paraffin. Tissue sections of 5 μm were either stained with heamatoxyline-eosine to 
determine cell size or with the endothelium-selective glycocalyx stain lectin (Lycopersicon esculentum 
Lectin, FITC-conjugate, Sigma-Aldrich) to determine the number of capillaries.  
 
Blood flow: Blood flow was determined with FluoSpheres polystyrene microspheres (15μm blue green 
fluorescent 430/465, Molecular probes, Invitrogen).16 Microspheres (2500 beads/gram body weight) 
were injected into the left ventricle, while a reference blood sample with constant flow (100μl/min) was 
collected. Blood flow of gastrocnemius muscle and subcutaneous adipose tissue of the hindlimb were 
calculated using a reference blood sample and is expressed as a mean muscle or adipose tissue blood 
flow. Fluorescent microspheres were extracted from muscle and adipose tissue according to Raab et 
al16 and fluorescence intensity was measured using a luminescence spectrophotometer. 
 
Vasoreactivity: After dissection, muscle and adipose arterioles were cannulated in a pressure 
myograph and studied at physiologic pressure and temperature in MOPS-buffer, as described.9 The 
arterioles were preconstricted to approximately 50% of the maximal diameter with 25mM KCl. 
Endothelial integrity was determined by measuring vasodilator response to acetylcholine (ACh: 0.1μM) 
before and after experiments. Acute effects of insulin (Novo Nordisk, Alphen a/d Rijn, the Netherlands), 
at four concentrations (0.02, 0.2, 2 and 20nM) on arteriolar diameter were studied and each 
concentration was recorded for 30 minutes.9 To study the interaction between PKCθ and insulin in 
arterioles, arteriolar segments were pre-treated with PA (100 μM) for 30 minutes to activate PKCθ and 
were thereafter subjected to insulin.  
 
Western blot:  Western blot analysis was performed as described.9 Segments of gracilis or adipose 
tissue arterioles from the same mouse (3mm in length) were exposed to solvent, insulin (2nM) or insulin 
with PA (100μM) for 15 minutes at 37ºC. The protein lysates of different arteriolar segments were 
stained with specific primary antibodies against phosphorylated Akt (60 kDa), phosphorylated PKCθ (79 
kDa), total Akt and total PKCθ (Antibodies obtained from Cell signaling technology, Boston, MA) and 
V
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were visualized with a chemiluminescence kit (Amersham). Differences in phosphorylated protein were 
adjusted for differences in the corresponding total protein staining. 
 
Chemicals: MOPS-buffer consisted of (in mM) 145 NaCl, 4.7 KCl, 2.5 CaCl2, 1.0 MgSO4, 1.2 NaH2PO4, 
2.0 pyruvate, 0.02 EDTA, 3.0 MOPS (3-(N-morpholino) propanesulfonic acid), 5.5 glucose and 0.1% 
bovine serum albumin, at pH 7.4.  Palmitic acid (PA, C16:0, 10 mM) was dissolved in 0.1M NaOH, 
coupled to 10% bovine albumin serum (BSA) as described9 and diluted to a final concentration of 100 
μM PA/0.1% BSA in MOPS-buffer (pH 7.4). Palmitic acid, BSA, L-NA, papaverine and acetylcholine 
(ACh) were obtained from Sigma (St. Louis, MO).  
 
Statistics: Values are expressed as mean±SEM. Statistical analyses for differences between lean 
control and obese Db/Db mice were performed by student t-test. Differences in protein expression were 
determined by column statistics at set value of one. Differences in probability values of p<0.05 were 
considered statistically significant. 
 
 
 
RESULTS 
 
PKCθ activation by palmitic acid caused insulin-mediated vasoconstriction in muscle 
but not adipose tissue arterioles in lean mice 
To investigate whether muscle and adipose tissue have functionally distinct vasculatures, 
we identified and isolated arterioles of skeletal muscle and adipose tissue in the upper hind 
leg of mice. These arterioles are 2nd order arterioles from the femoral artery, which supply 
either the gracilis muscle or a distinct subcutaneous adipose tissue pad. The arterioles 
(arrows in Figure 1A) were distinguished by the typical structure of the thick arteriolar 
smooth muscle layer. To investigate whether these arterioles have a different response to 
insulin and in the activation of PKCθ, we first examined muscle and adipose tissue arterioles 
from lean mice. PKCθ activation was induced by physiologic concentrations of palmitic acid 
(PA, 100μmol/l) and measured by the phosphorylation of PKCθ at thr538, which present 
protein activation. 
In muscle arterioles of lean mice, insulin induced an increase in PKCθ 
phosphorylation at thr538. The phosphorylation of PKCθ was further increased by the 
combination of insulin and PA (Fig 2A). However, in adipose tissue arterioles of lean mice, 
insulin did not change the phosphorylation of PKCθ. Stimulation of insulin together with 
palmitic acid even induced a decrease in PKCθ phosphorylation in these adipose arterioles 
(Fig 2B).  
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The increased phosphorylation of PKCθ observed in muscle arterioles after stimulation with 
insulin and PA (Fig 2A) was accompanied by a reduced insulin-mediated phosphorylation of 
Akt (Fig 2C). The adipose tissue arterioles responded reversely. Here, the decreased 
phosphorylation of PKCθ after stimulation with insulin and PA (Fig 2B) was accompanied by 
a moderate increase in insulin-mediated phosphorylation of Akt (Fig 2D). There were no 
significant changes in total protein expression of PKCθ or Akt between muscle and adipose 
tissue arterioles (data not shown).  
To study whether the different activation of PKCθ in muscle and adipose tissue 
arterioles also results in functional differences, isolated arteriolar segments were studied in a 
pressure myograph. In this setting the functional effects of insulin on arteriolar diameter can 
be evaluated under physiological conditions. PKCθ activation in muscle arterioles induced 
by PA and insulin causes an insulin-mediated vasoconstriction (Fig 2E), while in adipose 
tissue arterioles, PKCθ activation was associated with a slight insulin-mediated vasodilation 
during PA exposure (Fig 2F). The difference in responses of muscle and adipose arterioles 
to insulin and PA was highly significant (38±5% difference in diameter change; p<0.001). 
This indicates that PKCθ activation by the free fatty acid PA and the subsequent 
insulin-mediated vasoconstriction is only observed in muscle arterioles and not in adipose 
tissue arterioles of lean mice.  
 
 
 
 
 
Figure 1. Identification and diameters of muscle and adipose arterioles. 
Photo of the vasculature in the upper hindlimb of lean and obese mouse, which become visible after removing the skin 
(A). Arterioles from adipose tissue and skeletal muscle were dissected and arteriolar diameters at maximal dilator 
response to papavarin, were measured in vitro from lean control mice (n=14) and obese Db/Db mice (n=10). Data 
represent mean±SEM. *p<0.05. 
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Figure 2. PKCθ activation by palmitic acid induces opposite functional effects in muscle and adipose 
tissue arterioles from lean mice. Phosphorylation of PKCθ at thr538 was used to determine PKCθ activation in 
muscle, n=9 (A) and adipose tissue arterioles, n=7 (B); Phosphorylation of Akt at ser473 was used to determine 
Akt activation in muscle (n=9) ( C) and adipose tissue arterioles, n=7 (D) from lean mice in the following 
conditions: control (c) insulin (I) and insulin (I: 2nM) with palmitic acid (PA:100μM). Functional response to PKCθ 
activation, induced by insulin (I: 2nM) and insulin with palmitc acid (PA: 100μM) on % diameter change, in muscle 
(E) and adipose tissue arterioles (F). Data depicted as percental change from preconstricted diameter in lean 
control mice (n=5). Data represent mean±SEM. *p<0.05,  #p<0.01. 
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Figure 3. PKCθ activation is increased and Akt activation is not changed in obese muscle arterioles and 
decreased in obese adipose tissue arterioles. Phosphorylation of PKCθ at thr538 was used to determine 
PKCθ activation in muscle, n=9 (A) and adipose tissue arterioles, n=8 (B); Phosphorylation of Akt at ser473 
was used to determine Akt activation in muscle (n=9) ( C) and adipose arterioles, n=7 (D) from lean control and 
obese Db/Db mice in the following conditions: control (c) and insulin (I: 2nM ). Data represent mean±SEM. 
*p<0.05 compared c with I from lean and obese, $ p<0.05 compared I lean with I obese. E-F: Functional 
response to PKCθ activation, induced by insulin, on % diameter change, depicted as percental change from 
preconstricted diameter in muscle (E) and adipose arterioles (F) from lean control (n=6) and obese Db/Db mice 
(n=5). Data represent mean±SEM. *p<0.05   
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PKCθ activation is increased in muscle and decreased in adipose tissue arterioles 
from Db/Db mice 
As Db/Db mice have elevated levels of circulating free fatty acids, we subsequently 
investigated whether PKCθ activation by endogenous factors also bears impact on the 
regulation of muscle and adipose tissue perfusion by insulin. To that end, we compared 
muscle and adipose tissue arterioles of lean and obese diabetic Db/Db mice in control and 
insulin-stimulated conditions.  
In muscle arterioles from both lean and Db/Db mice, insulin induced an increase in 
PKCθ phosphorylation at thr538 (Fig 3A). Interestingly, the increase in PKCθ 
phosphorylation was approximately 3-fold higher in muscle arterioles isolated from Db/Db 
mice than in those of lean mice. In the adipose tissue arterioles from lean mice, insulin 
induced no change in PKCθ phosphorylation and even slightly reduced it in Db/Db mice (Fig 
3B). 
The different activation of PKCθ in muscle arterioles did not result in significantly 
different activations of Akt (Fig 3C and 3D), although the Db/Db arterioles tended to display 
less insulin-mediated Akt activation (p=0.40). Adipose tissue arterioles from lean and Db/Db 
showed a similar degree of insulin-mediated Akt activation (Fig 3D). The insulin-induced 
activation of Akt was considerably less than in muscle arterioles (comparing Fig 3C and 3D). 
Functional studies in isolated arteriolar segments revealed that PKCθ activation in 
muscle arterioles isolated from Db/Db mice resulted in insulin-mediated vasoconstriction, 
which was significantly different from muscle arterioles of lean mice (Fig 3E). In contrast, 
insulin-mediated vasoreactivity was similar in adipose tissue arterioles of lean and Db/Db 
mice, and their diameters did not change in response to insulin (Fig 3F). 
  This indicates that insulin-induced PKCθ activation in muscle arterioles isolated 
from Db/Db mice (Fig 3A) is comparable to the PKCθ activation induced by PA in lean mice 
(Fig 2A). As a consequence, the difference in insulin-induced PKCθ activation between in 
muscle and adipose tissue arterioles is blunted in Db/Db mice. 
 
Consequences of PKCθ activation for tissue vascularization in lean and Db/Db mice  
To investigate whether the different activation of PKCθ in muscle and adipose tissue 
arterioles influence tissue vascularization, we determined the maximal diameters of the 
arterioles, capillary density and blood flow of skeletal muscle and adipose tissue in lean and 
Db/Db mice. 
 The maximal diameter was measured of both arterioles towards gracilis muscle 
and adipose tissue from both lean and Db/Db mice. The diameter of muscle arterioles was 
less in lean mice (145±2μm) than in obese mice (130±4μm), while the diameter of adipose 
tissue arterioles was larger in lean (177±4μm) than in obese mice (189±5μm) (Table 1).  
The number of capillaries was less in skeletal muscle of Db/Db mice than in their 
lean control counterparts, as determined by both ratio of number of capillaries per myocyte 
and number of capillaries per mm2 muscle cross-section (Fig 4A). In contrast, adipose tissue 
was expanded in obese Db/Db mice, accompanied by fat cell enlargement (Fig 4B). While 
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the increase in adipocyte size was accompanied by an increase in capillary ratio per 
adipocyte, the number of capillaries per mm2 adipose tissue cross-section decreased   
(Table 1).  
The reduced vascularization of skeletal muscle of Db/Db mice was accompanied by a 40% 
reduction of skeletal muscle mass and a smaller size of muscle myocytes (Table 1). The 
increased vasculairzation of adipose tissue of Db/Db mice was accompanies by a 14-fold 
increase in adipose tissue mass  and enlarged adipocyte size (Table 1). This was despite a 
2-fold increase in body mass (40.6±0.8g as compared to 24.8±0.4g in lean mice). 
Taken these structural data together, increase in tissue mass was positively 
correlated with the ratio of number of capillaries per cell and maximal diameter of arterioles. 
 
Db/DbLean
Le
ct
in
H
E
B Lean Db/Db
Le
ct
in
H
E
A
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in
H
E
Le
ct
in
H
E Figure 4. Cross sections of 
skeletal muscle (A) and 
adipose tissue (B) of lean 
and Db/Db mice. 
Cross sectional area (CSA) of 
muscle myocytes and 
adipocytes were determined 
by HE staining. The ratio of 
number of capillaries per 
myocyte/adipocyte and the 
capillary density per mm2 
were determined by Lectin 
(Lycopersicon esculentum 
Lectin, FITC-conjugate) 
staining in lean and Db/Db 
mice. Scalebars represent 
100μm. 
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Blood flow to adipose tissue is increased in obese mice 
In a final experiment, we evaluate whether PKCθ activation in muscle arterioles is 
associated with changes in blood flow to muscle and adipose tissue in obese mice. Blood 
flow in muscle and adipose tissue was measured using fluorescent 15μm microspheres, 
which are retained in small blood vessels. Blood flow expressed as ratio of muscle and 
adipose tissue was predominated towards muscle in lean mice in total tissue blood flow   
(Fig 5A) and in tissue blood flow per gram (Fig 5B). In contrast, Blood flow in obese mice 
expressed as ratio of muscle and adipose tissue was predominated towards adipose tissue 
in total tissue blood flow (Fig 5A) and in tissue blood flow per gram (Fig 5B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Mice and tissue characteristics of skeletal muscle and adipose tissue 
<0.0011.50±0.070.93±0.05Capillary ratio(#/cell)
<0.05130±4145±2Maximal arteriolar diameter (μm)
<0.000115.8±0.07   1.1±0.01  Mass (g)
Adipose tissue
=0.16796±56989±115Capillary density (#/ mm2)
Mice / Tissue  characteristics Lean Db/Db P
Body weight (g) 24.8±0.4 40.6±0.8 <0.0001
Skeletal muscle
Mass (g) 1.7±0.08 1.1±0.05 <0.001
CSA myocytes (μm2) 1366±77 1142±56 <0.05
Capillary ratio (#/cell) 1.56±0.14 1.16±0.06 <0.05
CSA adipocytes (μm2) 1185±101 6187±104 <0.005
Maximal arteriolar diameter (μm) 177±4 189±5  <0.05
Capillary density (#/ mm2) 485±10 245±39 <0.001
Figure 5. Blood flow ratio of muscle and adipose tissue in lean and Db/Db mice.  Blood flow depicted 
as flow in ml/min (A) and flow in ml/min/mg (B) in ratio of BF in skeletal muscle divided by BF in adipose 
tissue.  P<0.01 
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DISCUSSION 
 
The novel finding of this study is that muscle and adipose tissue have functionally distinct 
vasculatures, in which PKCθ is activated differently by fatty acids and in obesity. In a 
previous study, we have shown that the free fatty acid PA enhances PKCθ activation in 
muscle arterioles, which subsequently results in insulin-mediated vasoconstriction.9 The 
present study extends these data by showing that in adipose tissue arterioles of lean mice, 
PA reduced insulin-mediated PKCθ activation. Furthermore, in the absence of PA (a) 
insulin-mediated PKCθ activation is higher in muscle arterioles of obese Db/Db mice than in 
those of lean mice, and (b) adipose tissue arterioles do not display this PKCθ activation. As 
the maximal diameter of muscle arterioles of obese Db/Db mice is decreased by 12% as 
compared to lean mice, while that of adipose tissue arterioles is increased by 10%. These 
effects cause a decrease in the ratio of blood flow between muscle and adipose tissue as 
calculated on total and per gram tissue basis.  
 
Increased PKCθ activation in muscle arterioles  
Our data suggest that PKCθ activation in muscle arterioles may contribute to a reduced 
muscle glucose uptake in obesity. PKCθ is activated in muscle arterioles by fatty acids and 
in obesity, leading to insulin-mediated vasoconstriction. Constriction of muscle arterioles is 
associated with reduced blood volume.3 Rattigan et al showed that a reduced blood volume 
is related to glucose uptake in muscle.3 In addition, other studies showed a reduced insulin-
mediated microvascular recruitment and impaired muscle glucose uptake both in an obese 
animal model and induced by FFA.17,18 Although blood volume was not directly measured in 
this study, the reduction in arteriolar diameter and decreased capillary density in skeletal 
muscle do suggest a decreased microvascular volume in muscle of the obese  Db/Db mice.  
Only the activation of PKCθ by FFA reduced the activation of Akt resulting in a 
prominent insulin-mediated vasoconstriction in muscle arterioles, whereas this was not 
observed in muscle arterioles in obese Db/Db mice. Similarly, another study described that 
arterioles of obese Zucker rats showed no difference in insulin-mediated Akt activation 
compared to lean controls.5 Because FFA levels are increased in obesity,8,19 it is probable  
that the in vivo vascular response to insulin, including Akt activation, will be affected. The 
activation of endogenous FFA will facilitate the insulin-mediated activation of PKCθ in obese 
Db/Db mice.  
 
Reduced PKCθ activation in adipose tissue arterioles and increased blood flow in 
adipose tissue of Db/Db mice  
Our data suggest that the lack of PKCθ activation in adipose tissue arterioles permits an 
increased blood flow and thereby an increased supply of nutrients to adipose tissue in 
obesity. Another study showed that postprandial adipose tissue blood flow (ATBF) is 
attenuated in obesity.14 However, the attenuated response of ATBF only accounts for 
postprandial conditions and does not imply long-term nutrient uptake. As nutrient uptake in 
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skeletal muscle is impaired in obesity,20 one can expect that nutrients persists in the 
circulation and eventually will be stored in adipose tissue. A possible mechanism of how 
nutrients are stimulated for adipose tissue storage is the increased blood flow induced by an 
increased arteriolar diameter of adipose tissue arterioles. In the arteriole towards adipose 
tissue, PKCθ activation was reduced resulting in an increased Akt activation and moderate 
vasodilation to insulin, which could stimulate an increase in ATBF.  
Unlike the increase in capillary ratio, the capillary density in this study and other 
studies21,22 was decreased in adipose tissue of obese  mice. In fast growing tissue, the 
number of cells that can be supported by a blood vessel varies, which in turn influences the 
capillary density.12,23 As a consequence of the expansion of adipose tissue, the surface of 
vascular-tissue exchange over the adipose tissue as a whole increased, but the relative 
perfusion per gram of tissue is decreased. The metabolic consequences of the latter in 
terms of local hypoxia and the subsequent activation of the enlarged adipocytes and 
accompanying macrophages are unknown. 
 
Effect of selective PKCθ activation in muscle arterioles on blood flow to adipose 
tissue and nutrient uptake in obesity 
Our data suggest that a selective PKCθ activation in muscle arterioles increases ATBF in 
obesity. Other studies showed that muscle-specific insulin receptor deficiency promotes the 
redistribution of substrates to adipose tissue24 and that the restriction of glucose uptake by 
skeletal muscle favors the uptake of triglycerides in connective tissue fat cells.25 The present 
study showed a connection between muscle and adipose tissue vascularization with a joint 
arteriole which branches either towards skeletal muscle or to a subcutaneous fat pad. PKCθ 
activation induced a selective insulin-mediated vasoconstriction in muscle arterioles and was 
associated with predominant blood flow towards adipose tissue opposed to muscle. This will 
probably lead to a decreased nutrient supply towards muscle, as muscle arterioles are 
described as nutritive arteries stimulating glucose uptake in skeletal muscle.26 This suggests 
that PKCθ can act as a switch in blood flow from muscle towards adipose tissue, supporting 
the storage of nutrients in adipose tissue in overnutritional conditions. 
As PKCθ is differently activated in muscle- and adipose tissue arterioles, it provides 
a potential target for improvement of vascular function, glucose delivery towards muscle and 
inhibition of adipose tissue expansion in obesity. 
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ABSTRACT 
 
Objective: Obesity is characterized by disturbed vascular insulin signaling and by low-grade 
inflammation of adipose tissue, which changes the secretion of adipokines. The presence 
and effects of accumulation of local adipose tissue around muscle arterioles is unknown. 
The aim of this study was to investigate the effects of muscle perivascular adipose tissue 
(PVAT) isolated from lean and Db/Db mice on insulin-mediated vasoreactivity.  
 
Research design and methods: Muscle arterioles from lean (C57Bl/6) mice were co-
incubated For 30 minutes with either PVAT isolated from lean (C57Bl/6) or from 
obese/diabetic (Db/Db) mice in a pressure myograph. After this incubation, the diameter of 
arterioles was recorded to determine vascular tone, and responses to insulin, acetylcholine 
and the AMPK inhibitor Compound C. Vasodilator effects of insulin were investigated by the 
activation of Akt by western blot analysis. 
 
Results: PVAT was present around the muscle microcirculation. In Db/Db mice, PVAT 
round the muscle arterioles was increased. PVAT isolated from both lean and Db/Db mice 
did not alter vascular tone or endothelium-dependent vasodilation to acetylcholine of lean 
muscle arterioles. However, PVAT isolated from lean mice induced insulin-mediated 
vasodilation. Insulin-mediated vasodilation and Akt activation was blunted after incubation of 
PVAT isolated from Db/Db mice in lean arterioles. The insulin-mediated vasodilation in 
response to PVAT isolated from lean mice was abolished by pretreatment of Compound C. 
Adiponectin secretion of PVAT was higher in PVAT isolated from lean compared PVAT 
isolated from Db/Db mice. Furthermore, both adiponectin and lean PVAT induced a 
vasodilator response to insulin.  
 
Conclusions: PVAT isolated from lean mice induces insulin-mediated vasodilation probably 
through the activation of AMPK. The vasodilator effect of PVAT was blunted in PVAT 
isolated from Db/Db mice and associated with decreased Akt activation. This differential 
response of PVAT isolated from lean and Db/Db mice locally influences vasoreactivity and 
thereby can influence vascular resistance. 
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INTRODUCTION 
Obesity is associated with impairment of insulin-mediated glucose uptake, insulin resistance 
and microvascular dysfunction, contributing to cardiovascular risk. Furthermore, obesity is 
associated with low-grade inflammation and endocrine activity of adipose tissue by the 
production of secreted factors, called adipokines.1,2 Mainly, abdominal fat pads were used 
for studies on insulin resistance,3 but interest has arissen in the local secretion of adipokines 
from fat pads round the vasculature in the development of insulin resistance.4-6  
In obesity, a low-grade inflammation alters the secretion profile of adipokines. 
Adipokines can be divided into adipokines that positively influence insulin sensitivity, e.g. 
adiponectin7,8 and possibly leptin,9 and into adipokines that negatively influence insulin 
sensitivity, in which TNFα10,11 and FFA12,13  were most described. Adipose tissue from lean 
subjects mainly produces adiponectin and low amounts of TNFα and FFA, whereas in 
adipose tissue from obese subjects this is the opposite, namely a production of low amounts 
of adiponectin7 and high amounts of TNFα14 and FFA.13 Previous studies have shown that 
perivascular adipose tissue (PVAT) has vasoactive properties.15-19 PVAT from healthy 
subjects has anticontractile effects,18,20 in which adiponectin is suggested as a predominant 
mediator of vasorelaxation effects.21 PVAT from obese patients showed reduced 
vasorelaxation in human fat arterioles, possible due to the release of TNFα.21 Furthermore, 
PVAT’s proinflammatory phenotype is increased after high fat feeding.22 However, whether 
PVAT is present and whether PVAT affects the muscle microcirculation is unknown. 
Skeletal muscle is the main site of insulin-mediated glucose uptake,23 which is 
disturbed in obesity and thereby causes whole body insulin resistance.24 Insulin-mediated 
glucose uptake depends in large part on the delivery of glucose and insulin through the 
microcirculation.25,26 In muscle arterioles, insulin regulates vascular diameter and muscle 
perfusion by the induction of both vasodilation (mediated by PI3K/Akt/pathway leading to NO 
production)27,28 and vasoconstriction (mediated by ERK1/2 pathway leading to ET-1 
production).29,30 These two pathways are in balance or result in net vasodilation in healthy 
conditions, while the balance is shifted towards vasoconstriction in obesity.31,32 TNFα and 
FFA cause insulin-mediated vasoconstriction through activation of JNK or PKCθ in muscle 
arterioles.33,34 Furthermore, the decreased levels of adiponectin in obesity7 contributes to 
impaired vascular function,35 probably due to decreased production of NO in the vascular 
endothelium.36,37 A recent paper of Deng et al showed that adiponectin directly improves 
endothelial dysfunction by activation of AMPK in aortic rings from obese rats.38 However, the 
levels of adiponectin and TNFα secretion of PVAT and the effects of adiponectin and PVAT 
on insulin signaling and insulin-mediated vasoreactivity are not known. 
The aim of this study was to investigate the effects of perivascular adipose tissue 
(PVAT) from lean and Db/Db mice on insulin-mediated vasoreactivity. In an incubation 
study, isolated muscle arterioles from lean mice were subjected to either PVAT isolated from 
lean or Db/Db mice. Furthermore, the secretion of adiponectin by PVAT of lean and Db/Db 
mice was measured to explain possible changes in insulin-mediated vasoreactivity. 
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RESEARCH DESIGN AND METHODS 
 
Mice: The investigation conformed to the Guide for the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (NIH publication No 85 to 23, revised 1996). The local ethics 
committee for animal experiments approved the procedures. Male C57Bl6 and Db/Db mice (Harlan; 
Zeist, the Netherlands) of 10 weeks were sacrificed by overdose of isoflurane inhalation. From C57Bl/6, 
the lean control mice, arterioles from the gracilis muscle and PVAT were isolated. Db/Db mice are 
hyperglycemic and extreme obese and were used as obese model in this study. From obese Db/Db 
mice, PVAT was isolated. PVAT isolated from lean and Db/Db mice that were used in the incubation 
studies were equalized to amounts of comparable size. 
 
Vasoreactivity: After dissection, muscle arterioles were placed in a pressure myograph and studied at 
a pressure of 80 mmHg and of temperature of 37°C in MOPS-buffer, as described.39 To study the 
interaction between PVAT and insulin in arterioles, artery segments were pre-exposed to PVAT from 
lean and Db/Db (experimental setup, see figure 1) mice for 30 minutes. After this incubation, the 
diameter of arterioles was recorded to determine vascular contraction after KCl exposure, responses to 
insulin (at concentration 0.02, 0.2, 2 and 20nM) and to the AMPK inhibitor Compound C  (Calbiochem, 
1μM) were examined. Endothelial integrity was determined by measuring responses to endothelium-
dependent vasodilator acetylcholine (0.1mM) after each experiment.  
 
 
  
 
 
 
 
 
 
 
  
 
 
Immunochemistry:  Samples of the gracilis muscle were fixed in 4% paraformaldehyde and thereafter 
embedded in paraffin. Tissue sections of 10μm were stained with hematoxyline-eosine to identify PVAT 
around muscle arterioles. 
 
Western blot:  Western blot analysis was performed as described.29 Segments of gracilis arteries from 
the same mouse were exposed to solvent or to insulin (2nM) with and without PVAT for 30 minutes at 
37ºC. The protein lysates of different arterial segments were stained with a specific primary antibody 
against phosphorylated Akt (60kDa) and total Akt (Antibodies obtained from Cell signaling technology, 
Figure 1. Study set up of 
in vitro PVAT 
transplantation study.   
Muscle arterioles from lean 
mice were canulated in a 
pressure myograph and 
either incubated with PVAT 
from lean (Setup 1) or from 
Db/Db mice (Setup 2). 
PVAT was attached to the 
canulea without direct 
contact to the artery. An 
incubation period of 30 
minutes allows the 
adipocytes to release 
adipokines (*,●,○,◌,?,) in 
pressure myograph. 
Canulated arteriole
of lean mice
Canulated arteriole
of lean mice
Release adipokines (*• ? )
Setup 1:
Setup 2:
*
*
*
*
*
*
*
*
*
•
?
?
mPAT of obese mice
mPAT of lean mice
•
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Boston, MA) and were visualized with a chemiluminescence kit (Amersham).  Differences in 
phosphorylated protein were adjusted for differences in the corresponding total protein staining. 
Adiponectin secretion: PVAT isolated from lean and Db/Db mice were equalized equalized to 
amounts of comparable size and incubated for 30 min at 37˚C for the release of adiponectin. 
Adiponectin secretion was measured with mouse adiponectin ELISA kit (Milipore) and adiponectin 
levels were detected with a luminex system.
Statistics: Values are expressed as mean±SEM. Statistical analyses for differences between the 
effects of PVAT isolated from lean and Db/Db mice were performed by 2-way-ANOVA. Differences in 
protein expression were determined by column statistics at set value of one. Differences in probability 
values of p<0.05 were considered statistically significant.
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Figure 2. Accumulation of PVAT in 
muscle of lean and Db/Db mice. A)
Close up of the vasculature of gracilis 
muscle, with visible PVAT round the 
arteriole in lean and Db/Db mice. B) 
HE staining of cross section of gracilis 
muscle of lean and Db/Db mice for 
illustrative pictures. C) quantification of 
cross sectional area (CSA) of single 
adipocytes in PVAT isolated from lean 
or Db/Db mice. (n=2) Abbreviations; 
A=arteriole, V= vene,M=muscle. 
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RESULTS 
 
General characteristics of Db/Db mice 
For this study we used obese Db/Db and lean control mice with similar genetic background 
to study the effects of PVAT on insulin responses in arterioles. Db/Db mice show impaired 
glucose tolerance, increased body weight and an overall increase in adipose tissue 
accumulation.  
 
PVAT characteristics 
Muscle PVAT was defined as accumulated adipose tissue around the muscle arterioles. 
Figure 2A shows increased accumulation of PVAT around gracilis arterioles of Db/Db mice 
compared to lean control. Fig 2B shows an example of cross-section of adipocytes from 
PVAT of Db/Db and lean mice. PVAT of Db/Db mice consists of hypertrophied adipocytes as 
compared to PVAT from lean mice (Fig 2C).  
 
General vasoregulatory effects of PVAT on muscle arterioles 
To study vasoregulatory effects muscle PVAT, arterioles of lean mice were incubated with 
PVAT isolated from lean or Db/Db mice (see study set up Fig 1). Vessels exposed to lean or  
Db/Db PVAT were incubated for 30 minutes to allow the adipocytes to release adipokines to 
the organ bath. After this incubation, the diameter of arterioles was recorded to determine 
vascular tone. PVAT isolated from either lean or Db/Db mice had no effect on 
vasoconstrictor effects of arterioles, as shown by the response to potassium (Fig 3A). The 
endothelium-dependent vasodilator response to acetylcholine was also not affected by 
PVAT isolated from both lean and Db/Db mice (Fig 3B). 
Figure 3. Effect of PVAT on smooth muscle tone and endothelium-dependent vasodilation. A) Smooth 
muscle tone is depicted as basal diameter after preconstriction with 25mM KCl, with no PVAT (gray bars), 
PVAT isolated from lean (white bars) or Db/Db (black bars) mice. Lean versus Db/Db PVAT: p=0.17. B) 
Endothelium-dependent vasodilation depicted by responses to acethylcholine, with no PVAT (rounds), PVAT 
isolated from lean (squares) or Db/Db (triangles) mice. Data represent mean±SEM.  
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Blunted Insulin-mediated vasodilation by PVAT isolated from Db/Db mice 
After an incubation period of 30 minutes with PVAT isolated from lean mice, arterioles 
showed a vasodilation to insulin (Fig 4A). This insulin-mediated vasodilation was not present 
after incubation with PVAT isolated from obese Db/Db mice. The insulin-mediated 
phosphorylation of Akt was increased by stimulation with PVAT isolated both from lean and 
Db/Db mice (Fig 4B). However, activation of Akt was less in arterioles stimulated with PVAT 
isolated from Db/Db mice compared to stimulation with PVAT isolated from lean mice (Fig 
4B). 
 
Adiponectin mimics interactions of PVAT with insulin-mediated vasoreactivity 
To examine a possible role of AMPK activation and adiponectin secretion in PVAT 
incubations, we investigated whether insulin-mediated vasodilation by PVAT isolated from 
lean mice was abolished with AMPK inhibition. Subsequently, we investigated whether 
adiponectin induced vasodilation and whether the secretion of adiponectin was different in 
PVAT isolated from lean and Db/Db mice. 
First, to investigate whether PVAT isolated from lean mice activates AMPK and 
thereby induces insulin-mediated vasodilation in arterioles, we inhibited AMPK with 
compound C. Fig 5A shows that Compound C abolished the vasodilator effects to insulin 
induced by PVAT isolated from lean mice.  
Subsequently, a possible candidate of adipokines that stimulates insulin-mediated 
vasodilation in arterioles is adiponectin. It was recently shown that adiponectin directly 
improve endothelial dysfunction by activation of AMPK in aortic rings from obese rats.38 To 
determine whether adiponectin induces a similar response as PVAT that was isolated from 
lean mice on insulin-mediated vasoreactivity, lean arterioles were subjected to globular 
adiponectin, the active part of the protein. Figure 5B shows that globular adiponectin 
induced vasodilation to insulin. This vasodilator response was similar compared to the 
response of PVAT from control mice to insulin as shown in Fig 4A. Furthermore, the 
vasodilator response to adiponectin was abolished by the inhibition of AMPK with compound 
C (Fig 5B). 
Finally we investigated whether, the secretion of adiponectin was different in PVAT 
isolated from lean and Db/Db mice. The concentration of adiponectin was measured in 
supernatant after 30 min of incubation of PVAT and showed that PVAT isolated from Db/Db 
mice secreted 64% (p<0.05) less adiponectin than PVAT isolated from lean mice (Fig 5C).  
This shows that PVAT isolated from Db/Db mice secretes decreased amounts of 
adiponectin compared to PVAT that was isolated from lean mice, resulting in blunted insulin-
mediated vasodilation. 
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Figure 4. PVAT regulates insulin-mediated vasoreactivity and Akt activation. A) Insulin mediated 
vasoreactivity incubated with PVAT isolated from lean (rounds) or Db/Db (squares) mice. Data represent 
mean±SEM, * P<0.05: insulin response to PVAT isolated from lean mice was significant different from PVAT 
isolated from Db/Db mice. B) Phosphorylation of Akt at ser473 in response to insulin in arterioles, incubated with 
PVAT isolated from lean or Db/Db mice. Data represent mean±SEM, * P<0.05: increase in Akt phosphorylation 
induced by insulin. # p<0.05 decrease in insulin-mediated Akt phosphorylation induced by PVAT isolated from 
Db/Db mice compared to insulin-mediated Akt phosphorylation induced by PVAT isolated from lean mice.  
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Figure 5. Insulin-mediated vasodilation 
induced by PVAT isolated from lean mice is 
mediated by AMPK. A) Insulin-mediated 
vasodilation induced by lean PVAT (rounds) 
was abolished with Compound C (n=3, 
squares) B) Vasodilation of insulin together 
with adiponectin (triangles, 1μg/ml) was 
abolished by pretreatment of the AMPK 
inhibitor compound C (squares,1μM). C) 
Adiponectin (Adn) release of PVAT from control 
and Db/Db mice (n=3). ** P<0.01. 
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DISCUSSION 
The main findings of this study are that perivascular adipose tissue (PVAT) is present and 
accumulates around muscle arterioles of obese Db/Db mice. Furthermore, co-incubation of 
PVAT isolated from lean mice with arterioles from lean mice induced insulin-mediated 
vasodilation, which was abolished by the inhibition of AMPK. Co-incubation of PVAT isolated 
from Db/Db mice with arterioles from lean mice induced blunted insulin-mediated 
vasodilation, which was associated with decreased Akt activation. Adiponectin secretion was 
reduced in PVAT isolated from Db/Db mice, which can partly explain the blunted insulin-
mediated vasodilation. 
 
PVAT regulates insulin-mediated vasoreactivity and Akt activation 
PVAT of healthy lean mice induced an insulin-mediated vasodilation in lean arterioles (Fig 
4A), which was not observed with PVAT that was isolated from Db/Db mice. The blunted 
insulin-mediated vasodilation by PVAT isolated from Db/Db mice was associated with a 
decrease in Akt activation. Previously, it has been observed that healthy PVAT has 
anticontractile effects in thoracic arteries and in small arteries of adipose tissue.16,21 
Furthermore, Greenstein et al showed a complete loss of anticontractile effects in obese 
patients, due to a downregulation of eNOS.21 However, this study used arteries isolated 
from fat biopsies and did not investigate responses to insulin. The results from the present 
study showed that PVAT isolated from lean mice had no effect on basal contractile function 
or acetylcholine dependent vasodilation, but induced insulin-mediated vasodilation. An 
explanation for the differences in anticontractile function is that this study examined the 
effects of PVAT in arterioles of skeletal muscle, and not from adipose tissue. In muscle 
arterioles insulin’s vasoactive properties play an important role in the regulation of vascular 
tone, insulin-mediated glucose uptake in-vivo.27 The blunted vasodilator effects of PVAT 
isolated from Db/Db mice in muscle arterioles found in this study therefore could contribute 
to obesity-associated disorders like insulin resistance. 
 
Insulin-mediated vasodilation induced by lean PVAT is mediated by AMPK activation 
We further examined the question whether the release of adiponectin from PVAT isolated 
from lean mice explain the blunted insulin mediated vasodilation in arterioles. We showed 
that arterioles incubated with adiponectin induced a similar insulin-mediated vasodilation as 
PVAT isolated from lean mice. Furthermore, we showed that adiponectin levels are higher in 
PVAT isolated from lean compared to PVAT isolated from Db/Db mice. Other studies also 
showed that adiponectin has vasodilator effect.21,40 and that adiponectin levels are higher in 
lean than in obese subjects7,8   This indicates that adiponectin could be an important effector 
of the insulin-mediated vasodilation induced by PVAT isolated from lean mice. However,
other adipokines should not be excluded in co-incubation studies with PVAT. Adipose tissue 
secretes a variety of adipokines, in which the identification of new adipokines is still in 
progress and others of which the effect on insulin signalling is unknown. In this study we 
showed that both lean PVAT and adiponectin induced insulin-mediated vasodilation in lean 
arterioles, which was abolished by AMPK inhibition with compound C.  
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A recent study of Deng et al showed that adiponectin activates AMPK and thereby 
stimulates eNOS activation in endothelial cells. This strongly suggests that adiponectin 
contributes to insulin-mediated vasodilation induced by lean PVAT through the activation of 
AMPK (and eNOS) in our study. 
 
Reponses of insulin depends on the secretion profile of PVAT  
PVAT isolated from Db/Db mice induced no change in diameter in response to insulin. In a 
previous study we showed that insulin without any PVAT induces no change in diameter in 
the same arterioles.33 This response to insulin induced by PVAT isolated from Db/Db mice 
could be caused by a net effect of different adipokines on insulin-mediated vasoreactivity. In 
our incubation studies, PVAT probably secretes both adipokines that are described to have 
positive (e.g. adiponectin, leptin) and negative (TNFα, FFA) effects on insulin sensitivity. All 
these factors can also influence insulin-mediated vasoreactivity. In future studies we will 
determine a secretion profile of PVAT to show which adipokines are responsible. However, 
until now we know that in obese adipose tissue the secretion of adiponectin is decreased,7,8 
and that the secretion of TNFα,14 FFA12 and leptin41 are increased. From these adipokines is 
known that adiponectin induces vasodilation and that TNFα and FFA induce 
vasoconstriction.34,42  
The effect of AMPK inhibition on the effects of PVAT isolated from Db/Db mice will 
also be investigated in the future. However, one can expect that the combination of AMPK 
inhibition and PVAT isolated from Db/Db mice will result in insulin-mediated 
vasoconstriction. AMPK is activated by PVAT isolated from Db/Db mice and the inhibition of 
AMPK will abolish vasodilator effects of insulin. Furthermore, the negative effects of TNFα or 
FFA will be dominant over positive effects of adiponectin.  
As stated before, AMPK activation is probably not the only source of altered insulin 
signaling. We already showed that TNFα induces insulin-mediated vasoconstriction by the 
impairment of Akt through JNK activation and that FFA induces insulin-mediated 
vasoconstriction by the impairment of Akt and stimulation of ERK1/2, through PKCθ 
activation. Several other adipokines were identified e.g resistin, acylation-stimulating protein 
(ASP), plasminogen activator inhibitor-1 (PAI-1), from which the influence on insulin 
signaling is not yet known. Each adipokine could differently affect insulin signaling and in 
obesity the different effects sum up to complicated disturbances in insulin signaling and 
insulin-mediated vasoreactivity. 
 
Pathophysiologic perspectives 
PVAT influence vasoreactivity by the local production of adipokines. PVAT isolated from 
Db/Db mice induced blunted insulin-mediated vasodilation, compared to PVAT that was 
isolated from lean mice. Impaired insulin-mediated vasodilation in muscle arterioles, 
changes the muscle perfusion leading to decreased muscle glucose uptake. The vasoactive 
responses to PVAT are caused by the production of different types of adipokines. The 
identification of a specific adipokine secretion profile from PVAT isolated from lean and 
Db/Db mice will help us to find specified treatment of vascular dysfunction in the 
development of obesity-induced insulin resistance. 
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VIII.   Conclusions, General Discussion and    
          Future Perspectives 
 
 
In the present thesis, we investigated the relationship between vascular insulin resistance 
and fat in muscle arterioles of the mouse. Different aspects of fat were investigated. Fat in 
this thesis comprises both adipose tissue and increased adiposity (obesity) in general, as 
well as free fatty acids (FFA). Vascular function in combination with these different aspects 
of fat was investigated in several strains of genetically modified mice, to gain insight in 
insulin signaling, vasoreactivity and mechanisms that control blood pressure and insulin-
mediated blood flow in skeletal muscle. 
 
 
The main conclusions of this thesis are: 
a. The vascular response to insulin in isolated arterioles of the mouse depends on 
genetic background. Arterioles isolated from mice with a Sv129*C57Bl/6 
background, as used in chapter III and IV, showed a vasoconstriction to insulin in 
control mice, whereas arterioles isolated from mice with a C57Bl/6 background 
showed no change in diameter to insulin (Chapter V-VII). This is caused by a 
balance between NO and ET-1 activity. 
b. Deficiency of either IRS1 or IRS2 leads to insulin-mediated vasodilation in muscle 
arterioles, due to an impaired ET-1 activation.  In IRS1 deficient mice, this 
vasodilation to insulin affects total muscle vascularization, compared to control 
siblings (Chapter III). In IRS2 deficient mice this vasodilation to insulin was 
associated with a lower blood pressure, compared to control siblings. (Chapter IV). 
c. FFAs activate PKCθ and induce insulin-mediated vasoconstriction in muscle 
arterioles. PKCθ activation in muscle arterioles caused a reduced Akt activation 
and an increased ERK1/2 activation by insulin (Chapter V). FFAs selectively 
activate PKCθ in muscle arterioles as opposed to adipose tissue arterioles in lean 
mice. In obese/diabetic mice, PKCθ activation is increased in muscle arterioles but 
not in adipose tissue arterioles, which is associated with increased adipose tissue 
blood flow (Chapter VI). 
d. Perivascular adipose tissue (PVAT) in muscle induces insulin-mediated 
vasodilation in a co-incubation with muscle arterioles of lean mice, by activating 
AMPK. This response was blunted in a co-incubation with perivascular adipose 
tissue from obese/diabetic mice.  (Chapter VII). 
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In figure 1, the main conclusions described in this thesis are depicted, as well as how these 
conclusions can be linked together and to blood pressure and perfusion of muscle and 
adipose tissue. The implications for vascular function that can be extracted from this figure 
will be discussed: 1) the role of IRS proteins in vascular insulin resistance; 2) PKCθ as a 
new vasoregulatory protein and 3) the effect of PVAT in vasoregulation. Furthermore, the 
methodological considerations and the possible influences of genetic background of mice 
strains will be discussed at the end of this chapter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Insulin receptor substrates (IRS) 
 
IRS in insulin signaling 
Until now, polymorphisms of the IRS1 proteins and disrupted IRS phosphorylation leading to 
decreased NO production in endothelial cells2 are reported  to be involved in insulin 
resistance and obesity. In obesity, levels of FFAs are increased3 and FFAs impair insulin-
dependent NO production through downregulation of cell signaling via IRS-1 and Akt.4 
PKCθ, which mediates the interaction between insulin and FFA (Chapter V), can directly 
phosphorylate IRS-1 at serine residues and thereby alter insulin signaling.5,6 These data link 
our findings on PKCθ activation by FFA (Chapter V) to the physiological role of IRS proteins 
described in Chapter III and IV.  
Figure 1. Summary of the main conclusions described in this thesis. The inducers PVAT and obesity secrete 
the adipokines adiponectin (Adn) and free fatty acids (FFAs).  FFAs activate PKCθ, which changes the balance of 
insulin’s vasodilator and vasoconstrictor effects, thereby influencing the responding muscle and adipose tissue 
perfusion. Adn is produced by PVAT and influences insulin-mediated vasoreactivity, possibly through modulation of 
IRS proteins. IRS proteins are complex signaling proteins and have been shown to be involved in blood pressure 
regulation and muscle tissue perfusion. Straight lines: findings in this thesis (b-d) or findings of other groups,2,3,5,6 
dashed lines: discussion points. Numbers implicates the main conclusions listed in the above text. Abbreviations: 
Adn: adiponectin, FFA:  free fatty acid, IRS: Insulin receptor substrate, PKCθ: Protein kinase C theta, PVAT: 
perivascular adipose tissue.  
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Although in the literature IRS proteins have mainly been linked to activation of the NO 
pathway of insulin,7,8 this thesis showed an important role of both IRS1 and IRS2 in the ET-1 
pathway of insulin. This means that the roles of IRS1 and IRS2 in the insulin signaling are 
more complex than previously thought, which may have important physiological implications 
for our understanding of the regulation of blood pressure and muscle perfusion. Although we 
have not reported a role of IRS1 in blood pressure regulation (Chapter III) or a role of IRS2 
in muscle vascularization (Chapter VI), it is most likely that both IRS1 and IRS2 are 
important regulators of both physiological parameters. Blood pressure measurement with 
radiotelemetry was unfortunately not possible in IRS1-/- mice due to their low body weight. 
However, in muscle of IRS2-/- mice a reduced capillary ratio and reduced arteriolar diameter 
in muscle was observed . Another point that has to be taken into account is that the role of 
NO in insulin-mediated vasoregulation could not be investigated in the model used in 
chapter III and IV (see also methodological considerations at the end of this chapter). The 
arterioles used in our studies did not show a prominent role of NO in insulin-mediated 
vasoreactivity. This was visible in the responses of insulin in arterioles from IRS1+/+ and 
IRS2+/+ mice, which showed a vasoconstriction to insulin. Nevertheless, our data extend 
existing knowledge with a novel role of IRS proteins in the ET-1 pathway of insulin in 
vasoregulation. 
The function of IRS proteins in the regulation of the production of NO and ET-1 
depends on the phosphorylation status of the IRS proteins. IRS proteins are very complex 
proteins containing approximately 20 putative tyrosine phosphorylation sites which 
determine the activity of various downstream signaling proteins.9 In addition, they contain 
more than 30 potential serine/threonine phosphorylation sites that are recognized by various 
kinases.10,11 Studies on phosphorylation of IRS proteins have mainly focused on IRS1 and 
therefore, little is known about the phosphorylation of IRS2. For example, tyrosine 
phosphorylation of IRS-1 by the tyrosine kinase activity of the insulin receptor is a crucial 
event for the signal transduction to activate downstream targets and serine/threonine 
phosphorylation appears to be responsible for the precise regulation and is thought to be  a 
major mechanism for the termination of the insulin signal.12,13 For example, PKCθ increases 
the phosphorylation of IRS1 at ser3075 and ser1101,6 which reduces the activation of PI3K 
by insulin.2 As one can imagine, the vascular wall and therefore also insulin signaling is 
exposed to several factors in different conditions. This results in a different phosphorylation 
status of IRS proteins, which probably changes every moment of the day and can constantly 
influence vascular diameter. In complex disorders like obesity, in which the production of 
several adipokines is altered, the phosphorylation and functioning of IRS proteins will be 
even more complicated.  
It is therefore very difficult to study the role of IRS proteins. In this thesis we deleted 
the complete protein of either IRS1 or IRS2. This means that the complete regulation and 
phosphorylation status of the protein is deleted, which has enormous impact on insulin 
signaling. The deletion of IRS1 or IRS2 leads to insulin-mediated vasodilation in isolated 
resistance arteries. Hence, defining the functional role of IRS1 or IRS2 in the onset of e.g. 
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obesity or insulin resistance is difficult. For example, IRS1 and IRS2 are structurally 
homologous and could act synergistically, making a study of the single function of either 
IRS1 or IRS2 more difficult.14 IRS1 and IRS2 have different tissue expression, but can take 
over each other’s functioning if necessary.14 In obesity, this could imply that the functioning 
and phosphorylation status is even more complex, but is very important in disturbed insulin 
signaling. Therefore more attention and investigation are needed to better understand IRS 
functioning; in the next paragraph I will give some suggestions for future research.  
 
 
Perspectives: IRS phosphorylation   
IRS proteins are important regulatory proteins in insulin signaling. For a better 
understanding of the in-vivo role of IRS1 and IRS2 in vasoregulation and its possible 
contribution to vascular dysfunction and insulin resistance more knowledge is needed about 
the effects of the different phosphorylation status of IRS proteins on insulin signaling. The 
exact role of IRS function in obesity can be investigated by deleting specific phosphorylation 
sites, altering the effects on insulin signaling and insulin-mediated vasoreactivity in a more 
subtle approach. An example of a subtle approach to change the phosphorylation profile of 
IRS proteins in the vasculature is a vascular specific activation of PKCθ. This can be 
accomplished by a mutation leading to constitutive phosphorylation of the activation site of 
PKCθ at thr538. Furthermore, using cultured endothelial cells, a phosphorylation profile of 
the IRS proteins in different environmental conditions, like high fatty acids, insulin or glucose 
can be determined. However, it is still hard to investigate the phosphorylation of IRS 
proteins, due to limitations of specific antibodies for all phosphorylation sites of IRS. 
Recently, a phosphotyrosine interactome discovered potential common and differential 
phosphotyrosine-mediated interactors, which influence the signaling capabilities of IRS1 and 
IRS2.15 For example differences in tyrosine-phosphorylation lead to different binding of IRS 
to downstream proteins; an increased tyrosine-phosphorylation results in more binding of 
PI3K-activating proteins.16 In contrast to previous reports, the proteomic analysis suggests 
that IRS1 an IRS2 have the same downstream signals, but that IRS1 is more active in the 
post-prandial state, whereas IRS2 is employed during fasting.17 Furthermore, the expression 
levels of IRS proteins and their interactors also play a role, and can even result in opposite 
functions depending on the cell type investigated.18  
Taken together, in the field of IRS proteins and insulin signaling there is still a lot to 
be discovered. Studies on the effects of different phosphorylation status in insulin signaling 
and insulin-mediated vasoreactivity during different nutritional status would give a more 
delicate insight into possible therapeutic targeting for the treatment of e.g. insulin resistance 
and hypertension.  
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Protein Kinase C theta (PKCθ) 
 
PKCθ as new vasoregulatory protein in insulin signaling 
PKCθ was first suggested to play a role in FFA-induced insulin resistance by Griffin et al.19 
Increased FFA levels induced by lipid infusion reduced muscle glucose uptake and was 
associated with increased translocation of PKCθ to the membrane in muscle cells.19 Other 
studies showed that PKCθ is present in cultured endothelial cells.20-22 The data described in 
chapter V and VI show that PKCθ is present in muscle arterioles and is activated by FFA, 
resulting in insulin-mediated vasoconstriction and offering a new mechanism in which FFA 
can induce decreased muscle glucose uptake and insulin resistance.  
PKCθ regulates insulin signaling as depicted in figure 2. In this figure, PKCθ is 
suggested to be a regulator switch of IRS proteins in the presence of FFA. PKCθ can 
directly modulate IRS phosphorylation at least at ser3075 and ser1101,6 which are 
associated with decreased insulin-mediated PI3K activity. This means that the 
phosphorylation status of IRS proteins determines which downstream proteins can be 
activated. IRS proteins are involved in both the Akt/NO pathway2 and the ERK1/2/ET-1 
pathway of insulin (Chapter III and IV). Furthermore, PKCθ activation induced by FFA 
induced an increased ERK1/2 activation and a decreased Akt activation (Chapter V). This 
implicates that increased phosphorylation of IRS1 at ser307 in the presence of FFA5 leads 
to an increased activation of ERK1/2 and ET-1 production and a reduced activation of Akt 
and NO production. This subsequently changes the balance of insulin-mediated 
vasoreactivity towards reduced vasoconstriction, which has been suggested to decrease 
muscle perfusion.23,24 
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Figure 2.  PKCθ in insulin 
signaling. In normal insulin 
signaling, the regulation of 
IRS proteins is mediated by 
the phosphorylation at several 
tyrosine and serine residues. 
The phosphorylation of the 
IRS protein determines the 
down stream signaling and 
depends on the environment 
of the cell. At high levels of 
FFA, PKCθ is activated and 
changes insulin signaling. 
PKCθ increases the 
phosphorylation at serine 
sites, which is associated with 
decreased activation of Akt by 
insulin.5,6 Furthermore, the 
activation of PKCθ in 
arterioles leads to reduced 
activation of Akt an increased 
activity of ET-1. 
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PKCθ is a kinase that has recently been discovered to be important in insulin signaling, 
probably by regulating the functioning of IRS proteins. This effect may be contextual, as 
other kinase are also involved in the regulation of the phosphorylation status of IRS proteins. 
For example, C-Jun-N-terminal kinase (JNK),25 Inhibitor κB kinase (IKK),26 Casein kinase II27 
and Glycogen synthase kinase-3β (GSK3β)28 are able to directly phosphorylate and thereby 
influence IRS proteins. It is likely that a combination of the different effects of the kinases 
that are activated, during e.g. obesity, determine the final phosphorylation status of IRS 
proteins and thereby influence downstream insulin signaling. 
 
 
PKCθ as a coordinator of nutrient storage 
Four decades ago, Neel postulated “the thrifty genotype” theory,29 in which a genetic 
selection for efficient food storage is suggested which in today’s western lifestyle 
predisposes to the development of obesity and diabetes. Does PKCθ activation in muscle 
arterioles support the thrifty genotype theory of Neel?  
In Chapter V and VI, we showed that the activation of PKCθ by FFA induces 
insulin-mediated vasoconstriction specifically in muscle arterioles and not in adipose tissue 
arterioles. This different response to insulin was associated with increased blood flow 
towards adipose tissue in states of obesity. This raises the question whether PKCθ could be 
a protective mechanism in muscle arterioles. This would imply that in conditions of increased 
levels of FFA in the circulation, PKCθ activation is switched on in muscle arterioles to protect 
the muscle from FFA overload and stimulate storage in adipose tissue for future starvations. 
Neel speculated that the tendency to develop insulin resistance is unlikely to be a 
genetic disorder.29 Instead, it must have evolved as an adaptive trait that later turned 
pathological due to changed life style and diet. He hypothesized that a "thrifty" genotype that 
helped survival in primitive life characterized by periods of "feast and famine" has now 
turned detrimental in the modern urban lifestyle and diet.29 Our data showed that PKCθ is 
both activated during acute exposure of muscle arterioles to FFA and in muscle arterioles of 
db/db mice, a model for chronic obesity and diabetes. During “feast”, when FFA is available, 
the storage of FFA is stimulated for more famine situations. PKCθ is a rather newly identified 
protein, which may have evolved by mutations to stimulate fat storage for future survival. In 
this situation, it would be interesting to investigate whether PKCθ activation is switched on in 
the adipose tissue arteries.  
 
 
Perspectives: PKCθ as selective therapeutic target 
Although PKCθ might have evolved as a storage coordinator during periods of alternating 
nourishment and starvation, overnourishment and the lack of starvation of the last 20 years 
turned this PKCθ activation into a metabolic problem in the western world. It would therefore 
be interesting to examine whether PKCθ inhibition in obese subjects can also restore 
muscle blood flow and metabolic problems. During obesity, PKCθ is activated in muscle 
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arterioles and not in adipose arterioles. PKCθ activation in muscle arterioles results in 
insulin-mediated vasoconstriction and is associated with decreased muscle blood flow and 
increased blood flow towards adipose tissue. The inhibition of PKCθ restored insulin-
mediated vasoreactivity to control condition. It would be interesting to examine whether 
PKCθ inhibition in obese subjects/mice could also restore in-vivo complications of obesity. 
For example, in mice, the effects of a PKCθ inhibitor on muscle blood flow, capillary 
recruitment and adipose tissue mass can be studied. According to the results described in 
this thesis, one may speculate that inhibition of PKCθ in a mouse model of obesity may 
result in increased muscle blood flow, increased insulin-mediated capillary recruitment and 
decreased adipose tissue mass. PKCθ inhibition selectively prevents vascular dysfunction of 
muscle arterioles, thereby increases blood flow and nutrient uptake in muscle. This results in 
less nutrients to be stored and even extra nutrients demanded in case of extra energy 
expenditure of the muscle, which may stabilize or reduce adipose tissue mass. 
 
 
Perivascular Adipose Tissue (PVAT) 
 
PVAT is present around all conduit arteries30-32 and in some microvascular beds, such as 
that of the mesentery.33 We observed that PVAT is present around skeletal muscle 
arterioles and that it is increased in obese mice (Chapter VII). In Chapter VII we showed that 
PVAT influences vasoreactivity by the local production of adipokines in-vitro. In our set-up, 
PVAT was not in direct contact with the arteriole and the effects on insulin-mediated 
vasoreactivity were entirely dependent on the secretion profile of the PVAT. The effects of 
PVAT on insulin-mediated vasoreactivity have not been studied before. Previous studies 
suggested that impaired insulin-mediated vasodilation in muscle arterioles results in 
decreased muscle perfusion and muscle glucose uptake.23,34,35 The influence of PVAT on 
the regulation of insulin responses on muscle arterioles might be an important new focus on 
the development of muscle insulin resistance. The local production of adipokines by PVAT 
can influence vasoregulatory proteins like IRS and PKCθ and regulate vascular function and 
thereby also affect blood pressure and muscle perfusion (as depicted in Figure 1). For 
example, the increased adipocyte cell size as observed in obese PVAT probably results in 
the production of high concentrations of FFA around arterioles and thereby increases the 
activation of PKCθ and affects the phosphorylation of IRS proteins.5 In addition, the reduced 
adiponectin secretion by obese PVAT influences insulin-mediated vasoreactivity by 
activation of AMPK, which also can influence IRS phosphorylation36 as depicted in Figure 1. 
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Perspectives on PVAT 
The identification of a specific adipokine secretion profile from lean and obese PVAT helps 
us to find specific treatment of vascular dysfunction to prevent increased blood pressure and 
blunted muscle perfusion in obesity. 
To investigate the mechanisms behind the effects of PVAT on vascular function 
between lean and obese mice or subjects, the change in adipokine secretion profile should 
be determined. Adipose tissue of lean and obese mice has different adipokine secretion 
profiles. Chapter VII showed e.g. that adiponectin is secreted in larger amounts by PVAT 
from lean mice compared to PVAT from obese mice. The switch in secretion of adipokines 
by adipose tissue might possibly be caused by inflammation. The number of macrophages 
in adipose tissue is related to the severity of metabolic disorders.37 In future experiments, 
cultured adipocytes isolated from obese and healthy PVAT could be stimulated with e.g. 
anti-inflammatory factors to investigate whether the secretion profile changes. The 
incubation of anti- or proinflammatory factors can change the adipokine secretion profile and 
thereby gives rise to future implications in the in-vivo studies of PVAT. 
It has to be considered that our data focused on the effects of PVAT on insulin 
signaling, mainly in the endothelial cell layer of arterioles. Other studies that investigated the 
effects of PVAT on arterial function mainly focused on the role of vasorelaxation of the 
smooth muscle cells.32,38-40 One study showed that healthy PVAT resulted in increased 
vasorelaxation, while ‘obese’ PVAT did not.39 Future studies on the role of PVAT on 
vascular function and insulin-mediated vasoreactivity should both include the effects of 
PVAT on the endothelium and on the smooth muscle cells. 
Another point of attention is whether PVAT really contributes to metabolic disorders 
in-vivo. Is the accumulation of PVAT in obesity not a logical correlate of the general increase 
of adipose tissue mass? In obesity, adipose tissue pads are increased in almost every part 
of the body. The effects of PVAT on arteries are interesting, but obesity is still a complex 
disorder. In future studies on PVAT, it has to be considered whether PVAT has the same 
effect in-vivo, and whether the systemic production of adipokines is not more important. The 
local production of adipokines by PVAT has to reach the arterial wall. The increased PVAT 
in obesity, and the possible change in adipokine profile can induce a different response in-
vitro, but in-vivo the huge amounts of PVAT might also induce a diffusion barrier for the 
exposure of adipokines to the vascular wall, while systemically produced adipokines are in 
direct contact with the endothelium of the vascular wall and can influence vasoreactivity 
directly. 
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Methodological Considerations 
 
In vitro versus in-vivo 
In this thesis, we studied isolated muscle and adipose tissue arterioles from the mouse in a 
pressure myograph to determine functional effects, to e.g. insulin, of these arterioles. The 
effects of insulin in muscle arterioles give more insight into in-vivo effects of insulin on blood 
flow and capillary recruitment. The advantages of this technique are that direct effects of 
vasoactive substances like insulin can be studied under physiological conditions. In addition 
in the same preparation vasoreactivity and intracellular mechanisms can be studied. 
Furthermore, this can be combined with interference by genetic or pharmacological inhibition 
to study intracellular mechanisms. However, in these isolated arterioles, there is no 
surrounding tissue, flow, interaction with the total vascular system, or metabolites in the 
blood. All these factors influence vasoreactivity. For example, in the PVAT study (Chapter 
VII) we showed that adipose tissue around an arteriole influences vasoreactivity. In-vivo, 
insulin has been reported to have no effect or vasodilator effects on diameter of 
arterioles.41,42 This in-vivo vasodilation may be partly due to flow, but also the role of PVAT 
could be important. PVAT has been found around several arteries in-vivo.30-32,39,40,43 
Furthermore, PVAT from healthy mice revealed insulin-mediated vasodilation in healthy 
muscle arterioles (Chapter VII). The systemic effects of insulin to induce vasodilation could 
be directly regulated by PVAT. In healthy subjects, this can result in vasodilation and 
increased blood flow towards muscle. In obese subjects this can result in impaired 
vasodilation and decrease in blood flow towards muscle. 
 
 
Mouse models and genetic backgrounds 
The genetic background of inbred mice used for research varies and influences the 
physiological phenotype.44 The most commonly used mouse strain for studying metabolic 
diseases is the C57Bl/6 strain, because this mouse strain is the most sensitive to metabolic 
changes.45 The studies described in Chapter V, VI and VII have been performed in C57Bl/6 
mice. However, the studies described in Chapter III and IV have been performed in mice 
with a combined background of C57Bl/6 and SV129 strain. These mice were genetically 
modified, by the deletion of either IRS1 or IRS2. Due to practical considerations, one mice 
strain (SV129) was used for the genetic interference and one mice strain was used for 
fertilization (C57Bl/6). All mice used for our experimental studies included a heterozygous 
background of both the C57Bl/6 and SV129 strain.  
Arterioles isolated from C57Bl/6*SV129 (Chapter III-IV) and C57Bl/6 mice (Chapter 
V-VII) show different responses to insulin. Wild type mice with a C57Bl/6*SV129 background 
induced insulin-mediated vasoconstriction, whereas wild type mice with a C57Bl/6 
background showed no change in diameter in response to insulin. The difference in insulin 
response is probably attributable to the mouse strain, as we showed that arteries isolated 
from mice with either a C57Bl/6 background or a SV129 background showed different 
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responses to insulin. The arterioles from the SV129-mice showed an insulin-mediated 
vasoconstriction. The results from our study still hold true, because the effects of the genetic 
deletion on insulin-mediated vasoreactivity were constantly compared within isolated arteries 
from sibling mice. In this way, only the deletion of the gene was different between a knock 
out and wild type mice, and secondary genetic effects were excluded. However, effects of 
insulin on vasodilation may have been underestimated in mice carrying this background. 
The fact that insulin induces different responses in arterioles from mice isolated 
with different genetic background is intriguing, because among man there are even more 
genetic differences. Together with the fact that obesity is highly sensitive to a genetic 
predisposition, the combination of genetic predisposition and metabolic diseases is 
interesting for future research. There were no big changes observed in the activation of Akt 
and ERK in the arterioles isolated either from SV or from Bl/6 mice. However, the exact 
balance of Akt and ERK activation in insulin signaling and its effects on the balance in 
insulin-mediated vasoreactivity is difficult to determine. Akt is more insulin sensitive than 
ERK1/2 activation in muscle myotubes. Akt activation already increases at insulin 
concentrations of 0.5nM, whereas the activation of ERK1/2 starts at 10nM.46 In addition, in a 
previous study ERK1/2 activation increased after an incubation of 2nM with a maximum 
activation after 15 minutes in isolated muscle arterioles,47 while Akt activation still increased 
after 15 minutes of incubation in isolated muscle arterioles.48 The activations of Akt and 
ERK1/2 have different activation peaks at different time points and at different 
concentrations of insulin. This makes the comparison of Akt and ERK1/2 activation in the 
balance of insulin-mediated vasoreactivity very complex.  
Taken together, mice studies with genetic interferences are helpful to unravel  
signaling pathways. However, the implication of secondary phenotypic changes and 
physiological relevance must be taken into consideration. 
 
 
In conclusion, adipose tissue and increased adiposity (obesity) in general, as well as fatty 
acids (FFAs), contribute to vascular insulin resistance. In isolated muscle arterioles, we 
showed that these different aspects of fat induce insulin-mediated vasoconstriction and have 
important implications for muscle perfusion and blood pressure regulation. Both IRS proteins 
and PKCθ are important regulatory proteins in vascular insulin signaling. Together with 
newly identified adipose tissue around muscle arterioles (PVAT), these are promising 
therapeutic targets for future studies on vascular dysfunction and insulin resistance.  
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Summary: Vascular Insulin Resistance through Fat 
 
As a consequence of the continuous rise in the prevalence of obesity, metabolic diseases 
like insulin resistance, type 2 diabetes and associated conditions such as hypertension have 
reached epidemic proportions. This thesis focuses on the contribution of vascular insulin 
resistance to the development of type 2 diabetes and hypertension, in order to elucidate 
mechanisms and to identify possible therapeutic targets. Insulin has an important regulatory 
role in controlling vascular diameter in arterioles. Insulin determines vascular diameter by 
the production of both the vasodilator nitric oxide and the vasoconstrictor endothelin-1 and 
thereby controls blood pressure and delivery of nutrients, like glucose, to insulin-responsive 
tissues. Insulin resistance is defined as insensitivity to insulin-mediated glucose uptake in 
(mainly) skeletal muscle. In vascular insulin resistance, insulin’s vasodilator effects are 
impaired resulting in insulin-mediated vasoconstriction, which can contribute to increased 
blood pressure (hypertension) and blunted glucose delivery to muscle, which can 
contribute to type 2 diabetes.  An important risk factor for the development of metabolic and 
vascular insulin resistance is fat, or obesity. Obesity is characterized by an increased fat 
mass, vascular dysfunction and decreased glucose uptake in muscle. The increased 
secretion of endocrine substances (adipokines) by excessive adipose tissue, like tumor 
necrosis factor alpha (TNFα) and free fatty acids (FFA), is associated with impairment of 
vasodilator responses in arterioles.  
Although obesity is strongly associated with the development of insulin resistance, 
type 2 diabetes and hypertension, the mechanisms behind obesity-induced vascular insulin 
resistance have not yet been elucidated.  
 
This thesis focuses on the relationships between vascular insulin resistance and fat in a 
mouse study. Vascular insulin resistance was studied by the determination of the effect of 
insulin to induce vasodilation and vasoconstriction in isolated arterioles in the pressure 
myograph. Different aspects of fat were investigated: adipose tissue and increased adiposity 
(obesity) in general and acute exposure to FFA. In order to gain insight in insulin signaling, 
vasoreactivity and mechanisms that control blood pressure and insulin-mediated blood flow 
in skeletal muscle, vascular function in combination with these different aspects of fat was 
investigated in several strains of genetically modified mice.  
 
Chapter II comprises two extensive reviews about the role of endothelial dysfunction and 
diabetes with a special focus on impaired insulin signaling and perivascular adipose tissue. 
The first review discusses the initial dysfunction of endothelial cells underlying metabolic and 
vascular alterations that contribute to the development of type 2 diabetes. The second 
review further emphasizes the role of perivascular adipose tissue and local production of 
adipokines on vasoregulation. 
 
IX
Chapter IX 
IX.4
In Chapters III-VII, vascular function of arterioles of different mouse strains was 
investigated. It appeared that vascular responses to insulin in isolated arterioles of the 
mouse depends on genetic background. Arterioles isolated from mice with a Sv129*C57Bl/6 
background, as used in chapter III and IV showed a vasoconstriction to insulin in control 
mice. In contrast, arterioles isolated from mice with a C57Bl/6 background showed no 
change in diameter to insulin (Chapter V-VII). To overcome discrepancies between different 
mouse strains, conclusions based on genetic mouse models were only made by using their 
control litter mates as reference. 
In Chapters III and IV, the role of insulin receptor substrates (IRSs) in insulin-mediated 
vasoreactivity and their physiologic effects on vascular function was investigated. IRS 
proteins are important mediators of insulin signaling. IRS proteins are targeted by FFA 
causing disturbed intracellular insulin signaling, which could possible play a role in obesity-
induced insulin resistance. However the exact role of IRS proteins in vascular insulin 
signaling is not known. The functional gene of either IRS1 or IRS2 was deleted in mice and 
arterioles were isolated to determine the functional effects on vascular insulin signaling. 
Previously, IRS proteins have mainly been linked to activation of the NO pathway of insulin, 
implying that IRS proteins have an important role in insulin-mediated vasodilation. However, 
the data presented in chapter III and IV show an important role of both IRS1 and IRS2 in the 
ET-1 pathway of insulin. The deletion of either IRS1 or IRS2 leads to insulin-mediated 
vasodilation in muscle arterioles, due to an impaired ET-1 activation. In IRS1 deficient mice, 
this vasodilation to insulin is accompanied by an altered muscle vascularization, compared 
to control siblings (Chapter III). Our data showed that reduced IRS1 expression may partly 
explain microvascular dysfunction associated with insulin resistance. In IRS2 deficient mice, 
the vasodilation to insulin was associated with a lower blood pressure, compared to control 
siblings. (Chapter IV). Blood pressure and cardiac function were measured with 
radiotelemetry and echocardiography. The decreased blood pressure in IRS2 deficient mice 
was caused by a decrease in cardiac output and a decrease in vascular resistance by a 
specific impairment of insulin’s vasoconstrictor effects. Our data suggest that decreased 
IRS2 activity protects against hypertension. 
Deficiencies in IRS expression and function in target tissues of insulin, like skeletal 
muscle are strongly associated with insulin resistance and type 2 diabetes. The additional 
role of IRS1 and IRS2 in insulin-mediated endothelin-1 production means that the roles of 
IRS1 and IRS2 in the insulin signaling are more complex than previously thought. This may 
have important physiological implications for our understanding of the regulation of blood 
pressure and muscle perfusion. 
In Chapter V and VI, the mechanisms by which FFAs affect insulin-mediated vasoreactivity 
were investigated. In obesity, plasma levels of FFA are increased and are associated with 
impaired insulin signaling, impaired capillary recruitment and impaired insulin-mediated 
glucose uptake in muscle. The data described in Chapter V demonstrate that PKCθ is 
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present in the endothelium of muscle arterioles and that PKCθ is activated by FFA in muscle 
arterioles. FFAs activate PKCθ and induce insulin-mediated vasoconstriction, by a reduced 
activation of Akt and an increased activation of ERK1/2 by insulin (Chapter V). These data 
provide a new mechanism linking PKCθ activation to insulin resistance. The strong evidence 
of PKCθ activation in muscle arterioles by FFA was further investigated in adipose tissue 
arterioles in Chapter VI. This chapter shows that muscle and adipose tissue have a 
functionally distinct vasculature and that PKCθ is specifically activated in muscle arterioles, 
as opposed to adipose tissue arterioles. PKCθ activation in muscle arterioles was 
associated with insulin-mediated vasoconstriction in these arterioles and an increased blood 
flow towards adipose tissue in obese mice. These effects may promote increased nutrient 
storage in adipose tissue. 
The data described in chapter V and VI show that PKCθ is present in muscle 
arterioles and is activated by FFA, resulting in insulin-mediated vasoconstriction and offers a 
new mechanism in which FFA can induce decreased muscle glucose uptake and insulin 
resistance. 
 
In Chapter VII, the preliminary results of the effects of local secretion of adipokines on 
vascular function are described. This chapter examines the effects of perivascular adipose 
tissue (PVAT) isolated from lean and obese mice on insulin sensitivity and insulin-mediated 
vasoreactivity of vessels of lean mice. The data described in this chapter shows that PVAT 
is present around skeletal muscle arterioles in lean mice and that it is increased in obese 
mice. PVAT isolated from lean mice induces insulin-mediated vasodilation in a co-incubation 
with muscle arterioles of lean mice, by activation of AMPK. This vasodilator response to 
insulin was blunted in a co-incubation with perivascular adipose tissue from obese mice 
(Chapter VII). The blunted vasodilation was probably a result from the reduced production of 
adiponectin by PVAT isolated from obese mice.  
Our data showed that PVAT influences vasoreactivity in-vitro by the local 
production of adipokines. In our set up, PVAT was not in direct contact with the arteriole and 
the effects on insulin-mediated vasoreactivity were entirely dependent on the secretion 
profile of the PVAT. The identification of specific adipokine secreted by lean and obese 
PVAT helps us to find specific treatment of vascular dysfunction to prevent increased blood 
pressure and blunted muscle perfusion in obesity. 
 
In conclusion, adipose tissue and increased adiposity (obesity) in general, as well as fatty 
acids (FFA) contribute to vascular insulin resistance. In isolated muscle arterioles, we 
showed that these different aspects of fat induce insulin-mediated vasoconstriction and have 
important implications for muscle perfusion and blood pressure regulation. Both IRS proteins 
and PKCθ are important regulatory proteins in vascular insulin signaling. Together with 
newly identified adipose tissue round arterioles (PVAT), these are promising therapeutic 
targets for future studies on vascular dysfunction and insulin resistance.  
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Samenvatting: Vasculaire Insulineresistentie door Vet 
 
De constante toename van obesitas leidt tot een toegenomen incidentie van metabole 
verstoringen zoals insulineresistentie, type 2-diabetes en hypertensie, en heeft een 
epidemische omvang aangenomen. Dit proefschrift richt zich op de bijdrage van vasculaire 
insulineresistentie aan de ontwikkeling van type 2-diabetes en hypertensie. We hebben 
mechanismen opgehelderd die als doelwit gebruikt kunnen worden bij het ontwikkelen van 
nieuwe therapeutische behandelingen voor hypertensie en type 2-diabetes.  
Insuline speelt een belangrijke rol in het reguleren van de diameter van 
weerstandsvaten door zowel de productie van de vaatverwijdende stof stikstofoxide en de 
vaatvernauwende stof endotheline te induceren. Hierdoor is insuline in staat om zowel de 
bloeddruk als het transport van glucose naar de spieren te reguleren. Insulineresistentie is 
gedefinieerd als ongevoeligheid voor insuline-geïnduceerde glucoseopname, met name in 
spierweefsel. Bij vasculaire insulineresistentie zijn de vaatverwijdende effecten van insuline 
verstoord. Dit leidt tot een (absolute of relatieve) vaatvernauwing en kan enerzijds bijdragen 
aan een verhoogde bloeddruk door toegenomen vaatweerstand en anderzijds bijdragen 
aan type 2-diabetes door een verstoord glucosetransport naar spieren. Vet of vetzucht 
(obesitas) is een belangrijke risicofactor voor de ontwikkeling van zowel vasculaire als 
metabole insulineresistentie. Obesitas wordt gekenmerkt door een toegenomen vetmassa, 
vaatdysfunctie en een verminderde glucoseopname in spierweefsel.  
Obesitas is sterk geassocieerd met insulineresistentie, de incidentie van type 2-
diabetes en hypertensie, maar de mechanismen die ten grondslag liggen aan door obesitas 
geïnduceerde vasculaire insulineresistentie zijn nog niet duidelijk.  
 
In dit proefschrift wordt de nadruk gelegd op de relatie tussen vasculaire insulineresistentie 
en vet in een studie aan muizen. Vasculaire insulineresistentie is bestudeerd door de 
effecten van insuline om vaatverwijding en vernauwing te induceren in arteriolen te 
onderzoeken in een drukmyograaf. In deze opstelling kunnen veranderingen in vaatdiameter 
als reactie op vasoactieve stoffen gemeten worden onder fysiologische omstandigheden. In 
dit proefschrift worden 2 aspecten van vet bestudeerd: vetweefsel en overmatig vetweefsel 
(obesitas) in het algemeen en acute blootstelling aan vetzuren. Vaatfunctie in combinatie 
met deze  aspecten van vet zijn bestudeerd in verschillende genetisch gemodificeerde 
muizenstammen. Deze muizen missen een gen dat betrokken is bij de signaaltransductie 
van insuline in o.a. endotheelcellen. Hierdoor kan meer inzicht worden verkregen in de 
signaaltransductie van insuline en in de mechanismen achter de regulatie van bloeddruk en 
doorbloeding in spier- en vetweefsel onder invloed van insuline.  
 
Hoofdstuk II bestaat uit twee uitgebreide overzichtsartikelen die de rol van 
endotheeldysfunctie in diabetes en haar complicaties bespreken, met speciale aandacht 
voor de verstoorde signaaltransductie van insuline en perivasculair vet. 
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In het eerste artikel wordt een uitgebreid overzicht gegeven van de huidige literatuur 
aangaande endotheelfunctie en diabetes. Hierin wordt ook ter discussie gesteld of de 
verstoring van endotheelfunctie, die bijdragen aan metabole en vasculaire veranderingen, 
kan bijdragen aan de ontwikkeling van type 2 diabetes. Het tweede overzichtsartikel gaat 
verder in op de rol van perivasculair vet en de lokale productie van adipokines op de 
vaatfunctie.  
In Hoofdstuk III-VII wordt de respons op insuline in arteriolen bestudeerd. Deze arteriolen 
zijn geisoleerd uit verschillende muismodellen. Wij vonden dat het effect van insuline op 
vaatfunctie afhankelijk is van de genetische achtergrond van de muis. Arteriolen geïsoleerd 
uit muizen met een Sv129*C57Bl/6 achtergrond, gebruikt in hoofdstuk III en IV, laten een 
vaatvernauwing zien op insuline. Dit in tegenstelling tot arteriolen geïsoleerd uit muizen met 
een C57Bl/6 achtergrond, die geen verandering in diameter laten zien op insuline 
(Hoofdstuk V-VII). Om de effecten van de genetische achtergrond op insulinerespons uit te 
sluiten, zijn er alleen conclusies getrokken uit verschillen tussen muizen met een gelijke 
genetische achtergrond.  
In Hoofdstuk III en IV is de rol van insulinereceptorsubstraateiwitten (IRS) in insuline-
gemedieerde vaatreactiviteit en daarbij behorende fysiologische eigenschappen bestudeerd. 
IRS-eiwitten zijn belangrijke mediatoren in de signaaltransductie van insuline. Vetzuren 
kunnen bijvoorbeeld de signaaltransductie van insuline verstoren door aan te grijpen op 
IRS-eiwitten en hierdoor een belangrijke sleutelrol vormen in obesitas-geinduceerde 
insulineresistentie. De precieze rol van IRS-eiwitten in de signaaltransductie van insuline in 
bloedvaten is echter nog niet bekend. De studies beschreven in hoofdstuk III en IV maken 
gebruik van een muismodel waarin het functionele gen voor IRS1 of IRS2 is uitgeschakeld. 
Uit deze muizen zijn arteriolen geisoleerd om de functionele effecten van de gendeletie op 
vaatfunctie, zoals insuline-gemedieerde vaatreactiviteit, te bestuderen, maar ook 
spierdoorbloeding en bloeddruk zijn bepaald. Eerdere studies van andere auteurs 
beschrijven voornamelijk dat IRS-eiwitten betrokken zijn bij de activatie van insuline-
gemedieerde NO-productie, wat een belangrijke rol in vaatverwijding impliceert. Echter, de 
data in hoofdstuk III en IV laten zien dat zowel IRS1 als IRS2 een belangrijke rol speelt in de 
insuline-gemedieerde ET-1-productie en vaatvernauwing. Zowel het uitschakelen van IRS1 
als van IRS2 leidt namelijk tot een insuline-gemedieerde vaatverwijding in spierarteriolen, 
die veroorzaakt wordt door een verstoorde ET-1-activatie door insuline.
  In IRS1-deficiënte muizen is de vaatverwijding op insuline geassocieerd met een 
afgenomen vascularisatie van spieren (Hoofdstuk III). Ondanks dat muizen die het gen 
voor IRS1 missen een groeivertraging hebben, groeien de spieren van deze muizen 
normaal en is de doorbloeding in orde. Dit kan komen doordat insuline een vaatverwijding 
geeft in spierarteriolen van deze muizen en hierdoor de bloedvoorziening naar de spier kan 
stimuleren. De resultaten van hoofdstuk III laten zien dat een verminderde IRS1-expressie 
de vasculaire dysfunctie die geassocieerd is met insulineresistentie gedeeltelijk kan 
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verklaren. In IRS2-deficiënte muizen is de vaatverwijding op insuline geassocieerd met een 
lagere bloeddruk, vergeleken met normale muizen met dezelfde genetische achtergrond 
(Hoofdstuk IV). Bloeddruk en cardiale functie zijn gemeten met radiotelemetrie en 
echocardiografie in de muis. De afgenomen bloeddruk in IRS2-deficiënte muizen wordt 
veroorzaakt door een afgenomen hartminuutvolume en afgenomen vaatweerstand door een 
specifieke verstoring in insuline-gemediëerde vaatvernauwing. De resultaten in dit hoofdstuk 
suggereren dat een verminderde IRS2-activiteit een beschermende rol kan spelen in de 
ontwikkeling van hypertensie.  
Verstoringen in de expressie en het functioneren van IRS-eiwitten in 
doelwitorganen van insuline, zoals skeletspieren, zijn sterk geassocieerd met het 
ontwikkelen van insulineresistentie en type 2-diabetes. De rollen van IRS1 en IRS2 in 
insuline-gemedieerde ET-1-productie betekenen dat IRS1 en IRS2 een complexere rol 
spelen in de insulinesignaaltransductie route dan voorafgaand aan dit onderzoek werd 
gedacht. Deze data kunnen belangrijke fysiologische implicaties hebben voor ons begrip 
van de verstoorde bloeddrukregulatie en spierperfusie in insulineresistentie en type 2-
diabetes. 
 
In patiënten met obesitas zijn de serumwaarden van vetzuren verhoogd, en dit is 
geassociëerd met een verstoorde insulinesignaaltransductie, verstoorde rekrutering van 
capillairen en verstoorde glucose-opname in spieren. De mechanismen achter verstoorde 
insulinesignaaltransductie door vetzuren en wat de consequenties zijn voor vaatfunctie zijn 
onderzocht in Hoofdstuk V and VI. De resultaten in Hoofdstuk V laten zien dat PKCθ 
geactiveerd wordt door vetzuren en dat PKCθ aanwezig is in het endotheel van 
spierarteriolen. De activatie van PKCθ door vetzuren leidt tot insuline-gemedieerde 
vaatvernauwing door een afgenomen activering van Akt en een toegenomen activering van 
ERK1/2 door insuline. Het sterke bewijs voor PKCθ-activering in spierarteriolen is verder 
bestudeerd in arteriolen in vetweefsel in Hoofdstuk VI. Dit hoofdstuk laat zien dat vaten in 
spier en vetweefsel functioneel verschillend zijn. PKCθ wordt selectief geactiveerd door 
insuline en vetzuren in spierarteriolen ten opzichte van arteriolen uit vetweefsel. Deze 
PKCθ-activatie is geassocieerd met insuline-gemedieerde vaatvernauwing in spierarteriolen 
en een toegenomen doorbloeding van vetweefsel in obese muizen. Dit kan mogelijk de 
opslag van voedingstoffen in vetweefsel sitmuleren. De data beschreven in hoofstuk V en VI 
bieden een nieuw mechanisme waarin selectieve PKCθ-activatie in spierarteriolen 
verbonden kan worden aan obesitas-geïnduceerde insulineresistentie. 
 
Preliminaire resultaten van de effecten van lokaal uitgescheiden adipokines op de 
vaatfunctie zijn beschreven in Hoofstuk VII. In hoofdstuk VII worden arteriolen uit gezonde 
dunne muizen geïncubeerd met perivasculair vetweefsel (PVAT) geisoleerd uit een dikke of 
dunne muis. De resultaten in dit hoofdstuk laten zien dat de incubatie met PVAT van dunne 
muizen leidt tot een insuline-gemedieerde vaatverwijding in arteriolen van dunne muizen. 
Deze vaatverwijding wordt gemedieerd door de activering van AMPK en is verstoord bij een 
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incubatie van PVAT uit dikke muizen. Deze verstoorde vaatverwijding op insuline wordt 
waarschijnljik veroorzaakt door een verminderde productie van adiponectine door het PVAT 
van de dikke muis. Deze data laten zien dat PVAT vaatreactiviteit kan beïnvloeden door de 
lokale productie van adipokines in een in-vitro opstelling. In deze opstelling was het PVAT 
niet in direct contact met de bestudeerde arteriole en zijn de effecten op vaatreactiviteit 
afhankelijk van de mate van adipokinesecretie. Het identificeren van een specifiek profiel 
van adipokinesecretie van “dun” en “dik” PVAT kan ons helpen bij het vinden van een 
specieke behandelingen voor vaatdysfunctie en kan daardoor gebruikt worden voor 
preventie van de ontwikkeling van hypertensie en insulineresistentie  in patiënten met 
obesitas.  
Concluderend  tonen de hiervoor beschreven studies aan dat vetweefsel, obesitas en 
vetzuren vasculaire insulineresistentie kunnen veroorzaken. Vasculaire insulineresistentie 
veroorzaakt door vetweefsel en zijn producten wordt gekenmerkt door een verstoorde 
insuline-gemedieerde vaatverwijding en draagt bij aan een verstoorde spierdoorbloeding en 
bloeddrukregulatie, en gaat gepaard met toegenomen vet doorbloeding. Vet grijpt in op de 
signaaltransductie van insuline waarbij IRS-eiwitten en PKCθ een cruciale rol spelen in de 
regulatie van insuline-gemedieerde vaatreactiviteit. IRS en PKCθ kunnen samen met 
perivasculair vetweefsel aangrijpingspunten vormen voor toekomstig onderzoek ter 
preventie en behandeling van vaatdysfunctie, hypertensie en type 2-diabetes.
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